

UNIVERSITÀ DEGLI STUDI DI MILANO

Procedura di selezione per la chiamata a professore di I fascia da ricoprire ai sensi dell'art. 24, comma 6, della Legge n. 240/2010 per il settore concorsuale 06/D3 - MALATTIE DEL SANGUE, ONCOLOGIA E REUMATOLOGIA, (settore scientifico-disciplinare MED/06 - ONCOLOGIA MEDICA) presso il Dipartimento di Oncologia ed Emato-Oncologia, Codice concorso 4674

GIUSEPPE CURIGLIANO

CURRICULUM VITAE

(N.B. IL CURRICULUM NON DEVE ECCEDERE LE 30 PAGINE E DEVE CONTENERE TUTTI GLI ELEMENTI UTILI ALLA VALUTAZIONE DEI TITOLI SOTTOPOSTI AL GIUDIZIO DELLA COMMISSIONE)

INFORMAZIONI PERSONALI (NON INSERIRE INDIRIZZO PRIVATO E TELEFONO FISSO O CELLULARE)

COGNOME	CURIGLIANO
NOME	GIUSEPPE
DATA DI NASCITA	27 MAGGIO 1968

TITOLI

TITOLO DI STUDIO

(indicare la Laurea conseguita inserendo titolo, Ateneo, data di conseguimento, ecc.)

Laurea in Medicina e Chirurgia, Medico Chirurgo, Università Cattolica del Sacro Cuore, Policlinico Gemelli, Roma, 19.10.1993 (110 e lode)

TITOLO DI DOTTORE DI RICERCA O EQUIVALENTI, OVVERO, PER I SETTORI INTERESSATI, DEL DIPLOMA DI SPECIALIZZAZIONE MEDICA O EQUIVALENTE, CONSEGUITO IN ITALIA O ALL'ESTERO

(inserire titolo, ente, data di conseguimento, ecc.)

Dottore di Ricerca, Dottorato di Ricerca in Fisiopatologia Medica e Farmacologia, Università di Pisa, 25.01.2008
Tesi "Determinanti farmacogenomici di risposta alla gemcitabina intravesicale"
Specializzazione in Oncologia Medica, Università Cattolica del Sacro Cuore, Policlinico Gemelli, Roma, 27.10.1998 (con pieni voti assoluti e lode)

ALTRI TITOLI CONSEGUITI

(inserire titolo, ente, data di conseguimento, ecc.)

Nomina a professore di seconda fascia, area scientifica MED/06, settore concorsuale 06/D3 "Oncologia Medica", Università degli Studi di Milano, 2017 (con attività assistenziale: Divisione Nuovi Farmaci per Terapie Innovative, IEO, Milano)
Abilitazione Scientifica Nazionale 2016-2018 alle funzioni di professore di prima fascia nel settore concorsuale MED/06 settore concorsuale 06/D3, MIUR, 31.10.2018-31.10.2027
Diploma di Formazione Manageriale per Direttore Responsabile di Struttura Complessa, svolta presso Regione Lombardia & Università Cattolica del Sacro Cuore di Milano (superamento con alto merito - tesi "Clinical Pathways e contabilità analitica nei processi diagnostico-terapeutici: il caso delle neoplasie mammarie"), 2012

ATTIVITÀ DIDATTICA

INSEGNAMENTI E MODULI

(inserire anno accademico, corso laurea, numero di ore frontali, eventuale CFU)

Insegnamenti in qualità di Professore Associato MED06/D3 (2017-2021)
CORSI DI LAUREA dell'Università degli Studi di Milano
A.A. 2017-2018, Corso di Laurea in Medicina e Chirurgia,
Modulo: Oncologia medica, Insegnamento Clinica Medica V anno, 4 ore
A.A. 2018-2019, Corso di Laurea in Medicina e Chirurgia,
Modulo: Oncologia medica, Insegnamento Clinica Medica V anno, 4 ore
A.A. 2019-2020, Corso di Laurea in Medicina e Chirurgia,
Modulo: Oncologia medica, Insegnamento Clinica Medica V anno, 4 ore
A.A. 2020-2021, Corso di Laurea in Medicina e Chirurgia,
Modulo: Oncologia medica, Insegnamento Clinica Medica V anno, 4 ore
A.A. 2017-2018, Corso di Laurea International Medical School,
Modulo: Medical Oncology, Insegnamento: Clinical Oncology and Radiotherapy, V anno, 8 ore
Modulo: Medical Oncology, Insegnamento, Clinical Oncology and Radiotherapy (clerkship), 50 ore
A.A. 2018-2019, Corso di Laurea International Medical School,

Modulo: Medical Oncology, Insegnamento: Clinical Oncology and Radiotherapy, V anno, 8 ore
 Modulo: Medical Oncology, Insegnamento, Clinical oncology and Radiotherapy (clerkship), 50 ore
A.A. 2019-2020, Corso di Laurea International Medical School,
 Modulo: Medical Oncology, Insegnamento: Clinical Oncology and Radiotherapy, V anno, 8 ore
 Modulo: Medical Oncology, Insegnamento, Clinical oncology and Radiotherapy (clerkship), 50 ore
A.A. 2020-2021, Corso di Laurea International Medical School,
 Modulo: Medical Oncology, Insegnamento: Clinical Oncology and Radiotherapy, V anno, 8 ore
 Modulo: Medical Oncology, Insegnamento Clinical oncology and Radiotherapy (clerkship), 50 ore
A.A. 2020-2021, Corso di Laurea Biomedical Omics,
 Modulo: Clinical Omics, Coordinamento 6 CFU, 48 ore didattica frontale, Insegnamento: Oncologia, 16 ore
MASTER UNIVERSITARI e Corsi di Perfezionamento dell'Università degli Studi di Milano
A.A. 2017-2018, 2019-2020, 2020-2021 "Master in "Farmacia e Farmacologia Oncologica", 4 ore per anno
A.A. 2020-2021, Master di II livello Master in Prevenzione Genetica e Trattamento del Tumore Mammario Ereditario. 4 ore
A.A. 2020-2021, Master di II Livello in "Psiconcologia", 4 ore
A.A. 2020-2021, Corso di Perfezionamento in Etica e Metodologia della Sperimentazione Clinica Oncologica, 4 ore
A.A. 2021-2022, Coordinatore del Master di Secondo Livello in "Artificial Intelligence and Machine Learning in Cancer Medicine" (approvato dal Consiglio di Amministrazione nella seduta del 25 maggio 2021)
A.A. 2021-2022, Master di Secondo Livello in "Artificial Intelligence and Machine Learning in Cancer Medicine" (approvato dal Consiglio di Amministrazione nella seduta del 25 maggio 2021), Modulo Il Molecular Tumor Board, Insegnamento: AI nella Medicina di Precisione
A.A. 2021-2022, Master di Secondo Livello in "Artificial Intelligence and Machine Learning in Cancer Medicine" (approvato dal Consiglio di Amministrazione nella seduta del 25 maggio 2021), Modulo: Cos'è l'IA e storia dell'IA, Insegnamento: Storia e fondamenti dell'intelligenza artificiale (IA)
SCUOLE DI SPECIALIZZAZIONE dell'Università degli Studi di Milano
A.A. 2017-18, Scuola di Specializzazione in Oncologia Medica, 24 ore frontali
A.A. 2018-19, Scuola di Specializzazione in Oncologia Medica, 24 ore frontali
A.A. 2019-20, Scuola di Specializzazione in Oncologia Medica, 24 ore frontali
A.A. 2020-21, Scuola di Specializzazione in Oncologia Medica, 24 ore frontali
DOTTORATI di RICERCA, Università di Milano
A.A. 2020-2021, Dottorato in Medicina Traslazionale, Insegnamento di Medicina Traslazionale
INSEGNAMENTI PRESSO ALTRE UNIVERSITÀ o SCUOLE INTERNAZIONALI
 Dal 2002 ad oggi: membro della Breast Cancer Faculty, European School of Oncology (ESO)
 Dal 2006 ad oggi: membro della Breast Cancer Faculty, European Society for Medical Oncology (ESMO)
 Luglio 2010: Incarico di Insegnamento presso la Harvard Summer Medical School, Boston, USA
 2015: Docente nell'International Clinical Trial Workshop, American Society of Clinical Oncology (ASCO)
 Dal 2016 ad oggi: Docente della ESMO Academy, Oxford Summer Medical School
 Ottobre 2017: Incarico di Insegnamento, Imperial College London, UK.
 Dal 2018 ad oggi: membro della Breast Cancer Faculty, European Society of Radiotherapy and Oncology (ESTRO)
 Dal 2019 al 2021: Chair della Breast Cancer Faculty di ESMO
 2019, 2020: Direttore del Breast Cancer Preceptorship di ESMO, Zurigo
 2021: Direttore Scientifico dell'ASCO International Clinical Trial Workshop

ATTIVITÀ DI DIDATTICA INTEGRATIVA E DI SERVIZIO AGLI STUDENTI

ATTIVITÀ DI RELATORE DI ELABORATI DI LAUREA, DI TESI DI LAUREA MAGISTRALE, DI TESI DI DOTTORATO E DI TESI DI SPECIALIZZAZIONE

(inserire anno accademico, ateneo, corso laurea, ecc.)

A.A. 2018-2019, Corso di Laurea in Medicina e Chirurgia, Università degli Studi di Milano, Relatore per Tesi di Laurea Magistrale
A.A. 2018-2019, Corso di Laurea in Medicina e Chirurgia, Università degli Studi di Milano, Relatore per Tesi di Laurea Magistrale
A.A. 2019-2020, Corso di Laurea in Medicina e Chirurgia, Università degli Studi di Milano, Relatore per Tesi di Laurea Magistrale
A.A. 2020-2021, Corso di Laurea in Medicina e Chirurgia, Università degli Studi di Milano, Relatore per Tesi di Laurea Magistrale
A.A. 2020-2021, Corso di Laurea International Medical School (IMS), Università degli Studi di Milano, Relatore per Tesi di Laurea Magistrale
A.A. 2018-2019, 2019-2020, 2020-2021 Scuola di Specializzazione in Oncologia Medica, Università degli Studi di Milano, Relatore per Tesi di Specializzazione
 Relatore, correlatore e membro di Commissione di Valutazione in tesi di Laurea in Medicina e Chirurgia e Tesi di Specializzazione in Oncologia Medica presso l'Università degli Studi di Milano

ATTIVITÀ DI TUTORATO DEGLI STUDENTI DI CORSI DI LAUREA E DI LAUREA MAGISTRALE E DI TUTORATO DI DOTTORANDI DI RICERCA

(inserire anno accademico, corso laurea, ecc.)

A.A. 2018-2019, Attività di Tutorato e Partecipazione al Collegio dei Docenti, Dottorato di Ricerca in "Medicina Sperimentale", Università degli Studi di Milano, Durata: 3 anni
A.A. 2019-2020, Attività di Tutorato e Partecipazione al Collegio dei Docenti, Dottorato di Ricerca in "Medicina dei Sistemi", Università degli Studi di Milano, Durata: 4 anni
A.A. 2020-2021, Attività di Tutorato e Partecipazione al Collegio dei Docenti, Dottorato di Ricerca in "Medicina dei Sistemi", Università degli Studi di Milano, Durata: 4 anni
A.A. 2021-2022, Attività di Tutorato e Partecipazione al Collegio dei Docenti, Dottorato di Ricerca in "Network Oncology and Precision Medicine", Università degli Studi "La Sapienza" di Roma, Durata: 4 anni

SEMINARI

(inserire data, luogo, titolo del seminario ecc.): La lista che segue include solo selezionate attività seminariali a livello nazionale ed internazionale

Luglio 2010, Harvard Medical School, Boston, USA, "Optimal treatment of Luminal B-like breast cancer"
Settembre 2013, University of Lausanne, Lausanne, Switzerland, "Breast Cancer Vaccine"
Maggio 2014, University of Zurich, Zurich, Switzerland, "Treatment of triple negative breast cancer"
Maggio 2015, University of Zurich, Zurich, Switzerland, "Immunotherapy in Breast Cancer"
Maggio 2016, University of Brussels, Brussels, Belgium, "Mechanisms of resistance in HER2 positive breast cancer"
Ottobre 2017, Imperial College, London, UK, "Immunotherapy in early breast cancer"
Maggio 2018, University of Zurich, Zurich, Switzerland, "Immunotherapy in Breast Cancer"
Maggio 2019, University of Zurich, Zurich, Switzerland, "Precision Medicine in Breast Cancer"
Giugno 2019, University of Zurich, Zurich, Switzerland, Direttore del Breast Cancer Preceptorship di ESMO, Zurigo
Giugno 2020, University of Zurich, Zurich, Switzerland, Direttore del Breast Cancer Preceptorship di ESMO, Zurigo
Febbraio 2021, Massachusetts General Hospital Cancer Center, Harvard Medical School, Seminar on "Breast Cancer Treatment"
Febbraio 2021, Università di Milano, Webinar on "Artificial Intelligence in Cancer Medicine"
Novembre 2021, Università di Milano ed ASCO, Direttore Scientifico dell'ASCO International Clinical Trial Workshop

ATTIVITÀ DI RICERCA SCIENTIFICA

PUBBLICAZIONI SCIENTIFICHE

(per ciascuna pubblicazione indicare: nomi degli autori, titolo completo, casa editrice, data e luogo di pubblicazione, codice ISBN, ISSN, DOI o altro equivalente)

Giuseppe Curigliano <https://orcid.org/0000-0003-1781-2518>

H-Index Google Scholar: 120; Citations: 83152

Scopus H Index: 60; Citations: 17706

Numero di Pubblicazioni: 459 dal 1996 ad Oggi estratte da PubMed

Anno 1996

- 1) Curigliano G, Zhang YJ, Wang LY, Flamini G, Alcini A, Ratto C, Giustacchini M, Alcini E, Cittadini A, Santella RM. Immunohistochemical quantitation of 4-aminobiphenyl-DNA adducts and p53 nuclear overexpression in T1 bladder cancer of smokers and nonsmokers. Carcinogenesis. 1996 May;17(5):911-6. doi: 10.1093/carcin/17.5.911. PMID: 8640937.
- 2) Flamini G, Curigliano G, Ratto C, Astone A, Ferretti G, Nucera P, Sofo L, Sgambato A, Boninsegna A, Crucitti F, Cittadini A. Prognostic significance of cytoplasmic p53 overexpression in colorectal cancer. An immunohistochemical analysis. Eur J Cancer. 1996 May;32A(5):802-6. doi: 10.1016/0959-8049(95)00625-7. PMID: 9081357.
- 3) Ratto C, Flamini G, Sofo L, Nucera P, Ippoliti M, Curigliano G, Ferretti G, Sgambato A, Merico M, Doglietto GB, Cittadini A, Crucitti F. Detection of oncogene mutation from neoplastic colonic cells exfoliated in feces. Dis Colon Rectum. 1996 Nov;39(11):1238-44. doi: 10.1007/BF02055116. PMID: 8918432.

Anno 1997

- 4) Flamini G, Magalini S, Curigliano G, Nanni G, Boninsegna A, Agnes S, Faticato D, Castagneto M, Cittadini A. Immunohistochemical analysis of p53 protein in transplant recipients with Kaposi's sarcoma. J Cancer Res Clin Oncol. 1997;123(4):240-2. doi: 10.1007/BF01240324. PMID: 9177500.
- 5) Romano G, Mancini R, Fedele P, Curigliano G, Flamini G, Giovagnoli MR, Malara N, Boninsegna A, Vecchione A, Santella RM, Cittadini A. Immunohistochemical analysis of 4-aminobiphenyl-DNA adducts in oral mucosal cells of smokers and nonsmokers. Anticancer Res. 1997 Jul-Aug;17(4A):2827-30. PMID: 9252724.

Anno 1998

- 6) Flamini G, Romano G, Curigliano G, Chiominto A, Capelli G, Boninsegna A, Signorelli C, Ventura L, Santella RM, Sgambato A, Cittadini A. 4-Aminobiphenyl-DNA adducts in laryngeal tissue and smoking habits: an immunohistochemical study. Carcinogenesis. 1998 Feb;19(2):353-7. doi: 10.1093/carcin/19.2.353. PMID: 9498288.
- 7) Ciaparrone M, Terribile D, Curigliano G, Marra A, Sgambato A, Boninsegna A, Masetti R, Carbone A, Flamini G, Picciocchi A, Cittadini A. P-170 Glycoprotein (MDR) and p53 Expression in Breast Cancer. Breast J. 1998 Jul;4(4):270-6. doi: 10.1046/j.1524-4741.1998.440270.x. PMID: 21223447.

Anno 1999

- 8) Romano G, Sgambato A, Boninsegna A, Flamini G, Curigliano G, Yang Q, La Gioia V, Signorelli C, Ferro A, Capelli G, Santella RM, Cittadini A. Evaluation of polycyclic aromatic hydrocarbon-DNA adducts in exfoliated oral cells by an immunohistochemical assay. Cancer Epidemiol Biomarkers Prev. 1999 Jan;8(1):91-6. PMID: 9950245.
- 9) Romano G, Garagnani L, Boninsegna A, Ferrari P, Flamini G, De Gaetani C, Sgambato A, Giovanni F, Curigliano G, Ferretti G, Cittadini A, Trentini G. Analysis of 4-ABP-DNA adducts and p53 alterations in urinary bladder carcinoma. Anticancer Res. 1999 Sep-Oct;19(5C):4571-6. PMID: 10650812.

Anno 2000

- 10) Orlando L, Colleoni M, Nolè F, Biffi R, Rocca A, Curigliano G, Ferretti G, Peruzzotti G, de Braud F, Masci G, Goldhirsch A. Incidence of venous thromboembolism in breast cancer patients during chemotherapy with vinorelbine, cisplatin, 5-fluorouracil as continuous infusion (ViFuP regimen): is prophylaxis required? Ann Oncol. 2000 Jan;11(1):117-8. doi: 10.1023/a:1008364801718. PMID: 10690401.
- 11) De Pas T, Curigliano G, Catania C, Comandone A, de Braud F. Ifosfamide in the elderly: clinical considerations for a better drug management. Crit Rev Oncol Hematol. 2000 Feb;33(2):129-35. doi: 10.1016/s1040-8428(99)00060-8. PMID: 10737374.
- 12) De Pas TM, Mandalà M, Curigliano G, Peccatori F. Acute vulvar vestibulitis occurring during chemotherapy with cryptophycin analogue LY355703. Obstet Gynecol. 2000 Jun;95(6 Pt 2):1030. PMID: 10808018.
- 13) Ferretti G, Curigliano G, Pastorino U, Cittadini A, Flamini G, Calabrò MG, De Pas T, Orlando L, Mandalà M, Colleoni M, Spaggiari L, Granone PL, Pagliari G, de Braud F, Fazio N, Goldhirsch A. Detection by denaturant gradient gel electrophoresis of tumor-specific mutations in biopsies and relative bronchoalveolar lavage fluid from resectable non-small cell lung cancer. Clin Cancer Res. 2000 Jun;6(6):2393-400. PMID: 10873091.
- 14) De Pas T, de Braud F, Danesi R, Sessa C, Catania C, Curigliano G, Fogli S, del Tacca M, Zampino G, Sbanotto A, Rocca A, Cinieri S, Marrocco E, Milani A, Goldhirsch A. Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-

naïve patients with advanced non-small-cell lung cancer. *Ann Oncol.* 2000 Jul;11(7):821-7. doi: 10.1023/a:1008319923516. PMID: 10997809.

15) Colleoni M, Minchella I, Mazzarol G, Nolè F, Peruzzotti G, Rocca A, Viale G, Orlando L, Ferretti G, **Curigliano G**, Veronesi P, Intra M, Goldhirsch A. Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. *Ann Oncol.* 2000 Aug;11(8):1057-9. doi: 10.1023/a:1008334404825. PMID: 11038046.

Anno 2001

16) De Pas T, de Braud F, Mandalà M, **Curigliano G**, Catania C, Ferretti G, Sozzi P, Solli P, Goldhirsch A. Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) resistant to taxol plus gemcitabine. *Lung Cancer.* 2001 Feb-Mar;31(2-3):267-70. doi: 10.1016/s0169-5002(00)00176-8. PMID: 11165406.

17) Mandalà M, Moro C, Ferretti G, Calabro MG, Nolè F, Rocca A, Munzone E, Castro A, **Curigliano G**. Effect of tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients. *Anticancer Res.* 2001 Jan-Feb;21(1B):585-8. PMID: 11299809.

18) Lissoni P, Mandalà M, **Curigliano G**, Ferretti G, Moro C, Ardizzoia A, Malugani F, Tancini G, Tisi E, Arrighi C, Barni S. Progress report on the palliative therapy of 100 patients with neoplastic effusions by intracavitary low-dose interleukin-2. *Oncology.* 2001;60(4):308-12. doi: 10.1159/000058525. PMID: 11408797.

19) **Curigliano G**, Ferretti G, Colleoni M, Marrocco E, Peruzzotti G, De Cicco C, Paganelli G, Goldhirsch A. Bone scan had no role in the staging of 765 consecutive operable T(1-2)N(0-1) breast cancer patients without skeletal symptoms. *Ann Oncol.* 2001 May;12(5):724-5. doi: 10.1023/a:1011173806900. PMID: 11432637.

20) **Curigliano G**, Ferretti G, Flamini G, Goldhirsch A, de Braud F, Calabro MG, Mandalà M, Nole F, De Pas T, D'Addessi A, Cittadini A. Diagnosis of T1 bladder transitional cell carcinoma by denaturing gradient gel electrophoresis urinalysis. *Anticancer Res.* 2001 Jul-Aug;21(4B):3015-20. PMID: 11712804.

21) Fogli S, Danesi R, De Braud F, De Pas T, **Curigliano G**, Giovannetti G, Del Tacca M. Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer. *Ann Oncol.* 2001 Nov;12(11):1553-9. doi: 10.1023/a:1013133415945. PMID: 11822754.

22) De Pas T, **Curigliano G**, Franceschelli L, Catania C, Spaggiari L, de Braud F. Gemcitabine-induced systemic capillary leak syndrome. *Ann Oncol.* 2001 Nov;12(11):1651-2. doi: 10.1023/a:1013163831194. PMID: 11822767.

23) **Curigliano G**, Ferretti G, Mandalà M, De Pas T, Calabrò MG, Solli P, Noverasco C, de Braud F. GSTM1, P53 and K-ras molecular detection in resectable non-small cell lung cancer by denaturing gradient gel electrophoresis-bronchoalveolar lavage fluid analysis. *Anticancer Res.* 2001 Sep-Oct;21(5):3461-9. PMID: 11848510.

Anno 2002

24) De Pas T, **Curigliano G**, Masci G, Catania C, Comandone A, Boni C, Tucci A, Pagani O, Marrocco E, de Braud F; Italian Sarcoma Group. Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas. *Ann Oncol.* 2002 Jan;13(1):161-6. doi: 10.1093/annonc/mdf004. PMID: 11863099.

25) **Curigliano G**, Mandalà M, Minchella I, Goldhirsch A. Mediastinal lymphadenopathy in a patient with breast cancer. *Lancet Oncol.* 2002 Mar;3(3):174. doi: 10.1016/s1470-2045(02)00681-2. PMID: 11902504.

26) Orlando L, Colleoni M, **Curigliano G**, Nolè F, Ferretti G, Masci G, Peruzzotti G, Minchella I, Intra M, Veronesi P, Viale G, Goldhirsch A. Chemotherapy with vinorelbine, cisplatin and continuous infusion of 5-fluorouracil in locally advanced breast cancer: a promising low-toxic regimen. *Anticancer Res.* 2001 Nov-Dec;21(6A):4135-9. PMID: 11911307.

27) De Pas T, Pastorino U, Spaggiari L, **Curigliano G**, de Braud F, Robertson C. Preoperative chemotherapy in non-small-cell lung cancer: nothing new in N2 disease. *J Clin Oncol.* 2002 May 15;20(10):2603-4; author reply 2605. doi: 10.1200/JCO.2002.20.10.2603. PMID: 12011140.

28) **Curigliano G**, Colleoni M, Renne G, Mazzarol G, Gennari R, Peruzzotti G, de Braud E, Robertson C, Maiorano E, Veronesi P, Nolè F, Mandalà M, Ferretti G, Viale G, Goldhirsch A. Recognizing features that are dissimilar in male and female breast cancer: expression of p21Waf1 and p27Kip1 using an immunohistochemical assay. *Ann Oncol.* 2002 Jun;13(6):895-902. doi: 10.1093/annonc/mdf166. PMID: 12123335.

29) Mandalà M, Lissoni P, Ferretti G, Rocca A, Torri V, Moro C, **Curigliano G**, Barni S. Postoperative hyperprolactinemia could predict longer disease-free and overall survival in node-negative breast cancer patients. *Oncology.* 2002;63(4):370-7. doi: 10.1159/000066228. PMID: 12417792.

30) Ferretti G, Mandalà M, Di Cosimo S, Moro C, **Curigliano G**, Barni S. Catheter-related bloodstream infections, part I: pathogenesis, diagnosis, and management. *Cancer Control.* 2002 Nov-Dec;9(6):513-23. doi: 10.1177/107327480200900610. PMID: 12514569.

31) Orlando L, **Curigliano G**, Colleoni M, Fazio N, Nole F, Martinelli G, Cinieri S, Graffeo R, Peruzzotti G, Goldhirsch A. Intrathecal chemotherapy in carcinomatous meningitis from breast cancer. *Anticancer Res.* 2002 Sep-Oct;22(5):3057-9. PMID: 12530042.

Anno 2003

32) Veronesi G, Spaggiari L, De Pas T, Solli PG, De Braud F, Catalano GP, **Curigliano G**, Leo F, Pastorino U. Preoperative chemotherapy is essential for conservative surgery of Askin tumors. *J Thorac Cardiovasc Surg.* 2003 Feb;125(2):428-9. doi: 10.1067/mtc.2003.198. PMID: 12579122.

33) Ferretti G, Mandalà M, Di Cosimo S, Moro C, **Curigliano G**, Barni S. Catheter-related bloodstream infections, part II: specific pathogens and prevention. *Cancer Control.* 2003 Jan-Feb;10(1):79-91. doi: 10.1177/107327480301000111. PMID: 12598858.

34) Danesi R, de Braud F, Fogli S, de Pas TM, Di Paolo A, **Curigliano G**, Del Tacca M. Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer. *Pharmacol Rev.* 2003 Mar;55(1):57-103. doi: 10.1124/pr.55.1.4. PMID: 12615954.

35) Di Cosimo S, Pistillucci G, Ferretti G, Cicchetti A, Leggio M, Silvestris N, Moro C, Mandalà M, **Curigliano G**, Battigaglia B, Di Chio G, Cirignotta S, D'Aprile M. Palliative home care and cost savings: encouraging results from Italy. *N Z Med J.* 2003 Mar 14;116(1170):U370. PMID: 12658325.

36) Di Cosimo S, Ferretti G, Fazio N, Mandalà M, **Curigliano G**, Bosari S, Intra M, Latronico A, Goldhirsch A. Breast and ovarian metastatic localization of signet-ring cell gastric carcinoma. *Ann Oncol.* 2003 May;14(5):803-4. doi: 10.1093/annonc/mdg218. PMID: 12702537.

37) Solli P, Leo F, Veronesi G, **Curigliano G**, Martinoni A, Spaggiari L, Cipolla C, Pastorino U. Impact of limited pulmonary function on the management of resectable lung cancer. *Lung Cancer.* 2003 Jul;41(1):71-9. doi: 10.1016/s0169-5002(03)00122-3. PMID: 12826315.

38) Colleoni M, **Curigliano G**, Minchella I, Peruzzotti G, Nolè F, Mazzarol G, Renne G, Orlando L, Rocca A, Veronesi P, Intra M, Viale G, Sandri MT, Severi G, Goldhirsch A. Preoperative and perioperative chemotherapy with 5-fluorouracil as continuous infusion in operable breast cancer expressing a high proliferation fraction: cytotoxic treatment during the surgical phase. *Ann Oncol.* 2003 Oct;14(10):1477-83. doi: 10.1093/annonc/mdg411. PMID: 14504046.

39) De Pas T, Danesi R, Catania C, **Curigliano G**, De Braud F; Italia Sarcoma Group. Imatinib administration in two patients with liver metastases from GIST and severe jaundice. *Br J Cancer.* 2003 Oct 20;89(8):1403-4. doi: 10.1038/sj.bjc.6601282. PMID: 14562006; PMCID: PMC2394355.

40) Mandalà M, Ferretti G, Cremonesi M, Cazzaniga M, **Curigliano G**, Barni S. Venous thromboembolism and cancer: new issues for an old topic. *Crit Rev Oncol Hematol*. 2003 Oct;48(1):65-80. doi: 10.1016/s1040-8428(03)00041-6. PMID: 14585484.

41) Fazio N, Orsi F, Grasso RF, Ferretti G, Medici M, Rocca A, Zampino G, **Curigliano G**, De Pas T, Colleoni M, Bonomo G, Marrocco E, Lunghi L, De Braud F. Hepatic intra-arterial chemotherapy using a percutaneous catheter in pretreated patients with metastatic colorectal carcinoma. *Anticancer Res*. 2003 Nov- Dec;23(6D):5023-30. PMID: 14981962.

Anno 2004

42) Gennari R, **Curigliano G**, Jereczek-Fossa BA, Zurrida S, Renne G, Intra M, Galimberti V, Luini A, Orecchia R, Viale G, Goldhirsch A, Veronesi U. Male breast cancer: a special therapeutic problem. Anything new? (Review). *Int J Oncol*. 2004 Mar;24(3):663-70. PMID: 14767551.

43) Mandalà M, **Curigliano G**, Bucciarelli P, Ferretti G, Mannucci PM, Colleoni M, Ventura A, Peruzzotti G, Severi G, Pelicci PG, Biffi R, Orsi F, Cinieri S, Goldhirsch A. Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. *Ann Oncol*. 2004 Apr;15(4):590-3. doi: 10.1093/annonc/mdh146. PMID: 15033664.

44) **Curigliano G**, Cipolla C, de Braud F. Drug-induced prolongation of the QT interval. *N Engl J Med*. 2004 Jun 17;350(25):2618-21; author reply 2618-21. PMID: 15208787.

45) **Curigliano G**, Rigo R, Colleoni M, Braud FD, Nole F, Formica V, Orlando L, Cinieri S, Torrisi R, Cardillo A, Peruzzotti G, Medici M, Ardito R, Minchella I, Goldhirsch A. Adjuvant therapy for very young women with breast cancer: response according to biologic and endocrine features. *Clin Breast Cancer*. 2004 Jun;5(2):125-30. doi: 10.3816/cbc.2004.n.016. PMID: 15245616.

46) Gennari R, **Curigliano G**, Rotmensz N, Robertson C, Colleoni M, Zurrida S, Nolè F, de Braud F, Orlando L, Leonardi MC, Galimberti V, Intra M, Veronesi P, Renne G, Cinieri S, Audisio RA, Luini A, Orecchia R, Viale G, Goldhirsch A. Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopausal patients. *Cancer*. 2004 Sep 15;101(6):1302-10. doi: 10.1002/cncr.20535. PMID: 15316944.

47) Colleoni M, Viale G, Zahrieh D, Pruneri G, Gentilini O, Veronesi P, Gelber RD, **Curigliano G**, Torrisi R, Luini A, Intra M, Galimberti V, Renne G, Nolè F, Peruzzotti G, Goldhirsch A. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. *Clin Cancer Res*. 2004 Oct 1;10(19):6622-8. doi: 10.1158/1078-0432.CCR-04-0380. PMID: 15475452.

48) Fazio N, De Pas T, de Braud F, Spaggiari L, Mazzarol G, Biffi R, Andreoni B, Zampino M, **Curigliano G**, Lorizzo K, Di Meglio G, Goldhirsch A. CDX-2 should be included in the work-up of patients with lung metastases from unknown primary. *Ann Oncol*. 2004 Dec;15(12):1850. doi: 10.1093/annonc/mdh482. PMID: 15550596.

49) De Pas T, **Curigliano G**, Veronesi G, Catalano G, Catania C, Jereczek-Fossa B, Orecchia R, Spaggiari L, de Braud F. Optimization of the schedule of gemcitabine-cisplatin combination as induction regimen for patients with biopsy- proven stage IIIa N2 - stage IIb non-small-cell lung cancer: a prospective phase-II study. *Bull Cancer*. 2004 Sep 1;91(9):E273-7. PMID: 15582897.

50) De Pas T, Pelosi G, de Braud F, Veronesi G, **Curigliano G**, Leon ME, Danesi R, Noverasco C, d'Aiuto M, Catalano G, Viale G, Spaggiari L. Modulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rare. *J Clin Oncol*. 2004 Dec 15;22(24):4966-70. doi: 10.1200/JCO.2004.01.195. PMID: 15611511.

51) Noverasco C, De Pas T, **Curigliano G**, Manzoni S, Dodaro L, Pelosi G, Spaggiari L, De Braud F. Immunohistochemical detection of HER1/HER2 can be considered a predictive marker of gefitinib activity in non-small-cell lung cancer? *J Clin Oncol*. 2005 Feb 1;23(4):921-2; author reply 922. doi: 10.1200/JCO.2005.05.700. PMID: 15681541.

52) De Pas T, Colleoni M, Orlando L, Masci G, Rocca A, Catania C, **Curigliano G**, Manzoni S, Goldhirsch A, de Braud F. Reply to the article "Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity" by V. R. Rozados et al. (*Ann Oncol* 2004; 15: 1543-1550): ... and in humans? *Ann Oncol*. 2005 Apr;16(4):673. doi: 10.1093/annonc/mdi101. Epub 2005 Feb 16. PMID: 15716290.

53) De Pas T, Sbanotto A, Catania C, Banfi MG, **Curigliano G**, Nolè F, Fazio N, Formica V, Veronesi G, de Braud F. Oral administration of vinorelbine can overcome intractable endovenous-vinorelbine-associated acute tumor pain. *Support Care Cancer*. 2005 Mar;13(3):194-5. doi: 10.1007/s00520-004-0706-2. Epub 2004 Nov 17. PMID: 15761704.

Anno 2005

54) de Braud F, De Pas T, Spaggiari L, Veronesi G, **Curigliano G**, Noverasco C, Pelosi G. Re: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. *J Natl Cancer Inst*. 2005 Mar 16;97(6):461-2; author reply 462-3. doi: 10.1093/jnci/dji076. PMID: 15770011.

55) Sessa C, De Braud F, Perotti A, Bauer J, **Curigliano G**, Noverasco C, Zanaboni F, Gianni L, Marsoni S, Jimeno J, D'Incalci M, Dall'ó E, Colombo N. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. *J Clin Oncol*. 2005 Mar 20;23(9):1867-74. doi: 10.1200/JCO.2005.09.032. PMID: 15774779.

56) Orlando L, Renne G, Rocca A, **Curigliano G**, Colleoni M, Severi G, Peruzzotti G, Cinieri S, Viale G, Sanna G, Goldhirsch A. Are all high-grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotype. *Ann Oncol*. 2005 Jul;16(7):1094-9. doi: 10.1093/annonc/mdi213. Epub 2005 Apr 26. PMID: 15855225.

57) De Pas T, Putzu C, Pelosi G, **Curigliano G**, Noverasco C, Zampino G, Fazio N, Formica V, Spaggiari L, de Braud F. Target-treatment and patients' selection: can we still neglect the timing of tissue collection? *J Clin Oncol*. 2005 Sep 1;23(25):6274-5; author reply 6275-6. doi: 10.1200/JCO.2005.01.9174. PMID: 16135503.

58) **Curigliano G**, Petit JY, Bertolini F, Colleoni M, Peruzzotti G, de Braud F, Gandini S, Giraldo A, Martella S, Orlando L, Munzone E, Pietri E, Luini A, Goldhirsch A. Systemic effects of surgery: quantitative analysis of circulating basic fibroblast growth factor (bFGF), Vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF-beta) in patients with breast cancer who underwent limited or extended surgery. *Breast Cancer Res Treat*. 2005 Sep;93(1):35-40. doi: 10.1007/s10549-005-3381-1. PMID: 16184456.

59) **Curigliano G**, Colleoni M, Mandalà M, De Pas T, Spitaleri G, de Braud F, Goldhirsch A. Prophylaxis for venous thromboembolism in cancer patients with a central vein catheter: new tones for an old song. *J Clin Oncol*. 2005 Oct 1;23(28):7243-4; author reply 7244. doi: 10.1200/JCO.2005.02.1816. PMID: 16192619.

Anno 2006

60) **Curigliano G**, Spitaleri G, Pietri E, Rescigno M, de Braud F, Cardillo A, Munzone E, Rocca A, Bonizzi G, Brichard V, Orlando L, Goldhirsch A. Breast cancer vaccines: a clinical reality or fairy tale? *Ann Oncol*. 2006 May;17(5):750-62. doi: 10.1093/annonc/mdj083. Epub 2005 Nov 17. PMID: 16293674.

61) **Curigliano G**, Formica V, De Pas T, Spitaleri G, Pietri E, Fazio N, de Braud F, Goldhirsch A. Life-threatening toxic epidermal necrolysis during voriconazole therapy for invasive aspergillosis after chemotherapy. *Ann Oncol*. 2006 Jul;17(7):1174-5. doi: 10.1093/annonc/mdj126. Epub 2006 Jan 12. PMID: 16410362.

62) Munzone E, **Curigliano G**, Rocca A, Bonizzi G, Renne G, Goldhirsch A, Nolè F. Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy. *Breast Cancer Res*.

2006;8(1):R4. doi: 10.1186/bcr1366. Epub 2005 Dec 7. Erratum in: Breast Cancer Res. 2006;8(5):407. PMID: 16417653; PMCID: PMC1413988.

63) **Curigliano G**, Magni E, Renne G, De Cobelli O, Rescigno M, Torrissi R, Spitaleri G, Pietri E, De Braud F, Goldhirsch A. "Burned out" phenomenon of the testis in retroperitoneal seminoma. *Acta Oncol.* 2006;45(3):335-6. doi: 10.1080/02841860500401175. PMID: 16644578.

64) Zampino MG, Verri E, Locatelli M, **Curigliano G**, Ascione G, Sbanotto A, Rocca A, Verweij F, Matei V, Scardino E, Decobelli O, Goldhirsch A, Nolè F. Vinorelbine-based chemotherapy in hormone-refractory prostate cancer. *Anticancer Res.* 2006 May-Jun;26(3B):2375-80. PMID: 16821619.

65) Mey V, Giovannetti E, De Braud F, Nannizzi S, **Curigliano G**, Verweij F, De Cobelli O, Pece S, Del Tacca M, Danesi R. In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. *Br J Cancer.* 2006 Aug 7;95(3):289-97. doi: 10.1038/sj.bjc.6603242. Epub 2006 Jul 25. PMID: 16868547; PMCID: PMC2360654.

66) De Pas T, Putzu C, **Curigliano G**, Noberasco C, Boselli S, Catania C, Orlando L, Milani A, Spaggiari L, de Braud F. A proper schedule of weekly paclitaxel and gemcitabine combination is highly active and very well tolerated in NSCLC patients. *Lung Cancer.* 2006 Dec;54(3):359-64. doi: 10.1016/j.lungcan.2006.08.016. Epub 2006 Oct 6. Erratum in: *Lung Cancer.* 2007 Dec;58(3):431. Sabrina, Boselli [corrected to Boselli, Sabrina]. PMID: 17028052.

67) Rocca A, Peruzzotti G, Ghisini R, Viale G, Veronesi P, Luini A, Intra M, Pietri E, **Curigliano G**, Giovanardi F, Maisonneuve P, Goldhirsch A, Colleoni M. A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer. *Anticancer Drugs.* 2006 Nov;17(10):1201-9. doi: 10.1097/01.cad.0000236306.43209.2b. PMID: 17075320.

68) **Curigliano G**, Spitaleri G, Zampino G. Treatment of rectal cancer. *N Engl J Med.* 2006 Dec 7;355(23):2487; author reply 2487-8. PMID: 17152682.

Anno 2007

69) **Curigliano G**, Pelosi G, De Pas T, Renne G, De Cobelli O, Manzotti M, Spitaleri G, de Braud F. Absence of epidermal growth factor receptor gene mutations in patients with hormone refractory prostate cancer not responding to gefitinib. *Prostate.* 2007 May 1;67(6):603-4. doi: 10.1002/pros.20530. PMID: 17290443.

70) **Curigliano G**, Balduzzi A, Cardillo A, Ghisini R, Peruzzotti G, Orlando L, Torrissi R, Dellapasqua S, Lunghi L, Goldhirsch A, Colleoni M. Low-dose aspirin for the prevention of venous thromboembolism in breast cancer patients treated with infusional chemotherapy after insertion of central vein catheter. *Support Care Cancer.* 2007 Oct;15(10):1213-7. doi: 10.1007/s00520-007-0277-0. Epub 2007 Jun 20. PMID: 17578607.

71) **Curigliano G**, Goldhirsch A. To switch or not to switch: implications of sequencing adjuvant endocrine therapy in patients with breast cancer. *Nat Clin Pract Oncol.* 2007 Sep;4(9):510-1. doi: 10.1038/ncponc0902. Epub 2007 Jul 10. PMID: 17622232.

72) Leo F, De Pas T, Catalano G, Piperno G, **Curigliano G**, Solli P, Veronesi G, Petrella F, Spaggiari L. Re: Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non small-cell lung cancer. *J Natl Cancer Inst.* 2007 Aug 1;99(15):1210; author reply 1210-1. doi: 10.1093/jnci/djm051. Epub 2007 Jul 24. PMID: 17652281.

73) De Pas T, Spitaleri G, Pruneri G, **Curigliano G**, Noberasco C, Luini A, Andreoni B, Testori A, de Braud F. Dendritic cell sarcoma: an analytic overview of the literature and presentation of original five cases. *Crit Rev Oncol Hematol.* 2008 Jan;65(1):1-7. doi: 10.1016/j.critrevonc.2007.06.003. Epub 2007 Jul 19. PMID: 17658269.

74) **Curigliano G**, De Braud F, Teresa Sandri M, Renne G, Zorzino L, Scardino E, Rocco B, Spitaleri G, De Pas T, Noberasco C, Nolè F, Verweij F, Matei V, De Cobelli O. Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity. *Anticancer Drugs.* 2007 Sep;18(8):949-54. doi: 10.1097/CAD.0b013e328136c162. PMID: 17667601.

75) **Curigliano G**, Rescigno M, Goldhirsch A. Immunology and breast cancer: therapeutic cancer vaccines. *Breast.* 2007 Dec;16 Suppl 2:S20-6. doi: 10.1016/j.breast.2007.07.004. Epub 2007 Aug 13. PMID: 17706425.

76) Rescigno M, Avogadri F, **Curigliano G**. Challenges and prospects of immunotherapy as cancer treatment. *Biochim Biophys Acta.* 2007 Sep;1776(1):108-23. doi: 10.1016/j.bbcan.2007.07.003. Epub 2007 Jul 17. PMID: 17720322.

77) Fazio N, Biffi R, **Curigliano G**, Lorusso K, Zampino MG, de Braud F, Chiappa A, Roth A, Goldhirsch A. Re: Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epirubicin in a randomized controlled trial. *J Natl Cancer Inst.* 2007 Sep 5;99(17):1345-6; author reply 1346-7. doi: 10.1093/jnci/djm092. Epub 2007 Aug 28. PMID: 17728219.

78) **Curigliano G**, Spitaleri G, Dettori M, Locatelli M, Scarano E, Goldhirsch A. Vaccine immunotherapy in breast cancer treatment: promising, but still early. *Expert Rev Anticancer Ther.* 2007 Sep;7(9):1225-41. doi: 10.1586/14737140.7.9.1225. PMID: 17892423.

79) **Curigliano G**, Spitaleri G, Fingert HJ, de Braud F, Sessa C, Loh E, Cipolla C, De Pas T, Goldhirsch A, Shah R. Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development. *Eur J Cancer.* 2008 Mar;44(4):494-500. doi: 10.1016/j.ejca.2007.10.001. Epub 2007 Nov 19. PMID: 18024014.

Anno 2008

80) De Pas T, Spitaleri G, Vigna PD, Toffalorio F, **Curigliano G**, Gambino A, Boselli S, Catania C, de Braud F. Gemcitabine-induced progressive and sustained tumour response in a patient with multi-drug resistant uterine leiomyosarcoma. *Ecancermedicalscience.* 2008;2:102. doi: 10.3332/ecancer.2008.102. Epub 2008 Nov 24. PMID: 22275981; PMCID: PMC3234072.

81) **Curigliano G**, Mandalà M, Sbanotto A, Colleoni M, Ferretti G, Bucciarelli P, Peruzzotti G, de Braud F, De Pas T, Spitaleri G, Pietri E, Orsi F, Banfi MG, Goldhirsch A. Factor v leiden mutation in patients with breast cancer with a central venous catheter: risk of deep vein thrombosis. *Support Cancer Ther.* 2006 Jan 1;3(2):98-102. doi: 10.3816/SCT.2006.n.005. PMID: 18632446.

Anno 2009

82) Pagani O, Gelber S, Simoncini E, Castiglione-Gertsch M, Price KN, Gelber RD, Holmberg SB, Crivellari D, Collins J, Lindtner J, Thürlimann B, Fey MF, Murray E, Forbes JF, Coates AS, Goldhirsch A; International Breast Cancer Study Group. Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93. *Breast Cancer Res Treat.* 2009 Aug;116(3):491-500. doi: 10.1007/s10549-008-0225-9. Epub 2008 Oct 25. PMID: 18953651; PMCID: PMC3589110.

83) De Pas T, Spitaleri G, Pelosi G, De Carlis L, Lorusso K, Locatelli M, **Curigliano G**, Toffalorio F, Catania C, de Braud F. Erlotinib combined with cyclosporine in a liver-transplant recipient with epidermal growth factor receptor-mutated non-small cell lung cancer. *J Thorac Oncol.* 2009 Jan;4(1):138-9. doi: 10.1097/JTO.0b013e31819151e5. PMID: 19096323.

84) **Curigliano G**, Spitaleri G, de Braud F, Cardinale D, Cipolla C, Civelli M, Colombo N, Colombo A, Locatelli M, Goldhirsch A. QTc prolongation assessment in anticancer drug development: clinical and methodological issues. *Ecancermedicalscience.* 2009;3:130. doi: 10.3332/ecancer.2009.130. Epub 2009 Jan 12. PMID: 22275999; PMCID: PMC3223992.

- 85) Spitaleri G, Matei DV, **Curigliano G**, Detti S, Verweij F, Zambito S, Scardino E, Rocco B, Nolè F, Ariu L, De Pas T, de Braud F, De Cobelli O. Phase II trial of estramustine phosphate and oral etoposide in patients with hormone-refractory prostate cancer. *Ann Oncol*. 2009 Mar;20(3):498-502. doi: 10.1093/annonc/mdn650. Epub 2009 Jan 12. PMID: 19139180.
- 86) **Curigliano G**, Spitaleri G, De Cobelli O, Scardino E, Sbanotto A, de Braud F. Health-related quality of life in patients with hormone refractory prostate cancer receiving gefitinib. *Urol Int*. 2009;82(2):196-202. doi: 10.1159/000200800. Epub 2009 Mar 19. PMID: 19322010.
- 87) Jereczek-Fossa BA, **Curigliano G**, Orecchia R. Systemic therapies for non- metastatic prostate cancer: review of the literature. *Onkologie*. 2009 Jun;32(6):359-63. doi: 10.1159/000215713. Epub 2009 May 14. PMID: 19521126.
- 88) Della Vigna P, Monfardini L, Bonomo G, **Curigliano G**, Agazzi A, Bellomi M, Orsi F. Coagulation disorders in patients with cancer: nontunneled central venous catheter placement with US guidance--a single-institution retrospective analysis. *Radiology*. 2009 Oct;253(1):249-52. doi: 10.1148/radiol.2531081963. Epub 2009 Jun 30. PMID: 19567651.
- 89) **Curigliano G**, Viale G, Bagnardi V, Fumagalli L, Locatelli M, Rotmensz N, Ghisini R, Colleoni M, Munzone E, Veronesi P, Zurrida S, Nolè F, Goldhirsch A. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. *J Clin Oncol*. 2009 Dec 1;27(34):5693-9. doi: 10.1200/JCO.2009.22.0962. Epub 2009 Nov 2. PMID: 19884553.
- 90) **Curigliano G**, Locatelli M, Fumagalli L, Goldhirsch A. Immunizing against breast cancer: a new swing for an old sword. *Breast*. 2009 Oct;18 Suppl 3:S51-4. doi: 10.1016/S0960-9776(09)70273-5. PMID: 19914543.
- 91) **Curigliano G**, Spitaleri G, Magni E, Lorizzo K, De Cobelli O, Locatelli M, Fumagalli L, Adamoli L, Cossu Rocca M, Verri E, De Pas T, Jereczek-Fossa B, Martinelli G, Goldhirsch A, Nolè F. Cisplatin, etoposide and continuous infusion bleomycin in patients with testicular germ cell tumors: efficacy and toxicity data from a retrospective study. *J Chemother*. 2009 Dec;21(6):687-92. doi: 10.1179/joc.2009.21.6.687. PMID: 20071294.

Anno 2010

- 92) Munzone E, Di Pietro A, Goldhirsch A, Minchella I, Verri E, Cossu Rocca M, Marengi C, **Curigliano G**, Radice D, Adamoli L, Nolè F. Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: a mono-institutional case-series report. *Breast*. 2010 Feb;19(1):33-7. doi: 10.1016/j.breast.2009.10.003. Epub 2009 Nov 1. PMID: 19884008.
- 93) Botteri E, Sandri MT, Bagnardi V, Munzone E, Zorzino L, Rotmensz N, Casadio C, Cassatella MC, Esposito A, **Curigliano G**, Salvatici M, Verri E, Adamoli L, Goldhirsch A, Nolè F. Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer. *Breast Cancer Res Treat*. 2010 Jul;122(1):211-7. doi: 10.1007/s10549-009-0668-7. Epub 2009 Dec 6. PMID: 19967556.
- 94) Noberasco C, Spitaleri G, Mancuso P, Zorzino L, Radice D, Milani A, Rocca A, Bertolini F, Sandri MT, **Curigliano G**, de Pas T, Jemos C, Omodeo Salè E, Boselli S, de Braud F. Safety, tolerability and biological effects of long-term metronomic administration of non-cytotoxic anti-angiogenic agents. *Oncology*. 2009;77(6):358-65. doi: 10.1159/000275830. Epub 2010 Jan 11. PMID: 20068365.
- 95) Orgera G, **Curigliano G**, Krokidis M, Bonomo G, Monfardini L, Della Vigna P, Zampino MG, Orsi F. High-intensity focused ultrasound effect in breast cancer nodal metastasis. *Cardiovasc Intervent Radiol*. 2010 Apr;33(2):447-9. doi: 10.1007/s00270-010-9824-z. PMID: 20162283.
- 96) **Curigliano G**. Personalizing medicine through personalized communication: individuality of the patient across borders and cultures. *J Natl Compr Canc Netw*. 2010 Mar;8(3):277-8. doi: 10.6004/jnccn.2010.0019. PMID: 20202460.
- 97) **Curigliano G**, Mayer EL, Burstein HJ, Winer EP, Goldhirsch A. Cardiac toxicity from systemic cancer therapy: a comprehensive review. *Prog Cardiovasc Dis*. 2010 Sep-Oct;53(2):94-104. doi: 10.1016/j.pcad.2010.05.006. PMID: 20728696.
- 98) **Curigliano G**, Viale G, Ghioni M, Jungbluth AA, Bagnardi V, Spagnoli GC, Neville AM, Nolè F, Rotmensz N, Goldhirsch A. Cancer-testis antigen expression in triple-negative breast cancer. *Ann Oncol*. 2011 Jan;22(1):98-103. doi: 10.1093/annonc/mdq325. Epub 2010 Jul 7. PMID: 20610479.
- 99) Johannsen M, Spitaleri G, **Curigliano G**, Roigas J, Weikert S, Kempkensteffen C, Roemer A, Kloeters C, Rogalla P, Pecher G, Miller K, Berndt A, Kosmehl H, Trachsel E, Kaspar M, Lovato V, González-Iglesias R, Giovannoni L, Menssen HD, Neri D, de Braud F. The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. *Eur J Cancer*. 2010 Nov;46(16):2926-35. doi: 10.1016/j.ejca.2010.07.033. Epub 2010 Aug 24. PMID: 20797845.
- 100) Munzone E, Nolè F, Goldhirsch A, Botteri E, Esposito A, Zorzino L, **Curigliano G**, Minchella I, Adamoli L, Cassatella MC, Casadio C, Sandri MT. Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer. *Clin Breast Cancer*. 2010 Oct 1;10(5):392-7. doi: 10.3816/CBC.2010.n.052. PMID: 20920984

Anno 2011

- 101) Farante G, Zurrida S, Galimberti V, Veronesi P, **Curigliano G**, Luini A, Goldhirsch A, Veronesi U. The management of ductal intraepithelial neoplasia (DIN): open controversies and guidelines of the Istituto Europeo di Oncologia (IEO), Milan, Italy. *Breast Cancer Res Treat*. 2011 Jul;128(2):369-78. doi: 10.1007/s10549-010-1124-4. Epub 2010 Aug 26. Erratum in: *Breast Cancer Res Treat*. 2011 Jul;128(2):379. Dosage error in article text. PMID: 20740312.
- 102) Petralia G, Bonello L, Summers P, Preda L, Malasevski A, Raimondi S, Di Filippi R, Locatelli M, **Curigliano G**, Renne G, Bellomi M. Intraobserver and interobserver variability in the calculation of apparent diffusion coefficient (ADC) from diffusion-weighted magnetic resonance imaging (DW-MRI) of breast tumours. *Radiol Med*. 2011 Apr;116(3):466-76. English, Italian. doi: 10.1007/s11547-011-0616-z. Epub 2011 Jan 12. PMID: 21225368.
- 103) Lohsiriwat V, **Curigliano G**, Rietjens M, Goldhirsch A, Petit JY. Autologous fat transplantation in patients with breast cancer: "silencing" or "fueling" cancer recurrence? *Breast*. 2011 Aug;20(4):351-7. doi: 10.1016/j.breast.2011.01.003. Epub 2011 Feb 5. PMID: 21295982.
- 104) **Curigliano G**, Bagnardi V, Viale G, Fumagalli L, Rotmensz N, Aurilio G, Locatelli M, Pruneri G, Giudici S, Bellomi M, Della Vigna P, Monfardini L, Orsi F, Nolè F, Munzone E, Goldhirsch A. Should liver metastases of breast cancer be biopsied to improve treatment choice? *Ann Oncol*. 2011 Oct;22(10):2227-33. doi: 10.1093/annonc/mdq751. Epub 2011 Feb 22. PMID: 21343379.
- 105) Macedo LT, Ribeiro J, **Curigliano G**, Fumagalli L, Locatelli M, Carvalheira JB, Quintela A, Bertelli S, De Cobelli O. Multidisciplinary approach in the treatment of patients with small cell bladder carcinoma. *Eur J Surg Oncol*. 2011 Jul;37(7):558-62. doi: 10.1016/j.ejso.2011.04.005. Epub 2011 May 8. PMID: 21555200.
- 106) Petit JY, Botteri E, Lohsiriwat V, Rietjens M, De Lorenzi F, Garusi C, Rossetto F, Martella S, Manconi A, Bertolini F, **Curigliano G**, Veronesi P, Santillo B, Rotmensz N. Locoregional recurrence risk after lipofilling in breast cancer patients. *Ann Oncol*. 2012 Mar;23(3):582-588. doi: 10.1093/annonc/mdr158. Epub 2011 May 24. PMID: 21610155.
- 107) Petit JY, Veronesi U, Lohsiriwat V, Rey P, **Curigliano G**, Martella S, Garusi C, De Lorenzi F, Manconi A, Botteri E, Didier F, Orecchia R, Rietjens M. Nipple- sparing mastectomy--is it worth the risk? *Nat Rev Clin Oncol*. 2011 Oct 25;8(12):742-7. doi: 10.1038/nrclinonc.2011.159. PMID: 22024947.

- 108) **Curigliano G.** Immunity and autoimmunity: revising the concepts of response to breast cancer. *Breast*. 2011 Oct;20 Suppl 3:S71-4. doi: 10.1016/S0960-9776(11)70298-3. PMID: 22015297.
- 109) **Curigliano G, Goldhirsch A.** The triple-negative subtype: new ideas for the poorest prognosis breast cancer. *J Natl Cancer Inst Monogr*. 2011;2011(43):108-10. doi: 10.1093/jncimonographs/lgr038. PMID: 22043054.
- 110) Berruti A, Generali D, Kaufmann M, Puztai L, **Curigliano G**, Aglietta M, Gianni L, Miller WR, Untch M, Sotiriou C, Daidone M, Conte P, Kennedy D, Damia G, Petronini P, Di Cosimo S, Bruzzi P, Dowsett M, Desmedt C, Mansel RE, Olivetti L, Tondini C, Sapino A, Fenaroli P, Tortora G, Thorne H, Bertolini F, Ferrozzi F, Danova M, Tagliabue E, de Azambuja E, Makris A, Tampellini M, Dontu G, Van't Veer L, Harris AL, Fox SB, Dogliotti L, Bottini A. International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). *J Natl Cancer Inst Monogr*. 2011;2011(43):147-51. doi: 10.1093/jncimonographs/lgr037. PMID: 22043063.
- Anno 2012**
- 111) Munzone E, **Curigliano G**, Burstein HJ, Winer EP, Goldhirsch A. CMF revisited in the 21st century. *Ann Oncol*. 2012 Feb;23(2):305-11. doi: 10.1093/annonc/mdr309. Epub 2011 Jun 29. PMID: 21715566.
- 112) **Curigliano G.** New drugs for breast cancer subtypes: targeting driver pathways to overcome resistance. *Cancer Treat Rev*. 2012 Jun;38(4):303-10. doi: 10.1016/j.ctrv.2011.06.006. Epub 2011 Jul 18. PMID: 21764517.
- 113) Ribeiro JT, Macedo LT, **Curigliano G**, Fumagalli L, Locatelli M, Dalton M, Quintela A, Carvalheira JBC, Manunta S, Mazzarella L, Brollo J, Goldhirsch A. Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: back to the future? *Ann Oncol*. 2012 Mar;23(3):547-555. doi: 10.1093/annonc/mdr382. Epub 2011 Sep 6. PMID: 21896541.
- 114) Orgera G, Krokidis M, Monfardini L, Arnone P, Bonomo G, Della Vigna P, **Curigliano G**, Orsi F. Ultrasound-guided high-intensity focused ultrasound (USgHIFU) ablation in pancreatic metastasis from renal cell carcinoma. *Cardiovasc Intervent Radiol*. 2012 Oct;35(5):1258-61. doi: 10.1007/s00270-011-0291-y. PMID: 22011784.
- 115) Botteri E, Disalvatore D, **Curigliano G**, Brollo J, Bagnardi V, Viale G, Orsi F, Goldhirsch A, Rotmensz N. Biopsy of liver metastasis for women with breast cancer: impact on survival. *Breast*. 2012 Jun;21(3):284-8. doi: 10.1016/j.breast.2011.12.014. Epub 2011 Dec 31. PMID: 22212746.
- 116) **Curigliano G**, Locatelli M, Fumagalli L, Brollo J, Munzone E, Nolè F, Criscitiello C, Goldhirsch A. Targeting the subtypes of breast cancer: rethinking investigational drugs. *Expert Opin Investig Drugs*. 2012 Feb;21(2):191-204. doi: 10.1517/13543784.2012.651456. Epub 2012 Jan 10. PMID: 22229343.
- 117) Petit JY, Veronesi U, Orecchia R, **Curigliano G**, Rey PC, Botteri E, Rotmensz N, Lohsiriwat V, Cassilha Kneubil M, Rietjens M. Risk factors associated with recurrence after nipple-sparing mastectomy for invasive and intraepithelial neoplasia. *Ann Oncol*. 2012 Aug;23(8):2053-2058. doi: 10.1093/annonc/mdr566. Epub 2012 Jan 9. PMID: 22231025.
- 118) Peccatori FA, Giovannetti E, Pistilli B, Bellettini G, Codacci-Pisanelli G, Losekoot N, **Curigliano G**, Azim HA Jr, Goldhirsch A, Peters GJ. "The only thing I know is that I know nothing": 5-fluorouracil in human milk. *Ann Oncol*. 2012 Feb;23(2):543-4. doi: 10.1093/annonc/mdr582. PMID: 22275286.
- 119) Munzone E, Botteri E, Sciandivasci A, **Curigliano G**, Nolè F, Mastropasqua M, Rotmensz N, Colleoni M, Esposito A, Adamoli L, Luini A, Goldhirsch A, Viale G. Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer. *Breast Cancer Res Treat*. 2012 Jul;134(1):277-82. doi: 10.1007/s10549-012-2040-6. Epub 2012 Apr 1. PMID: 22467243.
- 120) Munzone E, Botteri E, Esposito A, Sciandivasci A, Franchi D, Pruneri G, Rotmensz N, **Curigliano G**, Adamoli L, Bocciarelli L, Goldhirsch A, Nolè F. Outcome and clinical-biological characteristics of patients with advanced breast cancer undergoing removal of ovarian/pelvic metastases. *Ann Oncol*. 2012 Nov;23(11):2884-2890. doi: 10.1093/annonc/mds098. Epub 2012 Apr 29. PMID: 22547541.
- 121) Kneubil MC, Lohsiriwat V, **Curigliano G**, Brollo J, Botteri E, Rotmensz N, Martella S, Mastropasqua MG, Iera M, Coelho MB, Intra M, Orecchia R, Rey P, Rietjens M, Petit JY. Risk of locoregional recurrence in patients with false-negative frozen section or close margins of retroareolar specimen in nipple-sparing mastectomy. *Ann Surg Oncol*. 2012 Dec;19(13):4117-23. doi: 10.1245/s10434-012-2514-0. Epub 2012 Jul 21. PMID: 22820937.
- 122) Aurilio G, Munzone E, Botteri E, Sciandivasci A, Adamoli L, Minchella I, Esposito A, Cullurà D, **Curigliano G**, Colleoni M, Goldhirsch A, Nolè F. Oral metronomic cyclophosphamide plus fulvestrant in advanced breast cancer patients: a mono-institutional case-cohort report. *Breast J*. 2012 Sep;18(5):470-4. doi: 10.1111/j.1524-4741.2012.01278.x. Epub 2012 Jul 25. PMID: 22827581.
- 123) Munzone E, Botteri E, Sandri MT, Esposito A, Adamoli L, Zorzino L, Sciandivasci A, Cassatella MC, Rotmensz N, Aurilio G, **Curigliano G**, Goldhirsch A, Nolè F. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer. *Clin Breast Cancer*. 2012 Oct;12(5):340-6. doi: 10.1016/j.clbc.2012.07.001. PMID: 23040002.
- 124) **Curigliano G**, Cardinale D, Suter T, Platanotis G, de Azambuja E, Sandri MT, Criscitiello C, Goldhirsch A, Cipolla C, Roila F; ESMO Guidelines Working Group. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. *Ann Oncol*. 2012 Oct;23 Suppl 7:vii155-66. doi: 10.1093/annonc/mds293. PMID: 22997448.
- Anno 2013**
- 125) Brollo J, **Curigliano G**, Disalvatore D, Marrone BF, Criscitiello C, Bagnardi V, Kneubil MC, Fumagalli L, Locatelli M, Manunta S, Goldhirsch A. Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: a systematic review of randomized controlled trials. *Cancer Treat Rev*. 2013 Feb;39(1):44-50. doi:10.1016/j.ctrv.2012.03.009. Epub 2012 Apr 27. PMID: 22541668.
- 126) Andre F, Dieci MV, Dubsky P, Sotiriou C, **Curigliano G**, Denkert C, Loi S. Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. *Clin Cancer Res*. 2013 Jan 1;19(1):28-33. doi: 10.1158/1078-0432.CCR-11-2701. Epub 2012 Dec 20. PMID: 23258741.
- 127) Kneubil MC, Brollo J, Botteri E, **Curigliano G**, Rotmensz N, Goldhirsch A, Lohsiriwat V, Manconi A, Martella S, Santillo B, Petit JY, Rietjens M. Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction. *Eur J Surg Oncol*. 2013 Mar;39(3):260-5. doi: 10.1016/j.ejso.2012.12.004. Epub 2013 Jan 10. PMID: 23313014.
- 128) Aurilio G, Monfardini L, Rizzo S, Sciandivasci A, Preda L, Bagnardi V, Disalvatore D, Pruneri G, Munzone E, Della Vigna P, Renne G, Bellomi M, **Curigliano G**, Goldhirsch A, Nolè F. Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer. *Acta Oncol*. 2013 Nov;52(8):1649-56. doi: 10.3109/0284186X.2012.754990. Epub 2013 Jan 17. PMID: 23327413.
- 129) Petit JY, Rietjens M, Botteri E, Rotmensz N, Bertolini F, **Curigliano G**, Rey P, Garusi C, De Lorenzi F, Martella S, Manconi A, Barbieri B, Veronesi P, Intra M, Brambullo T, Gottardi A, Sommaro M, Lomeo G, Iera M, Giovannazzo V, Lohsiriwat V. Evaluation of fat grafting safety in patients with intraepithelial neoplasia: a matched-cohort study. *Ann Oncol*. 2013 Jun;24(6):1479-84. doi: 10.1093/annonc/mds660. Epub 2013 Feb 7. PMID: 23393126.
- 130) Criscitiello C, **Curigliano G**. HER2 signaling pathway and trastuzumab cardiotoxicity. *Future Oncol*. 2013 Feb;9(2):179-81. doi: 10.2217/fon.12.193. PMID: 23414468.

- 131) **Curigliano G.** A review of the CTRC-AACR San Antonio Breast Cancer Symposium 2012. *Ecancermedalscience*. 2013;7:291. doi: 10.3332/ecancer.2013.291. Epub 2013 Feb 11. PMID: 23441137; PMCID: PMC3575200.
- 132) Ferri N, Cazzaniga S, Mazzarella L, **Curigliano G**, Lucchini G, Zerla D, Gandolfi R, Facchetti G, Pellizzoni M, Rimoldi I. Cytotoxic effect of (1-methyl-1H-imidazol-2-yl)-methanamine and its derivatives in Pt(II) complexes on human carcinoma cell lines: a comparative study with cisplatin. *Bioorg Med Chem*. 2013 Apr 15;21(8):2379-2386. doi: 10.1016/j.bmc.2013.01.063. Epub 2013 Feb 5. PMID: 23462712.
- 133) **Curigliano G**, Criscitiello C, André F, Colleoni M, Di Leo A. Highlights from the 13th St Gallen International Breast Cancer Conference 2013. Access to innovation for patients with breast cancer: how to speed it up? *Ecancermedalscience*. 2013 Mar 26;7:299. doi: 10.3332/ecancer.2013.299. PMID: 23589728; PMCID: PMC3622446.
- 134) Brollo J, Kneubil MC, Botteri E, Rotmensz N, Duso BA, Fumagalli L, Locatelli MA, Criscitiello C, Lohsiriwat V, Goldhirsch A, Leonardi MC, Orecchia R, **Curigliano G**. Locoregional recurrence in patients with HER2 positive breast cancer. *Breast*. 2013 Oct;22(5):856-62. doi: 10.1016/j.breast.2013.03.010. Epub 2013 May 1. PMID: 23642529.
- 135) Gelao L, Criscitiello C, Fumagalli L, Locatelli M, Manunta S, Esposito A, Minchella I, Goldhirsch A, **Curigliano G**. Tumour dormancy and clinical implications in breast cancer. *Ecancermedalscience*. 2013 May 21;7:320. doi: 10.3332/ecancer.2013.320. PMID: 23717341; PMCID: PMC3660156.
- 136) Zurrida S, Bagnardi V, **Curigliano G**, Mastropasqua MG, Orecchia R, Disalvatore D, Greco M, Cataliotti L, D'Aiuto G, Talakhadze N, Goldhirsch A, Viale G. High Ki67 predicts unfavourable outcomes in early breast cancer patients with a clinically clear axilla who do not receive axillary dissection or axillary radiotherapy. *Eur J Cancer*. 2013 Oct;49(15):3083-92. doi: 10.1016/j.ejca.2013.05.007. Epub 2013 Jun 15. PMID: 23777741.
- 137) **Curigliano G**, Criscitiello C, Gelao L, Goldhirsch A. Molecular pathways: human leukocyte antigen G (HLA-G). *Clin Cancer Res*. 2013 Oct 15;19(20):5564-71. doi: 10.1158/1078-0432.CCR-12-3697. Epub 2013 Jul 29. PMID: 23897901.
- 138) Dubsy PC, **Curigliano G**. Immunotherapy in breast cancer - towards a new understanding of both tumor and host. *Breast Care (Basel)*. 2012 Aug;7(4):258-60. doi: 10.1159/000342629. PMID: 23904826; PMCID: PMC3515787.
- 139) Munzone E, **Curigliano G**, Colleoni M. Tailoring adjuvant treatments for the individual patient with luminal breast cancer. *Hematol Oncol Clin North Am*. 2013 Aug;27(4):703-14, vii-viii. doi: 10.1016/j.hoc.2013.05.012. Epub 2013 Jun 18. PMID: 23915740.
- 140) Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ; Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. *Ann Oncol*. 2013 Sep;24(9):2206-23. doi: 10.1093/annonc/mdt303. Epub 2013 Aug 4. PMID: 23917950; PMCID: PMC3755334.
- 141) Mazzarella L, Disalvatore D, Bagnardi V, Rotmensz N, Galbiati D, Caputo S, **Curigliano G**, Pelicci PG. Obesity increases the incidence of distant metastases in oestrogen receptor-negative human epidermal growth factor receptor 2-positive breast cancer patients. *Eur J Cancer*. 2013 Nov;49(17):3588-97. doi: 10.1016/j.ejca.2013.07.016. Epub 2013 Aug 15. PMID: 23953055.
- 142) **Curigliano G**, Pivot X, Cortés J, Elias A, Cesari R, Khosravan R, Collier M, Huang X, Cataruzolo PE, Kern KA, Goldhirsch A. Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer. *Breast*. 2013 Oct;22(5):650-6. doi: 10.1016/j.breast.2013.07.037. Epub 2013 Aug 17. PMID: 23958375.
- 144) Pivot X, Gligorov J, Müller V, Barrett-Lee P, Verma S, Knoop A, **Curigliano G**, Semiglazov V, López-Vivanco G, Jenkins V, Scotto N, Osborne S, Fallowfield L; PrefHer Study Group. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. *Lancet Oncol*. 2013 Sep;14(10):962-70. doi: 10.1016/S1470-2045(13)70383-8. Epub 2013 Aug 19. PMID: 23965225.
- 144) **Curigliano G**, Criscitiello C, Esposito A, Fumagalli L, Gelao L, Locatelli M, Minchella I, Goldhirsch A. Best management of locally advanced inoperable breast cancer. *EJC Suppl*. 2013 Sep;11(2):289-90. doi: 10.1016/j.ejcsup.2013.07.052. PMID: 26217148; PMCID: PMC4041552.
- 145) Wildiers H, Mauer M, Pallis A, Hurria A, Mohile SG, Luciani A, **Curigliano G**, Extermann M, Lichtman SM, Ballman K, Cohen HJ, Muss H, Wedding U. End points and trial design in geriatric oncology research: a joint European organisation for research and treatment of cancer--Alliance for Clinical Trials in Oncology-- International Society Of Geriatric Oncology position article. *J Clin Oncol*. 2013 Oct 10;31(29):3711-8. doi: 10.1200/JCO.2013.49.6125. Epub 2013 Sep 9. PMID: 24019549.
- 146) **Curigliano G**, Criscitiello C, Esposito A, Fumagalli L, Gelao L, Locatelli M, Minchella I, Goldhirsch A. Developing an effective breast cancer vaccine: challenges to achieving sterile immunity versus resetting equilibrium. *Breast*. 2013 Aug;22 Suppl 2:S96-9. doi: 10.1016/j.breast.2013.07.018. PMID: 24074802.
- 147) Criscitiello C, **Curigliano G**. Immunotherapeutics for breast cancer. *Curr Opin Oncol*. 2013 Nov;25(6):602-8. doi: 10.1097/CCO.000000000000020. PMID: 24076578.

Anno 2014

- 148) Criscitiello C, Disalvatore D, Santangelo M, Rotmensz N, Bazolli B, Maisonneuve P, Goldhirsch A, **Curigliano G**. No link between breast cancer and meningioma: results from a large monoinstitutional retrospective analysis. *Cancer Epidemiol Biomarkers Prev*. 2014 Jan;23(1):215-7. doi: 10.1158/1055-9965.EPI-13-1041. Epub 2013 Oct 28. PMID: 24165579.
- 149) Esposito A, Bardelli A, Criscitiello C, Colombo N, Gelao L, Fumagalli L, Minchella I, Locatelli M, Goldhirsch A, **Curigliano G**. Monitoring tumor-derived cell-free DNA in patients with solid tumors: clinical perspectives and research opportunities. *Cancer Treat Rev*. 2014 Jun;40(5):648-55. doi: 10.1016/j.ctrv.2013.10.003. Epub 2013 Oct 23. PMID: 24184333.
- 150) Aurilio G, Disalvatore D, Pruneri G, Bagnardi V, Viale G, **Curigliano G**, Adamoli L, Munzone E, Sciandivasci A, De Vita F, Goldhirsch A, Nolè F. A meta- analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. *Eur J Cancer*. 2014 Jan;50(2):277-89. doi: 10.1016/j.ejca.2013.10.004. Epub 2013 Nov 21. PMID: 24269135.
- 151) Criscitiello C, Disalvatore D, De Laurentiis M, Gelao L, Fumagalli L, Locatelli M, Bagnardi V, Rotmensz N, Esposito A, Minchella I, De Placido S, Santangelo M, Viale G, Goldhirsch A, **Curigliano G**. High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer. *Breast*. 2014 Feb;23(1):69-75. doi: 10.1016/j.breast.2013.11.007. Epub 2013 Dec 4. PMID: 24314620.
- 152) Criscitiello C, Esposito A, Gelao L, Fumagalli L, Locatelli M, Minchella I, Adamoli L, Goldhirsch A, **Curigliano G**. Immune approaches to the treatment of breast cancer, around the corner? *Breast Cancer Res*. 2014 Feb 25;16(1):204. doi: 10.1186/bcr3620. PMID: 25774617; PMCID: PMC3978442.
- 153) Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, Ficarra G, Mathieu MC, Delaloge S, **Curigliano G**, Andre F. Prognostic value of tumor- infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. *Ann Oncol*. 2014 Mar;25(3):611-618. doi: 10.1093/annonc/mdt556. Epub 2014 Jan 8. Erratum in: *Ann Oncol*. 2015 Jul;26(7):1518. PMID: 24401929; PMCID: PMC3933248.
- 154) Ballman KV, Mauer M, Wedding U, Mohile SG, Muss H, Extermann M, Luciani A, Cohen HJ, Hurria A, Lichtman SM, **Curigliano G**, Wildiers H. Reply to L.K. Mell et al. *J Clin Oncol*. 2014 Apr 1;32(10):1090-1. doi: 10.1200/JCO.2013.54.5236. Epub 2014 Feb 18. PMID: 24550420.

- 155) Cortés J, Curigliano G, Diéras V. Expert perspectives on biosimilar monoclonal antibodies in breast cancer. *Breast Cancer Res Treat.* 2014 Apr;144(2):233-9. doi: 10.1007/s10549-014-2879-9. Epub 2014 Feb 23. PMID: 24562824; PMCID: PMC3949011.
 - 156) Gelao L, Criscitiello C, Esposito A, Goldhirsch A, Curigliano G. Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander". *Toxins (Basel).* 2014 Mar 3;6(3):914-33. doi: 10.3390/toxins6030914. PMID: 24594636; PMCID: PMC3968368.
 - 157) Criscitiello C, Gelao L, Viale G, Esposito A, Curigliano G. Investigational platelet-derived growth factor receptor kinase inhibitors in breast cancer therapy. *Expert Opin Investig Drugs.* 2014 May;23(5):599-610. doi: 10.1517/13543784.2014.895323. Epub 2014 Mar 5. PMID: 24597540.
 - 158) Curigliano G, Criscitiello C. Successes and limitations of targeted cancer therapy in breast cancer. *Prog Tumor Res.* 2014;41:15-35. doi: 10.1159/000355896. Epub 2014 Feb 17. PMID: 24727984.
 - 159) Gelao L, Criscitiello C, Esposito A, De Laurentiis M, Fumagalli L, Locatelli MA, Minchella I, Santangelo M, De Placido S, Goldhirsch A, Curigliano G. Dendritic cell-based vaccines: clinical applications in breast cancer. *Immunotherapy.* 2014;6(3):349-60. doi: 10.2217/imt.13.169. PMID: 24762078.
 - 160) Leighl NB, Curigliano G. Early-stage lung cancer--what do the experts recommend? *Ann Oncol.* 2014 Aug;25(8):1451-3. doi: 10.1093/annonc/mdl220. Epub 2014 Jun 11. PMID: 24920789.
 - 161) Curigliano G, Perez EA. Immunoscoring breast cancer: TILs remember what they target. *Ann Oncol.* 2014 Aug;25(8):1455-6. doi: 10.1093/annonc/mdl227. Epub 2014 Jun 20. PMID: 24950980.
 - 162) Maisonneuve P, Disalvatore D, Rotmensz N, Curigliano G, Colleoni M, Dellapasqua S, Pruneri G, Mastropasqua MG, Luini A, Bassi F, Pagani G, Viale G, Goldhirsch A. Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes. *Breast Cancer Res.* 2014 Jun 20;16(3):R65. doi: 10.1186/bcr3679. PMID: 24951027; PMCID: PMC4095689.
 - 163) Criscitiello C, André F, Thompson AM, De Laurentiis M, Esposito A, Gelao L, Fumagalli L, Locatelli M, Minchella I, Orsi F, Goldhirsch A, Curigliano G. Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives. *Breast Cancer Res.* 2014;16(2):205. doi: 10.1186/bcr3630. PMID: 25032257; PMCID: PMC4052940.
 - 164) Pivot X, Gligorov J, Müller V, Curigliano G, Knoop A, Verma S, Jenkins V, Scotto N, Osborne S, Fallowfield L; PrefsHer Study Group. Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefsHer study. *Ann Oncol.* 2014 Oct;25(10):1979-1987. doi: 10.1093/annonc/mdl364. Epub 2014 Jul 28. PMID: 25070545.
 - 165) Esposito A, Criscitiello C, Salè EO, Curigliano G. Optimal adjuvant chemotherapy in breast cancer: selection of agents. *Expert Rev Clin Pharmacol.* 2014 Sep;7(5):605-11. doi: 10.1586/17512433.2014.945429. Epub 2014 Aug 1. PMID: 25080998.
 - 166) Criscitiello C, Viale G, Esposito A, Curigliano G. Dinaciclib for the treatment of breast cancer. *Expert Opin Investig Drugs.* 2014 Sep;23(9):1305-12. doi: 10.1517/13543784.2014.948152. Epub 2014 Aug 8. PMID: 25107301.
 - 167) Bouche G, André N, Banavali S, Berthold F, Berruti A, Bocci G, Brandi G, Cavallaro U, Cinieri S, Colleoni M, Curigliano G, Di Desidero T, Eniu A, Fazio N, Kerbel R, Hutchinson L, Ledzewicz U, Munzone E, Pasquier E, Graciela Scharovsky O, Shaked Y, Stérba J, Villalba M, Bertolini F. Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan. *Ecancermedicallscience.* 2014 Sep 9;8:463. doi: 10.3332/ecancer.2014.463. PMID: 25228919; PMCID: PMC4162678.
 - 168) Lammers P, Criscitiello C, Curigliano G, Jacobs I. Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging Markets. *Pharmaceuticals (Basel).* 2014 Sep 17;7(9):943-53. doi: 10.3390/ph7090943. PMID: 25232798; PMCID: PMC4190498.
 - 169) Curigliano G. 'Tu quoque Brute fili mihi!' (Julius Caesar, Ides of March, 44 BC): role of tumor microenvironment and immune system in breast cancer progression. *Curr Opin Oncol.* 2014 Nov;26(6):543-4. doi: 10.1097/CCO.0000000000000123. PMID: 25279960.
 - 170) Criscitiello C, Esposito A, Curigliano G. Tumor-stroma crosstalk: targeting stroma in breast cancer. *Curr Opin Oncol.* 2014 Nov;26(6):551-5. doi: 10.1097/CCO.0000000000000122. PMID: 25279962.
 - 171) Aurilio G, Bagnardi V, Graffeo R, Nolè F, Petit JY, Locatelli M, Martella S, Iera M, Rey P, Curigliano G, Rotmensz N, Munzone E, Goldhirsch A. Does immediate breast reconstruction after mastectomy and neoadjuvant chemotherapy influence the outcome of patients with non-endocrine responsive breast cancer? *Anticancer Res.* 2014 Nov;34(11):6677-83. PMID: 25368274.
 - 172) Curigliano G. From precision medicine to cancer care through the immunome: highlights from the European Society of Medical Oncology Congress, Madrid, 26-30th September 2014. *Ecancermedicallscience.* 2014 Oct 16;8:472. doi: 10.3332/ecancer.2014.472. PMID: 25374620; PMCID: PMC4203474.
- Anno 2015**
- 173) Locatelli M, Criscitiello C, Esposito A, Minchella I, Goldhirsch A, Cipolla C, Curigliano G. QTc prolongation induced by targeted biotherapies used in clinical practice and under investigation: a comprehensive review. *Target Oncol.* 2015 Mar;10(1):27-43. doi: 10.1007/s11523-014-0325-x. Epub 2014 Jun 27. PMID: 24970120.
 - 174) Criscitiello C, Viale G, Gelao L, Esposito A, De Laurentiis M, De Placido S, Santangelo M, Goldhirsch A, Curigliano G. Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment. *Cancer Treat Rev.* 2015 Feb;41(2):61-8. doi: 10.1016/j.ctrv.2014.12.001. Epub 2014 Dec 8. PMID: 25499997.
 - 175) Curigliano G, Disalvatore D, Esposito A, Pruneri G, Lazzaroni M, Guerrieri-Gonzaga A, Luini A, Orecchia R, Goldhirsch A, Rotmensz N, Bonanni B, Viale G. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ. *Ann Oncol.* 2015 Apr;26(4):682-687. doi: 10.1093/annonc/mdl013. Epub 2015 Jan 18. PMID: 25600567.
 - 176) Socinski MA, Curigliano G, Jacobs I, Gumbiner B, MacDonald J, Thomas D. Clinical considerations for the development of biosimilars in oncology. *MAbs.* 2015;7(2):286-93. doi: 10.1080/19420862.2015.1008346. PMID: 25621390; PMCID: PMC4623533.
 - 177) Curigliano G, Bagnardi V, Bertolini F, Alcalay M, Locatelli MA, Fumagalli L, Rabascio C, Calleri A, Adamoli L, Criscitiello C, Viale G, Goldhirsch A. Antiangiogenic therapy in recurrent breast cancer with lymphangitic spread to the chest wall: A randomized phase II trial of bevacizumab with sequential or concurrent oral vinorelbine and capecitabine. *Breast.* 2015 Jun;24(3):263-71. doi: 10.1016/j.breast.2015.02.036. Epub 2015 Mar 12. PMID: 25772326.
 - 178) Di Leo A, Curigliano G, Diéras V, Malorni L, Sotiriou C, Swanton C, Thompson A, Tutt A, Piccart M. New approaches for improving outcomes in breast cancer in Europe. *Breast.* 2015 Aug;24(4):321-30. doi: 10.1016/j.breast.2015.03.001. Epub 2015 Mar 31. PMID: 25840656.
 - 179) Ferri N, Facchetti G, Pellegrino S, Ricci C, Curigliano G, Pini E, Rimoldi I. Promising antiproliferative platinum(II) complexes based on imidazole moiety: synthesis, evaluation in HCT-116 cancer cell line and interaction with Ctr-1 Met-rich domain. *Bioorg Med Chem.* 2015 May 15;23(10):2538-47. doi: 10.1016/j.bmc.2015.03.044. Epub 2015 Mar 25. PMID: 25865132.
 - 180) Aurilio G, Bagnardi V, Nolè F, Pruneri G, Graffeo R, Petit JY, Culurà D, Martella S, Locatelli M, Iera M, Rey P, Curigliano G, Rotmensz N, Munzone E, Goldhirsch A. Outcome of Immediate Breast Reconstruction in Patients With Nonendocrine-Responsive

- Breast Cancer: A Monoinstitutional Case-Control Study. *Clin Breast Cancer*. 2015 Oct;15(5):e237-41. doi: 10.1016/j.clbc.2015.03.009. Epub 2015 Mar 24. PMID: 25908443.
- 181) Esposito A, Criscitiello C, **Curigliano G**. Highlights from the 14(th) St Gallen International Breast Cancer Conference 2015 in Vienna: Dealing with classification, prognostication, and prediction refinement to personalize the treatment of patients with early breast cancer. *Ecancermedicalscience*. 2015 Mar 31;9:518. doi: 10.3332/ecancer.2015.518. PMID: 25932042; PMCID: PMC4404037.
- 182) Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn HJ; Panel Members. Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. *Ann Oncol*. 2015 Aug;26(8):1533-46. doi: 10.1093/annonc/mdv221. Epub 2015 May 4. PMID: 25939896; PMCID: PMC4511219.
- 183) Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, Civelli M, Lamantia G, Colombo N, **Curigliano G**, Fiorentini C, Cipolla CM. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. *Circulation*. 2015 Jun 2;131(22):1981-8. doi: 10.1161/CIRCULATIONAHA.114.013777. Epub 2015 May 6. PMID: 25948538.
- 184) **Curigliano G**, Goldhirsch A. De-escalation attempts for adjuvant trastuzumab: longer beats shorter. *Ann Oncol*. 2015 Jul;26(7):1275-6. doi: 10.1093/annonc/mdv247. Epub 2015 May 22. PMID: 26002609.
- 185) Bossuyt V, Provenzano E, Symmans WF, Boughey JC, Coles C, **Curigliano G**, Dixon JM, Esserman LJ, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Viale G, Cameron D; Breast International Group-North American Breast Cancer Group (BIG-NABCG) collaboration. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG- NABCG collaboration. *Ann Oncol*. 2015 Jul;26(7):1280-91. doi: 10.1093/annonc/mdv161. Epub 2015 May 27. PMID: 26019189; PMCID: PMC4804123.
- 186) Esposito A, Criscitiello C, **Curigliano G**. Neoadjuvant Model for Testing Emerging Targeted Therapies in Breast Cancer. *J Natl Cancer Inst Monogr*. 2015 May;2015(51):51-5. doi: 10.1093/jncimonographs/lgv012. PMID: 26063887.
- 187) Amoroso V, Generali D, Buchholz T, Cristofanilli M, Pedersini R, **Curigliano G**, Daidone MG, Di Cosimo S, Dowsett M, Fox S, Harris AL, Makris A, Vassalli L, Ravelli A, Cappelletti MR, Hatzis C, Hudis CA, Pedrazzoli P, Sapino A, Semiglazov V, Von Minckwitz G, Simoncini EL, Jacobs MA, Barry P, Kühn T, Darby S, Hermelink K, Symmans F, Gennari A, Schiavon G, Dogliotti L, Berruti A, Bottini A. International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013). *J Natl Cancer Inst Monogr*. 2015 May;2015(51):90-6. doi: 10.1093/jncimonographs/lgv023. PMID: 26063896; PMCID: PMC5009414.
- 188) Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, Ficarra G, Mathieu MC, Delaloge S, **Curigliano G**, Andre F. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. *Ann Oncol*. 2015 Jul;26(7):1518. doi: 10.1093/annonc/mdv241. Erratum for: *Ann Oncol*. 2014 Mar;25(3):611-8. PMID: 26109735; PMCID: PMC5266091.
- 189) Santangelo ML, Criscitiello C, Renda A, Federico S, **Curigliano G**, Dodaro C, Scotti A, Tammaro V, Calogero A, Riccio E, Pisani A, Carlomagno N. Immunosuppression and Multiple Primary Malignancies in Kidney-Transplanted Patients: A Single-Institute Study. *Biomed Res Int*. 2015;2015:183523. doi: 10.1155/2015/183523. Epub 2015 Jun 22. PMID: 26185750; PMCID: PMC4491567.
- 190) Provenzano E, Bossuyt V, Viale G, Cameron D, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Boughey J, **Curigliano G**, Dixon JM, Esserman L, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Symmans WF; Residual Disease Characterization Working Group of the Breast International Group-North American Breast Cancer Group Collaboration. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. *Mod Pathol*. 2015 Sep;28(9):1185-201. doi: 10.1038/modpathol.2015.74. Epub 2015 Jul 24. PMID: 26205180.
- 191) Criscitiello C, Giuliano M, **Curigliano G**, De Laurentiis M, Arpino G, Carlomagno N, De Placido S, Golshan M, Santangelo M. Surgery of the primary tumor in de novo metastatic breast cancer: To do or not to do? *Eur J Surg Oncol*. 2015 Oct;41(10):1288-92. doi: 10.1016/j.ejso.2015.07.013. Epub 2015 Jul 29. PMID: 26238477.
- 192) Nailor A, Dejana E, Reynolds AR, Punwani S, **Curigliano G**, Bertolini F, Shah M, Danesi R, Kerbel R, McVie G. Lessons from the first ecancer symposium on angiogenesis in gastric cancer. *Ecancermedicalscience*. 2015 Jul 21;9:553. doi: 10.3332/ecancer.2015.553. PMID: 26284117; PMCID: PMC4531128.
- 193) Criscitiello C, **Curigliano G**. Immunotherapy of Breast Cancer. *Prog Tumor Res*. 2015;42:30-43. doi: 10.1159/000437183. Epub 2015 Sep 4. PMID: 26377084.
- 194) Esposito A, Criscitiello C, Gelao L, Pravettoni G, Locatelli M, Minchella I, Di Leo M, Liuzzi R, Milani A, Massaro M, **Curigliano G**. Mechanisms of anorexia-cachexia syndrome and rational for treatment with selective ghrelin receptor agonist. *Cancer Treat Rev*. 2015 Nov;41(9):793-7. doi: 10.1016/j.ctrv.2015.09.002. Epub 2015 Sep 11. PMID: 26386985.
- 195) Criscitiello C, Esposito A, De Placido S, **Curigliano G**. Targeting fibroblast growth factor receptor pathway in breast cancer. *Curr Opin Oncol*. 2015 Nov;27(6):452-6. doi: 10.1097/CCO.0000000000000224. PMID: 26397764.
- 196) Esposito A, Criscitiello C, **Curigliano G**. Immune checkpoint inhibitors with radiotherapy and locoregional treatment: synergism and potential clinical implications. *Curr Opin Oncol*. 2015 Nov;27(6):445-51. doi: 10.1097/CCO.0000000000000225. PMID: 26447875.
- Anno 2016**
- 197) **Curigliano G**, Valagussa P, Veronesi U, Gianni L. The influential and inspirational Gianni Bonadonna's life commitment to evidence-based cancer medicine. *Ann Oncol*. 2016 Jan;27(1):6-8. doi: 10.1093/annonc/mdv565. Epub 2015 Nov 23. PMID: 26598541.
- 198) Esposito A, Criscitiello C, Locatelli M, Milano M, **Curigliano G**. Liquid biopsies for solid tumors: Understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies. *Pharmacol Ther*. 2016 Jan;157:120-4. doi: 10.1016/j.pharmthera.2015.11.007. Epub 2015 Nov 23. PMID: 26615782.
- 199) Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Civelli M, Lamantia G, Colombo N, Cipolla CM, Veglia F, Fiorentini C, **Curigliano G**. Response to Letters Regarding Article, "Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy". *Circulation*. 2016 Jan 26;133(4):e363. doi: 10.1161/CIRCULATIONAHA.115.018780. PMID: 26811280.
- 200) Pravettoni G, Mazzocco K, Gorini A, **Curigliano G**. Understanding cognitive processes behind acceptance or refusal of phase I trials. *Crit Rev Oncol Hematol*. 2016 Apr;100:69-73. doi: 10.1016/j.critrevonc.2016.01.023. Epub 2016 Jan 23. PMID: 26852078.
- 201) Cairns L, **Curigliano G**. Highlights from the 38th SABCS annual meeting, 8th-12th December 2015, San Antonio, USA. *Ecancermedicalscience*. 2016 Feb 2;10:618. doi: 10.3332/ecancer.2016.618. PMID: 26913069; PMCID: PMC4754120.
- 202) **Curigliano G**, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D, Cipolla CM. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. *CA Cancer J Clin*. 2016 Jul;66(4):309-25. doi: 10.3322/caac.21341. Epub 2016 Feb 26. PMID: 26919165.
- 203) **Curigliano G**, Romieu G, Campone M, Dorval T, Duck L, Canon JL, Roemer-Becuwe C, Roselli M, Neciosup S, Burny W, Callegaro A, de Sousa Alves PM, Louahed J, Brichard V, Lehmann FF. A phase I/II trial of the safety and clinical activity of a HER2-

- protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer. *Breast Cancer Res Treat.* 2016 Apr;156(2):301-10. doi: 10.1007/s10549-016-3750-y. Epub 2016 Mar 14. PMID: 26975189.
- 204) Limentani SA, Campone M, Dorval T, **Curigliano G**, de Boer R, Vogel C, White S, Bachelot T, Canon JL, Disis M, Awada A, Berlière M, Amant F, Levine E, Burny W, Callegaro A, de Sousa Alves PM, Louahed J, Brichard V, Lehmann FF. A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors. *Breast Cancer Res Treat.* 2016 Apr;156(2):319-30. doi: 10.1007/s10549-016-3751-x. Epub 2016 Mar 18. PMID: 26993131.
- 205) Lenihan DJ, Hartlage G, DeCara J, Blaes A, Finet JE, Lyon AR, Cornell RF, Moslehi J, Oliveira GH, Murtagh G, Fisch M, Zeevi G, Iakobishvili Z, Witteles R, Patel A, Harrison E, Fradley M, **Curigliano G**, Lenneman CG, Magalhaes A, Krone R, Porter C, Parasher S, Dent S, Douglas P, Carver J. Cardio-Oncology Training: A Proposal From the International Cardioncology Society and Canadian Cardiac Oncology Network for a New Multidisciplinary Specialty. *J Card Fail.* 2016 Jun;22(6):465-71. doi: 10.1016/j.cardfail.2016.03.012. Epub 2016 Mar 30. PMID: 27038642.
- 206) Criscitiello C, Bagnardi V, Esposito A, Gelao L, Santillo B, Viale G, Rotmensz N, Goldhirsch A, **Curigliano G**. Impact of autoimmune diseases on outcome of patients with early breast cancer. *Oncotarget.* 2016 Aug 9;7(32):51184-51192. doi: 10.18632/oncotarget.9966. PMID: 27323400; PMCID: PMC5239468.
- 207) **Curigliano G**, Gómez Pardo P, Meric-Bernstam F, Conte P, Lolkema MP, Beck JT, Bardia A, Martínez García M, Penault-Llorca F, Dhuria S, Tang Z, Solovieff N, Miller M, Di Tomaso E, Hurvitz SA. Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study. *Breast.* 2016 Aug;28:191-8. doi: 10.1016/j.breast.2016.06.008. Epub 2016 Jun 20. PMID: 27336726.
- 208) **Curigliano G**, O'Connor DP, Rosenberg JA, Jacobs I. Biosimilars: Extrapolation for oncology. *Crit Rev Oncol Hematol.* 2016 Aug;104:131-7. doi: 10.1016/j.critrevonc.2016.06.002. Epub 2016 Jun 15. PMID: 27354233.
- 209) Criscitiello C, Bagnardi V, Viale G, Disalvatore D, Rotmensz N, Esposito A, Goldhirsch A, **Curigliano G**. HER2 Equivocal Status in Early Breast Cancer Is Not Associated with Higher Risk of Recurrence. *Anticancer Res.* 2016 Jul;36(7):3537-40. PMID: 27354620.
- 210) Pruneri G, Gray KP, Vingiani A, Viale G, **Curigliano G**, Criscitiello C, Lång I, Ruhstaller T, Gianni L, Goldhirsch A, Kammler R, Price KN, Cancellaro G, Munzone E, Gelber RD, Regan MM, Colleoni M. Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. *Breast Cancer Res Treat.* 2016 Jul;158(2):323-31. doi: 10.1007/s10549-016-3863-3. Epub 2016 Jul 2. PMID: 27372069; PMCID: PMC4977583.
- 211) Tsiatas M, Mountzios G, **Curigliano G**. Future perspectives in cancer immunotherapy. *Ann Transl Med.* 2016 Jul;4(14):273. doi: 10.21037/atm.2016.07.14. PMID: 27563660; PMCID: PMC4971381.
- 212) Zamorano JL, Lancellotti P, Rodríguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GY, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM, Zamorano JL, Aboyans V, Achenbach S, Agewall S, Badimon L, Barón-Esquivias G, Baumgartner H, Bax JJ, Bueno H, Carerj S, Dean V, Erol Ç, Fitzsimons D, Gaemperli O, Kirchhof P, Kolh P, Lancellotti P, Lip GY, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Roffi M, Torbicki A, Vaz Carneiro A, Windecker S; Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); Document Reviewers. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). *Eur J Heart Fail.* 2017 Jan;19(1):9-42. doi: 10.1002/ehjhf.654. Epub 2016 Aug 27. PMID: 27565769.
- 213) Zamorano JL, Lancellotti P, Rodríguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GYH, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM; ESC Scientific Document Group. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). *Eur Heart J.* 2016 Sep 21;37(36):2768-2801. doi: 10.1093/eurheartj/ehw211. Epub 2016 Aug 26. Erratum in: *Eur Heart J.* 2016 Dec 24;: PMID: 27567406.
- 214) Migali C, Milano M, Trapani D, Criscitiello C, Esposito A, Locatelli M, Minchella I, **Curigliano G**. Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond. *Ther Adv Med Oncol.* 2016 Sep;8(5):360-74. doi: 10.1177/1758834016658423. Epub 2016 Jul 10. PMID: 27583028; PMCID: PMC4981297.
- 215) **Curigliano G**. Being more precise in assessing the value of precision medicine in breast cancer. *Breast.* 2016 Oct;29:186-7. doi: 10.1016/j.breast.2016.08.010. PMID: 27600532.
- 216) Criscitiello C, Esposito A, Trapani D, **Curigliano G**. Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer. *Cancer Treat Rev.* 2016 Nov;50:205-207. doi: 10.1016/j.ctrv.2016.09.019. Epub 2016 Oct 6. PMID: 27744144.
- 217) D'Alesio C, Punzi S, Cicalese A, Fornasari L, Furia L, Riva L, Carugo A, **Curigliano G**, Criscitiello C, Pruneri G, Pelicci PG, Faretta M, Bossi D, Lanfranccone L. RNAi screens identify CHD4 as an essential gene in breast cancer growth. *Oncotarget.* 2016 Dec 6;7(49):80901-80915. doi: 10.18632/oncotarget.12646. PMID: 27779108; PMCID: PMC5348363.
- 218) Criscitiello C, **Curigliano G**, Burstein HJ, Wong S, Esposito A, Viale G, Giuliano M, Veronesi U, Santangelo M, Golshan M. Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity? *Eur J Surg Oncol.* 2016 Dec;42(12):1780-1786. doi: 10.1016/j.ejso.2016.10.011. Epub 2016 Oct 29. PMID: 27825710.
- Anno 2017**
- 219) Toesca A, Peradze N, Manconi A, Galimberti V, Intra M, Colleoni M, Bonanni B, **Curigliano G**, Rietjens M, Viale G, Sacchini V, Veronesi P. Robotic nipple-sparing mastectomy for the treatment of breast cancer: Feasibility and safety study. *Breast.* 2017 Feb;31:51-56. doi: 10.1016/j.breast.2016.10.009. Epub 2016 Nov 2. PMID: 27810700; PMCID: PMC5278881.
- 220) **Curigliano G**, Criscitiello C, Esposito A, Pruneri G. Over-using chemotherapy in the adjuvant setting. *Breast.* 2017 Feb;31:303-308. doi: 10.1016/j.breast.2016.11.011. Epub 2016 Nov 17. PMID: 27866835.
- 221) **Curigliano G**, Cardoso F, Costa A, Galimberti V, Goldhirsch A, Pelicci PG, Veronesi P, Viale G, Orecchia R. From the maximum tolerable to the minimum effective treatment: The Umberto Veronesi's life commitment to breast cancer care. *Breast.* 2017 Feb;31:241-243. doi: 10.1016/j.breast.2016.11.013. Epub 2016 Nov 19. PMID: 27876474.
- 222) Locatelli MA, Aftimos P, Dees EC, LoRusso PM, Pegram MD, Awada A, Huang B, Cesari R, Jiang Y, Shaik MN, Kern KA, **Curigliano G**. Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer. *Oncotarget.* 2017 Jan 10;8(2):2320-2328. doi: 10.18632/oncotarget.13727. PMID: 27906684; PMCID: PMC5356802.
- 223) Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, **Curigliano G**, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E. 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). *Breast.* 2017 Feb;31:244-259. doi: 10.1016/j.breast.2016.10.001. Epub 2016 Dec 5. Erratum in: *Breast.* 2017 Apr;32:269-270. PMID: 27927580.

- 224) Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, **Curigliano G**, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E. Corrigendum to "3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)" [Breast 31 (February 2017) 244-259]. *Breast*. 2017 Apr;32:269-270. doi: 10.1016/j.breast.2017.01.001. Epub 2017 Jan 18. Erratum for: *Breast*. 2017 Feb;31:244-259. PMID: 28109648.
- 225) Esposito A, Criscitiello C, Trapani D, **Curigliano G**. The Emerging Role of "Liquid Biopsies," Circulating Tumor Cells, and Circulating Cell-Free Tumor DNA in Lung Cancer Diagnosis and Identification of Resistance Mutations. *Curr Oncol Rep*. 2017 Jan;19(1):1. doi: 10.1007/s11912-017-0564-y. PMID: 28110461.
- 226) Higgins M, **Curigliano G**, Dieras V, Kuemmel S, Kunz G, Fasching PA, Campone M, Bachelot T, Krivorotko P, Chan S, Ferro A, Schwartzberg L, Gillet M, De Sousa Alves PM, Wascotte V, Lehmann FF, Goss P. Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study. *Breast Cancer Res Treat*. 2017 Apr;162(3):479-488. doi: 10.1007/s10549-017-4130-y. Epub 2017 Feb 7. PMID: 28176175; PMCID: PMC5332485.
- 227) Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, **Curigliano G**, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). *Ann Oncol*. 2017 Jan 1;28(1):16-33. doi: 10.1093/annonc/mdw544. Erratum in: *Ann Oncol*. 2017 Dec 1;28(12):3111. PMID: 28177437; PMCID: PMC5378224.
- 228) Roviello G, Bachelot T, Hudis CA, **Curigliano G**, Reynolds AR, Petrioli R, Generali D. The role of bevacizumab in solid tumours: A literature based meta-analysis of randomised trials. *Eur J Cancer*. 2017 Apr;75:245-258. doi: 10.1016/j.ejca.2017.01.026. Epub 2017 Feb 24. PMID: 28242502.
- 229) Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, **Curigliano G**, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). *Ann Oncol*. 2017 Dec 1;28(12):3111. doi: 10.1093/annonc/mdx036. Erratum for: *Ann Oncol*. 2017 Jan 1;28(1):16-33. PMID: 28327998; PMCID: PMC5834023.
- 230) Hendrickx W, Simeone I, Anjum S, Mokrab Y, Bertucci F, Finetti P, **Curigliano G**, Seliger B, Cerulo L, Tomei S, Delogu LG, Maccalli C, Wang E, Miller LD, Marincola FM, Ceccarelli M, Bedognetti D. Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. *Oncoimmunology*. 2017 Feb 6;6(2):e1253654. doi: 10.1080/2162402X.2016.1253654. PMID: 28344865; PMCID: PMC5353940.
- 231) Meattini I, **Curigliano G**, Terziani F, Becherini C, Airoldi M, Allegrini G, Amoroso D, Barni S, Bengala C, Guarneri V, Marchetti P, Martella F, Piovano P, Vannini A, Desideri I, Tarquini R, Galanti G, Barletta G, Livi L. SAFE trial: an ongoing randomized clinical study to assess the role of cardiotoxicity prevention in breast cancer patients treated with anthracyclines with or without trastuzumab. *Med Oncol*. 2017 May;34(5):75. doi: 10.1007/s12032-017-0938-x. Epub 2017 Mar 31. PMID: 28364270.
- 232) **Curigliano G**, Criscitiello C, Esposito A, Intra M, Minucci S. Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer. *Expert Opin Drug Metab Toxicol*. 2017 May;13(5):575-581. doi: 10.1080/17425255.2017.1318848. Epub 2017 Apr 21. PMID: 28395543.
- 233) Pruneri G, Lazzeroni M, Bagnardi V, Tiburzio GB, Rotmensz N, DeCensi A, Guerrieri-Gonzaga A, Vingiani A, **Curigliano G**, Zurrada S, Bassi F, Salgado R, Van den Eynden G, Loi S, Denkert C, Bonanni B, Viale G. The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast. *Ann Oncol*. 2017 Feb 1;28(2):321-328. doi: 10.1093/annonc/mdw623. PMID: 28426105.
- 234) **Curigliano G**, Goldhirsch A. Dual HER2 inhibition and pathological complete response in early breast cancer: increasing success of treatment by improving patient selection. *Ann Oncol*. 2017 Mar 1;28(3):441-443. doi: 10.1093/annonc/mdx016. PMID: 28426119.
- 235) Gligorov J, **Curigliano G**, Müller V, Knoop A, Jenkins V, Verma S, Osborne S, Lauer S, Machackova Z, Fallowfield L, Pivot X. Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial. *Breast*. 2017 Aug;34:89-95. doi: 10.1016/j.breast.2017.05.004. Epub 2017 May 23. PMID: 28549309.
- 236) **Curigliano G**, Criscitiello C. Maximizing the Clinical Benefit of Anthracyclines in Addition to Taxanes in the Adjuvant Treatment of Early Breast Cancer. *J Clin Oncol*. 2017 Aug 10;35(23):2600-2603. doi: 10.1200/JCO.2017.72.5960. Epub 2017 Jun 29. PMID: 28661760.
- 237) Trapani D, Esposito A, Criscitiello C, Mazzarella L, Locatelli M, Minchella I, Minucci S, **Curigliano G**. Entinostat for the treatment of breast cancer. *Expert Opin Investig Drugs*. 2017 Aug;26(8):965-971. doi: 10.1080/13543784.2017.1353077. Epub 2017 Jul 24. PMID: 28718331.
- 238) **Curigliano G**, Cardoso F. Breast cancer mortality in European Union: An outlook of good news and bad news in a two-speed Europe! *Breast*. 2017 Dec;36:86-88. doi: 10.1016/j.breast.2017.07.010. Epub 2017 Jul 19. PMID: 28734762.
- 239) Viale G, Trapani D, **Curigliano G**. Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy. *Biomed Res Int*. 2017;2017:4719194. doi: 10.1155/2017/4719194. Epub 2017 Jul 10. PMID: 28770222; PMCID: PMC5523547.
- 240) Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, **Curigliano G**, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Hortlings RH, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltneane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB. Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. *Adv Anat Pathol*. 2017 Sep;24(5):235-251. doi: 10.1097/PAP.000000000000162. PMID: 28777142; PMCID: PMC5564448.
- 241) Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S,

- Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, **Curigliano G**, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB. Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. *Adv Anat Pathol.* 2017 Nov;24(6):311-335. doi: 10.1097/PAP.0000000000000161. PMID: 28777143; PMCID: PMC5638696.
- 242) **Curigliano G**. How to Achieve Optimal Care in Early Breast Cancer with 'Less' or 'More' Treatment. *Breast Care (Basel).* 2017 Jul;12(3):136-137. doi: 10.1159/000478652. Epub 2017 Jun 27. PMID: 28785179; PMCID: PMC5527166.
- 243) Locatelli MA, **Curigliano G**, Eniu A. Extended Adjuvant Chemotherapy in Triple-Negative Breast Cancer. *Breast Care (Basel).* 2017 Jul;12(3):152-158. doi: 10.1159/000478087. Epub 2017 Jun 27. PMID: 28785182; PMCID: PMC5527164.
- 244) **Curigliano G**, Burstein HJ, Winer EP, Gnant M, Dubsy P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B; St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Hussein K, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. *Ann Oncol.* 2017 Aug 1;28(8):1700-1712. doi: 10.1093/annonc/mdx308. Erratum in: *Ann Oncol.* 2018 Oct 1;29(10):2153. Erratum in: *Ann Oncol.* 2019 Jan 9; Erratum in: *Ann Oncol.* 2019 Jul;30(7):1181. PMID: 28838210; PMCID: PMC6246241.
- 245) Criscitiello C, Viale G, **Curigliano G**. Extending indication of cyclin-dependent kinase 4/6 inhibitors in the adjuvant and neoadjuvant setting. *Curr Opin Oncol.* 2017 Nov;29(6):428-433. doi: 10.1097/CCO.0000000000000401. PMID: 28872469.
- 246) Locatelli M, **Curigliano G**. Notch inhibitors and their role in the treatment of triple negative breast cancer: promises and failures. *Curr Opin Oncol.* 2017 Nov;29(6):411-427. doi: 10.1097/CCO.0000000000000406. PMID: 28914645.
- 247) Bellomi M, De Piano F, Ancona E, Lodigiani AF, **Curigliano G**, Raimondi S, Preda L. Evaluation of inter-observer variability according to RECIST 1.1 and its influence on response classification in CT measurement of liver metastases. *Eur J Radiol.* 2017 Oct;95:96-101. doi: 10.1016/j.ejrad.2017.08.001. Epub 2017 Aug 4. PMID: 28987705.
- 248) Roviello G, Andre F, Venturini S, Pistilli B, **Curigliano G**, Cristofanilli M, Rosellini P, Generali D. Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies. *Eur J Cancer.* 2017 Nov;86:257-265. doi: 10.1016/j.ejca.2017.09.018. Epub 2017 Oct 19. PMID: 29055841.
- 249) de Melo Gagliato D, Cortes J, **Curigliano G**, Loi S, Denkert C, Perez-Garcia J, Holgado E. Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice. *Biochim Biophys Acta Rev Cancer.* 2017 Dec;1868(2):527-537. doi: 10.1016/j.bbcan.2017.10.003. Epub 2017 Oct 20. PMID: 29061314.
- 250) Criscitiello C, Bagnardi V, Pruneri G, Vingiani A, Esposito A, Rotmensz N, **Curigliano G**. Prognostic value of tumour-infiltrating lymphocytes in small HER2-positive breast cancer. *Eur J Cancer.* 2017 Dec;87:164-171. doi: 10.1016/j.ejca.2017.10.011. Epub 2017 Nov 15. PMID: 29154173.
- Anno 2018**
- 251) Dubsy P, **Curigliano G**, Burstein HJ, Winer EP, Gnant M, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B; Panel Members of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B. Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al. *Ann Oncol.* 2018 Jan 1;29(1):281-282. doi: 10.1093/annonc/mdx543. PMID: 29045519; PMCID: PMC6246427.
- 252) Criscitiello C, Bayar MA, **Curigliano G**, Symmans FW, Desmedt C, Bonnefoi H, Sinn B, Pruneri G, Vicier C, Pierga JY, Denkert C, Loibl S, Sotiriou C, Michiels S, André F. A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer. *Ann Oncol.* 2018 Jan 1;29(1):162-169. doi: 10.1093/annonc/mdx691. PMID: 29077781.
- 253) Di Cosimo S, Campbell C, Azim HA Jr, Galli G, Bregni G, **Curigliano G**, Criscitiello C, Izquierdo M, de la Pena L, Fumagalli D, Fein L, Vinhou J, Ng WMJ, Colleoni M, Ferro A, Naume BJ, Patel A, Huober J, Piccart-Gebhart MJ, Baselga J, de Azambuja E. The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO. *Eur J Cancer.* 2018 Jan;89:42-48. doi: 10.1016/j.ejca.2017.10.036. Epub 2017 Dec 8. PMID: 29227816; PMCID: PMC5777154.
- 254) Botteri E, Krendyukov A, **Curigliano G**. Comparing granulocyte colony-stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: A meta-analysis of randomised clinical trials in breast cancer patients. *Eur J Cancer.* 2018 Jan;89:49-55. doi: 10.1016/j.ejca.2017.10.034. Epub 2017 Dec 8. PMID: 29227817.
- 255) Duso BA, Trapani D, Viale G, Criscitiello C, D'Amico P, Belli C, Mazzarella L, Locatelli M, Minchella I, **Curigliano G**. Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer. *Expert Opin Pharmacother.* 2018 Feb;19(3):299-305. doi: 10.1080/14656566.2018.1429407. Epub 2018 Jan 22. PMID: 29355400.
- 256) Cardoso F, **Curigliano G**. A rude awakening from tumour cells. *Nature.* 2018 Feb;554(7690):35-36. doi: 10.1038/d41586-018-01140-z. PMID: 32094835.
- 257) Cardoso F, **Curigliano G**. A rude awakening from tumour cells. *Nature.* 2018 Feb 1;554(7690):35-36. doi: 10.1038/d41586-018-01140-z. PMID: 29388969.
- 258) Mazzarella L, **Curigliano G**. A new approach to assess drug sensitivity in cells for novel drug discovery. *Expert Opin Drug Discov.* 2018 Apr;13(4):339-346. doi: 10.1080/17460441.2018.1437136. Epub 2018 Feb 7. PMID: 29415581.
- 259) Criscitiello C, Viale G, **Curigliano G**, Goldhirsch A. Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date. *Breast Cancer (Dove Med Press).* 2018 Jan 30;10:23-29. doi: 10.2147/BCTT.S134641. Erratum in: *Breast Cancer (Dove Med Press).* 2018 Mar 16;10 :51. PMID: 29430197; PMCID: PMC5796458.
- 260) Wildiers H, Tryfonidis K, Dal Lago L, Vuylsteke P, **Curigliano G**, Waters S, Brouwers B, Altintas S, Touati N, Cardoso F, Brain E. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic

breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group. *Lancet Oncol.* 2018 Mar;19(3):323-336. doi: 10.1016/S1470-2045(18)30083-4. Epub 2018 Feb 9. PMID: 29433963.

261) **Curigliano G.** Addition of platinum salts to neoadjuvant chemotherapy in triple-negative breast cancer: a new standard of care? *Lancet Oncol.* 2018 Apr;19(4):434-436. doi: 10.1016/S1470-2045(18)30129-3. Epub 2018 Feb 28. Erratum in: *Lancet Oncol.* 2018 Apr;19(4):e184. PMID: 29501365.

262) Belli C, Trapani D, Viale G, D'Amico P, Duso BA, Della Vigna P, Orsi F, **Curigliano G.** Targeting the microenvironment in solid tumors. *Cancer Treat Rev.* 2018 Apr;65:22-32. doi: 10.1016/j.ctrv.2018.02.004. Epub 2018 Feb 22. PMID: 29502037.

263) Mazzarella L, Guida A, **Curigliano G.** Cetuximab for treating non-small cell lung cancer. *Expert Opin Biol Ther.* 2018 Apr;18(4):483-493. doi: 10.1080/14712598.2018.1452906. PMID: 29534625.

264) Cardinale D, Ciceri F, Latini R, Franzosi MG, Sandri MT, Civelli M, Cucchi G, Menatti E, Mangiavacchi M, Cavina R, Barbieri E, Gori S, Colombo A, **Curigliano G,** Salvatici M, Rizzo A, Ghisoni F, Bianchi A, Falci C, Aquilina M, Rocca A, Monopoli A, Milandri C, Rossetti G, Bregni M, Sicuro M, Malossi A, Nassiados D, Verusio C, Giordano M, Staszewsky L, Barlera S, Nicolis EB, Magnoli M, Masson S, Cipolla CM; ICOS-ONE Study Investigators. Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society- one trial. *Eur J Cancer.* 2018 May;94:126-137. doi: 10.1016/j.ejca.2018.02.005. Epub 2018 Mar 20. PMID: 29567630.

265) **Curigliano G,** Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B, André F, Baselga J, Bergh J, Bonnefoi H, Brucker SY, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlersen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Khaled H, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tull A, Viale G, Watanabe T, Whelan TJ, Xu B. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. *Ann Oncol.* 2018 Oct 1;29(10):2153. doi: 10.1093/annonc/mdx806. Erratum for: *Ann Oncol.* 2017 Aug 1;28(8):1700-1712. PMID: 29733336; PMCID: PMC6887963.

266) Criscitiello C, Golshan M, Barry WT, Viale G, Wong S, Santangelo M, **Curigliano G.** Impact of neoadjuvant chemotherapy and pathological complete response on eligibility for breast-conserving surgery in patients with early breast cancer: A meta-analysis. *Eur J Cancer.* 2018 Jul;97:1-6. doi: 10.1016/j.ejca.2018.03.023. Epub 2018 May 17. PMID: 29734046.

267) **Curigliano G.** Gyneco-oncological genomics and emerging biomarkers for cancer treatment with immune-checkpoint inhibitors. *Semin Cancer Biol.* 2018 Oct;52(Pt 2):253-258. doi: 10.1016/j.semcancer.2018.05.004. Epub 2018 May 27. PMID: 29775688.

268) Cardoso F, **Curigliano G.** The PROMISE to increase precision in adjuvant therapy for early breast cancer: To "Type" or to "Print"? *NPJ Breast Cancer.* 2018 May 22;4:12. doi: 10.1038/s41523-018-0064-8. PMID: 29845111; PMCID: PMC5964184.

269) Janjigian YY, Bissig M, **Curigliano G,** Coppola J, Latymer M. Talking to patients about biosimilars. *Future Oncol.* 2018 Oct;14(23):2403-2414. doi: 10.2217/fon-2018-0044. Epub 2018 Jun 1. PMID: 29856243.

270) Malorni L, **Curigliano G,** Minisini AM, Cinieri S, Tondini CA, D'Hollander K, Arpino G, Bernardo A, Martignetti A, Criscitiello C, Puglisi F, Pestrin M, Sanna G, Moretti E, Risi E, Biagioni C, McCartney A, Boni L, Buyse M, Migliaccio I, Biganzoli L, Di Leo A. Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TReND trial. *Ann Oncol.* 2018 Aug 1;29(8):1748-1754. doi: 10.1093/annonc/mdy214. PMID: 29893790; PMCID: PMC6454527.

271) Calabrò MG, **Curigliano G.** Edoxaban for Cancer-Associated Venous Thromboembolism. *N Engl J Med.* 2018 Jul 5;379(1):93. doi: 10.1056/NEJMc1806646. PMID: 29975029.

272) Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, Harbeck N, Aguilar Lopez B, Barrios CH, Bergh J, Biganzoli L, Boers-Doets CB, Cardoso MJ, Carey LA, Cortés J, **Curigliano G,** Diéras V, El Saghir NS, Eniu A, Fallowfield L, Francis PA, Gelmon K, Johnston SRD, Kaufman B, Koppikar S, Krop IE, Mayer M, Nakigudde G, Offersen BV, Ohno S, Pagani O, Paluch-Shimon S, Penault-Llorca F, Prat A, Rugo HS, Sledge GW, Spence D, Thomssen C, Vorobiof DA, Xu B, Norton L, Winer EP. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†. *Ann Oncol.* 2018 Aug 1;29(8):1634-1657. doi: 10.1093/annonc/mdy192. PMID: 30032243; PMCID: PMC7360146.

273) **Curigliano G.** Inflammatory breast cancer and chest wall disease: The oncologist perspective. *Eur J Surg Oncol.* 2018 Aug;44(8):1142-1147. doi: 10.1016/j.ejso.2018.05.019. Epub 2018 May 22. PMID: 30032791.

274) Rubio IT, Wyld L, Cardoso F, **Curigliano G,** Kovacs T, Poortmans P, Cortes J. Perspectives on preoperative systemic treatment and breast conservative surgery: One step forward or two steps back? *Breast.* 2018 Oct;41:133-135. doi: 10.1016/j.breast.2018.07.008. Epub 2018 Jul 23. PMID: 30056250.

275) Rodon J, **Curigliano G,** Delord JP, Harb W, Azaro A, Han Y, Wilke C, Donnet V, Sellami D, Beck T. A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors. *Oncotarget.* 2018 Aug 3;9(60):31709-31718. doi: 10.18632/oncotarget.25854. PMID: 30167089; PMCID: PMC6114962.

276) Lambertini M, Di Maio M, Pagani O, **Curigliano G,** Poggio F, Del Mastro L, Paluch-Shimon S, Loibl S, Partridge AH, Demeestere I, Azim HA Jr, Peccatori FA. The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients. *Breast.* 2018 Dec;42:41-49. doi: 10.1016/j.breast.2018.08.099. Epub 2018 Aug 22. PMID: 30170202.

277) Galimberti V, Cole BF, Viale G, Veronesi P, Vicini E, Intra M, Mazzarol G, Massarut S, Zgajnar J, Taffurelli M, Littlejohn D, Knauer M, Tondini C, Di Leo A, Colleoni M, Regan MM, Coates AS, Gelber RD, Goldhirsch A; International Breast Cancer Study Group Trial 23-01. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. *Lancet Oncol.* 2018 Oct;19(10):1385-1393. doi: 10.1016/S1470-2045(18)30380-2. Epub 2018 Sep 5. PMID: 30196031.

278) Hofstädter-Thalmann E, Dafni U, Allen T, Arnold D, Banerjee S, **Curigliano G,** Garralda E, Garassino MC, Haanen J, Robert C, Sessa C, Tsourtis Z, Zygoura P, Peters S. Report on the status of women occupying leadership roles in oncology. *ESMO Open.* 2018 Sep 21;3(6):e000423. doi: 10.1136/esmoopen-2018-000423. PMID: 30273418; PMCID: PMC6157529.

279) Banerjee S, Dafni U, Allen T, Arnold D, **Curigliano G,** Garralda E, Garassino MC, Haanen J, Hofstädter-Thalmann E, Robert C, Sessa C, Tsourtis Z, Zygoura P, Peters S. Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey. *ESMO Open.* 2018 Sep 21;3(6):e000422. doi: 10.1136/esmoopen-2018-000422. PMID: 30273420; PMCID: PMC6157518.

280) **Curigliano G.** Targeting DNA Repair. *Handb Exp Pharmacol.* 2018;249:161-180. doi: 10.1007/164_2017_31. PMID: 30341723.

281) **Curigliano G.** Cancer Evolution as the New Frontier of Precision Medicine. *Handb Exp Pharmacol.* 2018;249:289-297. doi: 10.1007/164_2018_147. PMID: 30406442.

282) Belli C, Zuin M, Mazzarella L, Trapani D, D'Amico P, Guerini-Rocco E, Achutti Duso B, **Curigliano G**. Liver toxicity in the era of immune checkpoint inhibitors: A practical approach. *Crit Rev Oncol Hematol*. 2018 Dec;132:125-129. doi: 10.1016/j.critrevonc.2018.09.019. Epub 2018 Oct 3. PMID: 30447917.

Anno 2019

283) Esposito A, Viale G, Criscitiello C, **Curigliano G**. A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancer. *Expert Rev Clin Pharmacol*. 2019 Jan;12(1):9-16. doi: 10.1080/17512433.2019.1552134. Epub 2018 Dec 4. PMID: 30466330.

284) Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cescon DW, Iwata H, Campone M, Nanda R, Hui R, **Curigliano G**, Toppmeyer D, O'Shaughnessy J, Loi S, Paluch-Shimon S, Tan AR, Card D, Zhao J, Karantz V, Cortés J. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. *Ann Oncol*. 2019 Mar 1;30(3):397-404. doi: 10.1093/annonc/mdy517. PMID: 30475950.

285) Zucchetti B, Shimada AK, Katz A, **Curigliano G**. The role of histone deacetylase inhibitors in metastatic breast cancer. *Breast*. 2019 Feb;43:130-134. doi: 10.1016/j.breast.2018.12.001. Epub 2018 Dec 6. PMID: 30553187.

286) Luen SJ, Salgado R, Dieci MV, Vingiani A, **Curigliano G**, Gould RE, Castaneda C, D'Alfonso T, Sanchez J, Cheng E, Andreopoulou E, Castillo M, Adams S, Demaria S, Symmans WF, Michiels S, Loi S. Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy. *Ann Oncol*. 2019 Feb 1;30(2):236-242. doi: 10.1093/annonc/mdy547. PMID: 30590484.

287) **Curigliano G**, Burstein HJ, P Winer E, Gnant M, Dubsy P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B; Panel Members of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. *Ann Oncol*. 2019 Jul 1;30(7):1181. doi: 10.1093/annonc/mdy537. Erratum for: *Ann Oncol*. 2017 Aug 1;28(8):1700-1712. PMID: 30624592; PMCID: PMC6637369.

288) Shah RR, **Curigliano G**. Safety of Novel Targeted Therapies in Oncology. *Drug Saf*. 2019 Feb;42(2):157-158. doi: 10.1007/s40264-018-0770-z. PMID: 30649739.

289) **Curigliano G**, Shah RR. Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology. *Drug Saf*. 2019 Feb;42(2):247-262. doi: 10.1007/s40264-018-0778-4. PMID: 30649751.

290) Morganti S, Tarantino P, Ferraro E, D'Amico P, Viale G, Trapani D, Duso BA, **Curigliano G**. Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life. *Crit Rev Oncol Hematol*. 2019 Jan;133:171-182. doi: 10.1016/j.critrevonc.2018.11.008. Epub 2018 Nov 26. PMID: 30661654.

291) Fogli S, Del Re M, **Curigliano G**, van Schaik RH, Lancellotti P, Danesi R. Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors. *Cancer Treat Rev*. 2019 Mar;74:21-28. doi: 10.1016/j.ctrv.2019.01.006. Epub 2019 Jan 19. Erratum in: *Cancer Treat Rev*. 2019 Dec;81:101913. PMID: 30685576.

292) Cardoso MJ, Wyld L, Rubio IT, Leidenius M, **Curigliano G**, Cutuli B, Marotti L, Biganzoli L. EUSOMA position regarding breast implant associated anaplastic large cell lymphoma (BIA-ALCL) and the use of textured implants. *Breast*. 2019 Apr;44:90-93. doi: 10.1016/j.breast.2019.01.011. Epub 2019 Jan 26. Erratum in: *Breast*. 2019 Dec;48:102. PMID: 30703669.

293) Loi S, Giobbie-Hurder A, Gombos A, Bachelot T, Hui R, **Curigliano G**, Campone M, Biganzoli L, Bonnefoi H, Jerusalem G, Bartsch R, Rabaglio-Poretti M, Kammiller R, Maibach R, Smyth MJ, Di Leo A, Colleoni M, Viale G, Regan MM, André F; International Breast Cancer Study Group and the Breast International Group. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. *Lancet Oncol*. 2019 Mar;20(3):371-382. doi: 10.1016/S1470-2045(18)30812-X. Epub 2019 Feb 11. PMID: 30765258.

294) Criscitiello C, Viale G, **Curigliano G**. Peptide vaccines in early breast cancer. *Breast*. 2019 Apr;44:128-134. doi: 10.1016/j.breast.2019.02.003. Epub 2019 Feb 7. PMID: 30769238.

295) Bachelot T, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Bondarenko I, Paluch-Shimon S, Wardley A, Merot JL, du Toit Y, Easton V, Lindegger N, Miles D; PERUSE investigators. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). *Ann Oncol*. 2019 May 1;30(5):766-773. doi: 10.1093/annonc/mdz061. PMID: 30796821.

296) Belli C, Duso BA, Ferraro E, **Curigliano G**. Homologous recombination deficiency in triple negative breast cancer. *Breast*. 2019 Jun;45:15-21. doi: 10.1016/j.breast.2019.02.007. Epub 2019 Feb 20. PMID: 30818144.

297) Tarantino P, **Curigliano G**. Defining the immunogram of breast cancer: a focus on clinical trials. *Expert Opin Biol Ther*. 2019 May;19(5):383-385. doi: 10.1080/14712598.2019.1598372. Epub 2019 Apr 1. PMID: 30892954.

298) Lambertini M, Di Maio M, Poggio F, Pagani O, **Curigliano G**, Mastro LD, Paluch-Shimon S, Loibl S, Partridge AH, Azim HA Jr, Peccatori FA, Demeestere I. Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in youngBRCA-mutated breast cancer patients. *Reprod Biomed Online*. 2019 May;38(5):835-844. doi: 10.1016/j.rbmo.2018.11.031. Epub 2019 Jan 10. PMID: 30914152.

299) Esposito A, Viale G, **Curigliano G**. Safety, Tolerability, and Management of Toxic Effects of Phosphatidylinositol 3-Kinase Inhibitor Treatment in Patients With Cancer: A Review. *JAMA Oncol*. 2019 Sep 1;5(9):1347-1354. doi: 10.1001/jamaoncol.2019.0034. PMID: 30920609.

300) Marra A, **Curigliano G**. T-cell bispecific antibodies to bypass MHC class I loss in breast cancer. *Ann Oncol*. 2019 Jun 1;30(6):877-879. doi: 10.1093/annonc/mdz115. PMID: 30938431.

301) Elgendy M, Cirò M, Hosseini A, Weizmann J, Mazzarella L, Ferrari E, Cazzoli R, **Curigliano G**, DeCensi A, Bonanni B, Budillon A, Pelicci PG, Janssens V, Ogris M, Baccarini M, Lanfranccone L, Weckwerth W, Foiani M, Minucci S. Combination of Hypoglycemia and Metformin Impairs Tumor Metabolic Plasticity and Growth by Modulating the PP2A-GSK3B-MCL-1 Axis. *Cancer Cell*. 2019 May 13;35(5):798-815.e5. doi: 10.1016/j.ccell.2019.03.007. Epub 2019 Apr 25. PMID: 31031016.

302) **Curigliano G**, de Azambuja E, Lenihan D, Calabrò MG, Cardinale D, Cipolla CM. Prevention, Monitoring, and Management of Cardiac Dysfunction in Patients with Metastatic Breast Cancer. *Oncologist*. 2019 Nov;24(11):e1034-e1043. doi: 10.1634/theoncologist.2018-0773. Epub 2019 May 7. PMID: 31064888; PMCID: PMC6853111.

303) Marra A, Viale G, **Curigliano G**. Recent advances in triple negative breast cancer: the immunotherapy era. *BMC Med*. 2019 May 9;17(1):90. doi: 10.1186/s12916-019-1326-5. PMID: 31068190; PMCID: PMC6507064.

304) Cardoso MJ, Biganzoli L, Rubio IT, M L, G C, B C, L M, Kovacs T, Wyld L. About the French prohibition of textured breast implants: is it justified or over-cautious? The EUSOMA, ESSO/BRESSO position. *Breast*. 2019 Aug;46:95-96. doi: 10.1016/j.breast.2019.05.005. Epub 2019 May 3. Erratum in: *Breast*. 2019 Dec;48:103. PMID: 31125932.

305) Rossi L, Biagioni C, McCartney A, Migliaccio I, **Curigliano G**, Sanna G, Moretti E, Minisini AM, Cinieri S, Tondini C, Arpino G, Bernardo A, Martignetti A, Risi E, Pestrin M, Boni L, Benelli M, Biganzoli L, Di Leo A, Malorni L. Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TReEnd trial. *Breast Cancer Res*. 2019 May 29;21(1):71. doi: 10.1186/s13058-019-1149-5. PMID: 31142370; PMCID: PMC6542028.

- 306) Punzi S, Meliksetian M, Riva L, Marocchi F, Pruneri G, Criscitiello C, Orsi F, Spaggiari L, Casiraghi M, Della Vigna P, Luzi L, **Curigliano G**, Pelicci PG, Lanfrancone L. Development of Personalized Therapeutic Strategies by Targeting Actionable Vulnerabilities in Metastatic and Chemotherapy-Resistant Breast Cancer PDXs. *Cells*. 2019 Jun 18;8(6):605. doi: 10.3390/cells8060605. PMID: 31216647; PMCID: PMC6627522.
- 307) Criscitiello C, **Curigliano G**. Treatment in real-life patients with HER2-positive metastatic breast cancer: What we learn from the KAMILLA trial? *Eur J Cancer*. 2019 Aug;117:1-4. doi: 10.1016/j.ejca.2019.04.028. Epub 2019 Jun 21. PMID: 31229945.
- 308) Mazzarella L, Duso BA, Trapani D, Belli C, D'Amico P, Ferraro E, Viale G, **Curigliano G**. The evolving landscape of 'next-generation' immune checkpoint inhibitors: A review. *Eur J Cancer*. 2019 Aug;117:14-31. doi: 10.1016/j.ejca.2019.04.035. Epub 2019 Jun 21. PMID: 31229946.
- 309) Migliaiavacca Zucchetti B, Nicolò E, **Curigliano G**. Biosimilars for breast cancer. *Expert Opin Biol Ther*. 2019 Oct;19(10):1015-1021. doi: 10.1080/14712598.2019.1638362. Epub 2019 Jul 10. PMID: 31248290.
- 310) Ochi T, Bianchini G, Ando M, Nozaki F, Kobayashi D, Criscitiello C, **Curigliano G**, Iwamoto T, Niikura N, Takei H, Yoshida A, Takei J, Suzuki K, Yamauchi H, Hayashi N. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer. *Eur J Cancer*. 2019 Sep;118:41-48. doi: 10.1016/j.ejca.2019.05.014. Epub 2019 Jul 11. PMID: 31302586.
- 311) Burstein HJ, **Curigliano G**, Loibl S, Dubsy P, Gnant M, Poortmans P, Colleoni M, Denkert C, Piccart-Gebhart M, Regan M, Senn HJ, Winer EP, Thurlimann B; Members of the St. Gallen International Consensus Panel on the Primary Therapy of Early Breast Cancer 2019. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. *Ann Oncol*. 2019 Oct 1;30(10):1541-1557. doi: 10.1093/annonc/mdz235. PMID: 31373601.
- 312) Pivot X, Pegram M, Cortes J, Lüftner D, Lyman GH, **Curigliano G**, Bondarenko I, Yoon YC, Kim Y, Kim C. Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer. *Eur J Cancer*. 2019 Oct;120:1-9. doi: 10.1016/j.ejca.2019.07.015. Epub 2019 Aug 21. PMID: 31445454.
- 313) Viale G, Morganti S, Ferraro E, Zagami P, Marra A, **Curigliano G**. What therapies are on the horizon for HER2 positive breast cancer? *Expert Rev Anticancer Ther*. 2019 Sep;19(9):811-822. doi: 10.1080/14737140.2019.1660164. Epub 2019 Aug 28. PMID: 31448640.
- 314) Morganti S, **Curigliano G**. Editorial: Optimizing treatment strategy in early breast cancer: less is more, or more is better? *Curr Opin Oncol*. 2019 Nov;31(6):469-471. doi: 10.1097/CCO.0000000000000582. PMID: 31464761.
- 315) Marra A, **Curigliano G**. Are all cyclin-dependent kinases 4/6 inhibitors created equal? *NPJ Breast Cancer*. 2019 Aug 29;5:27. doi: 10.1038/s41523-019-0121-y. PMID: 31482107; PMCID: PMC6715721.
- 316) Ferraro E, Trapani D, Marrucci E, **Curigliano G**. Evaluating triptorelin as a treatment option for breast cancer. *Expert Opin Pharmacother*. 2019 Oct;20(15):1809-1818. doi: 10.1080/14656566.2019.1650020. Epub 2019 Sep 9. PMID: 31500470.
- 317) Zinzani PL, Dreyling M, Gradishar W, Andre M, Esteva FJ, Boulos S, González Barca E, **Curigliano G**. Are Biosimilars the Future of Oncology and Haematology? *Drugs*. 2019 Oct;79(15):1609-1624. doi: 10.1007/s40265-019-01193-y. PMID: 31541401.
- 318) Park JH, Jonas SF, Bataillon G, Criscitiello C, Salgado R, Loi S, Viale G, Lee HJ, Dieci MV, Kim SB, Vincent-Salomon A, **Curigliano G**, André F, Michiels S. Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. *Ann Oncol*. 2019 Dec 1;30(12):1941-1949. doi: 10.1093/annonc/mdz395. PMID: 31566659.
- 319) Criscitiello C, Viale G, **Curigliano G**. Harmonizing gene signatures to predict benefit from adjuvant chemotherapy in early breast cancer. *Curr Opin Oncol*. 2019 Nov;31(6):472-479. doi: 10.1097/CCO.0000000000000570. PMID: 31593974.
- 320) Abdel-Aziz AK, Saadeldin MK, D'Amico P, Orecchioni S, Bertolini F, **Curigliano G**, Minucci S. Preclinical models of breast cancer: Two-way shuttles for immune checkpoint inhibitors from and to patient bedside. *Eur J Cancer*. 2019 Nov;122:22-41. doi: 10.1016/j.ejca.2019.08.013. Epub 2019 Oct 10. PMID: 31606656.
- 321) Hui R, Pearson A, Cortes J, Campbell C, Poirat C, Azim HA Jr, Fumagalli D, Lambertini M, Daly F, Arahmani A, Perez-Garcia J, Aftimos P, Bedard PL, Xuereb L, Scheepers ED, Vicente M, Goulioti T, Loibl S, Loi S, Pierrat MJ, Turner NC, Andre F, **Curigliano G**. Lucitanib for the Treatment of HR positive/HER2 negative Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study. *Clin Cancer Res*. 2020 Jan 15;26(2):354-363. doi: 10.1158/1078-0432.CCR-19-1164. Epub 2019 Oct 16. PMID: 31619444.
- 322) Cardoso MJ, Wyld L, Rubio IT, Leidenius M, **Curigliano G**, Cutuli B, Marotti L, Biganzoli L. Corrigendum to "EUSOMA position regarding breast implant associated anaplastic large cell lymphoma (BIA-ALCL) and the use of textured implants" [Breast 44 (April 2019) 90-93]. *Breast*. 2019 Dec;48:102. doi: 10.1016/j.breast.2019.10.005. Erratum for: *Breast*. 2019 Apr;44:90-93. PMID: 31706463.
- 323) Cardoso MJ, Biganzoli L, Rubio IT, Leidenius M, **Curigliano G**, Cutuli B, Marotti L, Kovacs T, Wyld L. Corrigendum to "About the French prohibition of textured breast implants: Is it justified or over-cautious? The EUSOMA, ESSO/BRESSO position" [Breast 46 (August 2019) 95-96]. *Breast*. 2019 Dec;48:103. doi: 10.1016/j.breast.2019.10.010. Erratum for: *Breast*. 2019 Aug;46:95-96. PMID: 31706464.
- 324) Fogli S, Del Re M, **Curigliano G**, van Schaik RH, Lancellotti P, Danesi R. Corrigendum to "Drug-drug interactions in breast cancer patients treated with CDK4/6 inhibitors" [Cancer Treatm. Rev. 74 (2019) 21-28]. *Cancer Treat Rev*. 2019 Dec;81:101913. doi: 10.1016/j.ctrv.2019.101913. Epub 2019 Nov 6. Erratum for: *Cancer Treat Rev*. 2019 Mar;74:21-28. PMID: 31706687.
- 325) Morganti S, Tarantino P, Ferraro E, D'Amico P, Duso BA, **Curigliano G**. Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer. *Adv Exp Med Biol*. 2019;1168:9-30. doi: 10.1007/978-3-030-24100-1_2. PMID: 31713162.
- 326) Punzi S, Balestrieri C, D'Alesio C, Bossi D, Dellino GI, Gatti E, Pruneri G, Criscitiello C, Lovati G, Meliksetyan M, Carugo A, **Curigliano G**, Natoli G, Pelicci PG, Lanfrancone L. WDR5 inhibition halts metastasis dissemination by repressing the mesenchymal phenotype of breast cancer cells. *Breast Cancer Res*. 2019 Nov 21;21(1):123. doi: 10.1186/s13058-019-1216-y. PMID: 31752957; PMCID: PMC6873410.
- Anno 2020**
- 327) Heinhuis KM, Carlino M, Joerger M, Di Nicola M, Meniawy T, Rottey S, Moreno V, Gazzah A, Delord JP, Paz-Ares L, Britschgi C, Schilder RJ, O'Byrne K, **Curigliano G**, Romano E, Patah P, Wang R, Liu Y, Bajaj G, Siu LL. Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort- Expansion Clinical Trial. *JAMA Oncol*. 2020 Jan 1;6(1):100-107. doi: 10.1001/jamaoncol.2019.3848. PMID: 31697308; PMCID: PMC6865300.
- 328) Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, Sohn J, Denduluri N, Perrin C, Aogi K, Tokunaga E, Im SA, Lee KS, Hurvitz SA, Cortes J, Lee C, Chen S, Zhang L, Shahidi J, Yver A, Krop I; DESTINY-Breast01

Investigators. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. *N Engl J Med*. 2020 Feb 13;382(7):610-621. doi: 10.1056/NEJMoa1914510. Epub 2019 Dec 11. PMID: 31825192; PMCID: PMC7458671.

329) Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, Lin NU, Borges V, Abramson V, Anders C, Bedard PL, Oliveira M, Jakobsen E, Bachelot T, Shachar SS, Müller V, Braga S, Duhoux FP, Greil R, Cameron D, Carey LA, **Curigliano G**, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pegram M, Slamon D, Palanca-Wessels MC, Walker L, Feng W, Winer EP. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. *N Engl J Med*. 2020 Feb 13;382(7):597-609. doi: 10.1056/NEJMoa1914609. Epub 2019 Dec 11. Erratum in: *N Engl J Med*. 2020 Feb 6;382(6):586. PMID: 31825569.

330) **Curigliano G**, Loibl S. CDK4/6 inhibitors in breast cancer: one more step towards reduced mortality. *Lancet Oncol*. 2020 Feb;21(2):191-192. doi: 10.1016/S1470-2045(19)30808-3. Epub 2019 Dec 16. PMID: 31859247.

331) **Curigliano G**, Bagnardi V, Ghioni M, Louahed J, Brichard V, Lehmann FF, Marra A, Trapani D, Criscitiello C, Viale G. Expression of tumor-associated antigens in breast cancer subtypes. *Breast*. 2020 Feb;49:202-209. doi: 10.1016/j.breast.2019.12.002. Epub 2019 Dec 12. PMID: 31869767; PMCID: PMC7375652.

332) Biganzoli L, Marotti L, Cardoso MJ, Cataliotti L, **Curigliano G**, Cuzick J, Goldhirsch A, Leidenius M, Mansel R, Markopoulos C, Wyld L, Rubio IT. European Guidelines on the Organisation of Breast Centres and Voluntary Certification Processes. *Breast Care (Basel)*. 2019 Dec;14(6):359-365. doi: 10.1159/000503603. Epub 2019 Oct 16. PMID: 31933581; PMCID: PMC6940462.

333) Trapani D, **Curigliano G**, Eniu A. Breast Cancer: Reimbursement Policies and Adoption of New Therapeutic Agents by National Health Systems. *Breast Care (Basel)*. 2019 Dec;14(6):373-381. doi: 10.1159/000502637. Epub 2019 Sep 24. PMID: 31933583; PMCID: PMC6940432.

334) McCartney A, Bonechi M, De Luca F, Biagioni C, **Curigliano G**, Moretti E, Minisini AM, Bergqvist M, Benelli M, Migliaccio I, Galardi F, Risi E, De Santo I, Romagnoli D, Biganzoli L, Di Leo A, Malorni L. Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial. *Clin Cancer Res*. 2020 May 1;26(9):2131-2139. doi: 10.1158/1078-0432.CCR-19-3271. Epub 2020 Jan 14. PMID: 31937617.

335) Marra A, Viale G, Pileri SA, Pravettoni G, Viale G, De Lorenzi F, Nolè F, Veronesi P, **Curigliano G**. Breast implant-associated anaplastic large cell lymphoma: A comprehensive review. *Cancer Treat Rev*. 2020 Mar;84:101963. doi: 10.1016/j.ctrv.2020.101963. Epub 2020 Jan 13. PMID: 31958739.

336) **Curigliano G**, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, Herrmann J, Porter C, Lyon AR, Lancellotti P, Patel A, DeCara J, Mitchell J, Harrison E, Moslehi J, Witteles R, Calabro MG, Orecchia R, de Azambuja E, Zamorano JL, Krone R, Iakobishvili Z, Carver J, Armenian S, Ky B, Cardinale D, Cipolla CM, Dent S, Jordan K; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. *Ann Oncol*. 2020 Feb;31(2):171-190. doi: 10.1016/j.annonc.2019.10.023. PMID: 31959335; PMCID: PMC8019325.

337) Criscitiello C, **Curigliano G**. Tumour infiltrating lymphocytes and correlation with response to intensified platinum-based chemotherapy in BRCA- like tumours. *Eur J Cancer*. 2020 Mar;127:236-239. doi: 10.1016/j.ejca.2019.12.004. Epub 2020 Jan 20. PMID: 31973961.

338) Triberti S, Durosini I, **Curigliano G**, Pravettoni G. Is Explanation a Marketing Problem? The Quest for Trust in Artificial Intelligence and Two Conflicting Solutions. *Public Health Genomics*. 2020;23(1-2):2-5. doi: 10.1159/000506014. Epub 2020 Jan 28. PMID: 31991406.

339) Stebbing J, Mainwaring PN, **Curigliano G**, Pegram M, Latymer M, Bair AH, Rugo HS. Understanding the Role of Comparative Clinical Studies in the Development of Oncology Biosimilars. *J Clin Oncol*. 2020 Apr 1;38(10):1070-1080. doi: 10.1200/JCO.19.02953. Epub 2020 Feb 14. PMID: 32058846; PMCID: PMC7106981.

340) Cortes J, Perez-García JM, Llombart-Cussac A, **Curigliano G**, El Saghir NS, Cardoso F, Barrios CH, Wagle S, Roman J, Harbeck N, Eniu A, Kaufman PA, Tabernero J, García-Estévez L, Schmid P, Arribas J. Enhancing global access to cancer medicines. *CA Cancer J Clin*. 2020 Mar;70(2):105-124. doi: 10.3322/caac.21597. Epub 2020 Feb 18. PMID: 32068901.

341) Kovacs T, Rubio IT, Markopoulos C, Audisio RA, Knox S, Kühn T, Mansel R, Matrai Z, Meani F, Nava M, Wyld L; BRESO Structure Working Group. Theoretical and practical knowledge curriculum for European Breast Surgeons. *Eur J Surg Oncol*. 2020 Apr;46(4 Pt B):717-736. doi: 10.1016/j.ejso.2020.01.027. Epub 2020 Feb 8. PMID: 32075718.

342) Aurilio G, Verri E, Frasson S, Bagnardi V, Cossu Rocca M, Cullurà D, Milani M, Mascia R, **Curigliano G**, Orsi F, Jereczek-Fossa BA, Musi G, Omodeo Salè E, De Cobelli O, Nolè F. Modified-BEP Chemotherapy in Patients With Germ-Cell Tumors Treated at a Comprehensive Cancer Center. *Am J Clin Oncol*. 2020 Jun;43(6):381-387. doi: 10.1097/COC.0000000000000679. PMID: 32079853.

343) Passaro A, Mackenzie G, Lambertini M, Morgan G, Zimmermann S, Garrido P, **Curigliano G**, Trapani D. European Society for Medical Oncology (ESMO) 2018 Congress Twitter analysis: from ethics to results through the understanding of communication and interaction flows. *ESMO Open*. 2020 Feb;5(1):e000598. doi: 10.1136/esmoopen-2019-000598. Epub 2020 Feb 5. Erratum in: *ESMO Open*. 2020 Mar;5(2): PMID: 32133983; PMCID: PMC7046424.

344) Paluch-Shimon S, Cardoso F, Partridge AH, Abulkhair O, Azim HA Jr, Bianchi- Micheli G, Cardoso MJ, **Curigliano G**, Gelmon KA, Harbeck N, Mersdorf J, Poortmans P, Pruneri G, Senkus E, Spanic T, Stearns V, Wengström Y, Peccatori F, Pagani O. ESO-ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4). *Ann Oncol*. 2020 Jun;31(6):674-696. doi: 10.1016/j.annonc.2020.03.284. Epub 2020 Mar 19. PMID: 32199930.

345) Gelber RD, Coates AS, Gelber S, Orecchia R, Veronesi P, Di Leo A, Colleoni M, Winer EP, Burstein HJ, Viale G, Senn HJ, Piccart M, **Curigliano G**. The legacy of Professor Aron Goldhirsch. *Ann Oncol*. 2020 Jun;31(6):671-673. doi: 10.1016/j.annonc.2020.03.288. Epub 2020 Mar 23. PMID: 32217075.

346) Oliveri S, Ongaro G, Durosini I, **Curigliano G**, Pravettoni G. Breast implant-associated anaplastic large cell lymphoma: emotional impact and guidelines for psychological support. *Breast Cancer Res Treat*. 2020 May;181(1):221-224. doi: 10.1007/s10549-020-05601-w. Epub 2020 Mar 31. PMID: 32232699.

347) Mazzarella L, Morganti S, Marra A, Trapani D, Tini G, Pelicci P, **Curigliano G**. Master protocols in immuno-oncology: do novel drugs deserve novel designs? *J Immunother Cancer*. 2020 Mar;8(1):e000475. doi: 10.1136/jitc-2019-000475. PMID: 32238471; PMCID: PMC7174064.

348) File D, **Curigliano G**, Carey LA. Escalating and De-escalating Therapy for Early-Stage HER2-Positive Breast Cancer. *Am Soc Clin Oncol Educ Book*. 2020 Mar;40:1-11. doi: 10.1200/EDBK_100023. PMID: 32239987.

349) Al-Shamsi HO, Alhazzani W, Alhuraiji A, Coomes EA, Chemaly RF, Almuhamma M, Wolff RA, Ibrahim NK, Chua MLK, Hotte SJ, Meyers BM, Elfiki T, **Curigliano G**, Eng C, Grothey A, Xie C. A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group. *Oncologist*. 2020 Jun;25(6):e936-e945. doi: 10.1634/theoncologist.2020-0213. Epub 2020 Apr 27. PMID: 32243668; PMCID: PMC7288661.

350) Tarantino P, Morganti S, **Curigliano G**. Biologic therapy for advanced breast cancer: recent advances and future directions. *Expert Opin Biol Ther*. 2020 Sep;20(9):1009-1024. doi: 10.1080/14712598.2020.1752176. Epub 2020 Apr 21. PMID: 32255704.

- 351) Curigliano G. How to Guarantee the Best of Care to Patients with Cancer During the COVID-19 Epidemic: The Italian Experience. *Oncologist*. 2020 Jun;25(6):463-467. doi: 10.1634/theoncologist.2020-0267. Epub 2020 Apr 27. PMID: 32298029; PMCID: PMC7262348.
- 352) Trapani D, Curigliano G. How can biosimilars change the trajectory of breast cancer therapy? *Expert Rev Anticancer Ther*. 2020 May;20(5):325-328. doi: 10.1080/14737140.2020.1757438. Epub 2020 Apr 28. PMID: 32298188.
- 353) Tarantino P, Trapani D, Curigliano G. Conducting phase 1 cancer clinical trials during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related disease pandemic. *Eur J Cancer*. 2020 Jun;132:8-10. doi: 10.1016/j.ejca.2020.03.023. Epub 2020 Apr 6. PMID: 32305011; PMCID: PMC7136890.
- 354) Tarantino P, Hamilton E, Tolaney SM, Cortes J, Morganti S, Ferraro E, Marra A, Viale G, Trapani D, Cardoso F, Penault-Llorca F, Viale G, André F, Curigliano G. HER2-Low Breast Cancer: Pathological and Clinical Landscape. *J Clin Oncol*. 2020 Jun 10;38(17):1951-1962. doi: 10.1200/JCO.19.02488. Epub 2020 Apr 24. PMID: 32330069.
- 355) Curigliano G, Cardoso MJ, Poortmans P, Gentilini O, Pravettoni G, Mazzocco K, Houssami N, Pagani O, Senkus E, Cardoso F; editorial board of The Breast. Recommendations for triage, prioritization and treatment of breast cancer patients during the COVID-19 pandemic. *Breast*. 2020 Aug;52:8-16. doi: 10.1016/j.breast.2020.04.006. Epub 2020 Apr 16. PMID: 32334323; PMCID: PMC7162626.
- 356) Saini KS, de Las Heras B, de Castro J, Venkitaraman R, Poelman M, Srinivasan G, Saini ML, Verma S, Leone M, Aftimos P, Curigliano G. Effect of the COVID-19 pandemic on cancer treatment and research. *Lancet Haematol*. 2020 Jun;7(6):e432-e435. doi: 10.1016/S2352-3026(20)30123-X. Epub 2020 Apr 24. PMID: 32339482; PMCID: PMC7195053.
- 357) Meessen JMTA, Cardinale D, Ciceri F, Sandri MT, Civelli M, Bottazzi B, Cucchi G, Menatti E, Mangiavacchi M, Condorelli G, Barbieri E, Gori S, Colombo A, Curigliano G, Salvatici M, Pastori P, Ghisoni F, Bianchi A, Falci C, Cortesi P, Farolfi A, Monopoli A, Milandri C, Bregni M, Malossi A, Nassiacos D, Verusio C, Staszewsky L, Leone R, Novelli D, Balconi G, Nicolis EB, Franzosi MG, Masson S, Garlanda C, Mantovani A, Cipolla CM, Latini R; ICOS-ONE Study Investigators. Circulating biomarkers and cardiac function over 3 years after chemotherapy with anthracyclines: the ICOS-ONE trial. *ESC Heart Fail*. 2020 Aug;7(4):1452-1466. doi: 10.1002/ehf2.12695. Epub 2020 May 1. PMID: 32358917; PMCID: PMC7373944.
- 358) Pietrantonio F, Loupakis F, Randon G, Raimondi A, Salati M, Trapani D, Pagani F, Depetris I, Maddalena G, Morano F, Corallo S, Prisciandaro M, Corti F, Guarini V, Bocconi A, Marra A, Belli C, Spallanzani A, Fassan M, Lonardi S, Curigliano G, Fucà G, Di Bartolomeo M, de Braud F. Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden. *Oncologist*. 2020 Sep;25(9):803-809. doi: 10.1634/theoncologist.2020-0014. Epub 2020 May 20. PMID: 32369650; PMCID: PMC7485362.
- 359) Roelands J, Hendrickx W, Zoppoli G, Mall R, Saad M, Halliwill K, Curigliano G, Rinchai D, Decock J, Delogu LG, Turan T, Samayoa J, Chouchane L, Ballestrero A, Wang E, Finetti P, Bertucci F, Miller LD, Galon J, Marincola FM, Kuppen PJK, Ceccarelli M, Bedognetti D. Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response. *J Immunother Cancer*. 2020 Apr;8(1):e000617. doi: 10.1136/jitc-2020-000617. Erratum in: *J Immunother Cancer*. 2020 Jun;8(1):PMID: 32376723; PMCID: PMC7223637.
- 360) Coomes EA, Al-Shamsi HO, Meyers BM, Alhazzani W, Alhurairi A, Chemaly RF, Almuhan M, Wolff RA, Ibrahim NK, Chua MLK, Hotte SJ, Elfiki T, Curigliano G, Eng C, Grothey A, Xie C. In Reply. *Oncologist*. 2020 Aug;25(8):e1252-e1253. doi: 10.1634/theoncologist.2020-0329. Epub 2020 May 27. PMID: 32378772; PMCID: PMC7267302.
- 361) Trapani D, Marra A, Curigliano G. The experience on coronavirus disease 2019 and cancer from an oncology hub institution in Milan, Lombardy Region. *Eur J Cancer*. 2020 Jun;132:199-206. doi: 10.1016/j.ejca.2020.04.017. Epub 2020 Apr 29. PMID: 32380430; PMCID: PMC7188643.
- 362) Di Tano M, Raucci F, Vernieri C, Caffa I, Buono R, Fanti M, Brandhorst S, Curigliano G, Nencioni A, de Braud F, Longo VD. Synergistic effect of fasting- mimicking diet and vitamin C against KRAS mutated cancers. *Nat Commun*. 2020 May 11;11(1):2332. doi: 10.1038/s41467-020-16243-3. PMID: 32393788; PMCID: PMC7214421.
- 363) Amgad M, Stovgaard ES, Balslev E, Thagaard J, Chen W, Dudgeon S, Sharma A, Kerner JK, Denkert C, Yuan Y, AbdulJabbar K, Wienert S, Savas P, Voorwerk L, Beck AH, Madabhushi A, Hartman J, Sebastian MM, Horlings HM, Hudeček J, Ciompi F, Moore DA, Singh R, Roblin E, Balancin ML, Mathieu MC, Lennerz JK, Kirtani P, Chen IC, Braybrooke JP, Pruneri G, Demaria S, Adams S, Schnitt SJ, Lakhani SR, Rojo F, Comerma L, Badve SS, Khojasteh M, Symmans WF, Sotiriou C, Gonzalez- Ericsson P, Pogue-Geile KL, Kim RS, Rimm DL, Viale G, Hewitt SM, Bartlett JMS, Penault-Llorca F, Goel S, Lien HC, Loibl S, Kos Z, Loi S, Hanna MG, Michiels S, Kok M, Nielsen TO, Lazar AJ, Bago-Horvath Z, Kooreman LFS, van der Laak JAWM, Saltz J, Gallas BD, Kurkure U, Barnes M, Salgado R, Cooper LAD; International Immuno-Oncology Biomarker Working Group. Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. *NPJ Breast Cancer*. 2020 May 12;6:16. doi: 10.1038/s41523-020-0154-2. PMID: 32411818; PMCID: PMC7217824.
- 364) Kos Z, Roblin E, Kim RS, Michiels S, Gallas BD, Chen W, van de Vijver KK, Goel S, Adams S, Demaria S, Viale G, Nielsen TO, Badve SS, Symmans WF, Sotiriou C, Rimm DL, Hewitt S, Denkert C, Loibl S, Luen SJ, Bartlett JMS, Savas P, Pruneri G, Dillon DA, Cheang MCU, Tutt A, Hall JA, Kok M, Horlings HM, Madabhushi A, van der Laak J, Ciompi F, Laenholm AV, Bellolio E, Gruosso T, Fox SB, Araya JC, Floris G, Hudeček J, Voorwerk L, Beck AH, Kerner J, Larsimont D, Declercq S, Van den Eynden G, Pusztai L, Ehinger A, Yang W, AbdulJabbar K, Yuan Y, Singh R, Hiley C, Bakir MA, Lazar AJ, Naber S, Wienert S, Castillo M, Curigliano G, Dieci MV, André F, Swanton C, Reis-Filho J, Sparano J, Balslev E, Chen IC, Stovgaard EIS, Pogue-Geile K, Blenman KRM, Penault-Llorca F, Schnitt S, Lakhani SR, Vincent-Salomon A, Rojo F, Braybrooke JP, Hanna MG, Soler-Monsó MT, Bethmann D, Castaneda CA, Willard-Gallo K, Sharma A, Lien HC, Fineberg S, Thagaard J, Comerma L, Gonzalez-Ericsson P, Brogi E, Loi S, Saltz J, Klausen F, Cooper L, Amgad M, Moore DA, Salgado R; International Immuno-Oncology Biomarker Working Group. Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. *NPJ Breast Cancer*. 2020 May 12;6:17. doi: 10.1038/s41523-020-0156-0. PMID: 32411819; PMCID: PMC7217863.
- 365) Roberto M, Basta F, Mazzuca F, Curigliano G, Marchetti P. Risk of coronavirus disease 2019 in patients treated for cancer: An immune response- based hypothesis. *Eur J Cancer*. 2020 Jul;134:6-8. doi: 10.1016/j.ejca.2020.05.003. Epub 2020 May 18. PMID: 32425367; PMCID: PMC7231735.
- 366) Hudeček J, Voorwerk L, van Seijen M, Nederlof I, de Maaker M, van den Berg J, van de Vijver KK, Sikorska K, Adams S, Demaria S, Viale G, Nielsen TO, Badve SS, Michiels S, Symmans WF, Sotiriou C, Rimm DL, Hewitt SM, Denkert C, Loibl S, Loi S, Bartlett JMS, Pruneri G, Dillon DA, Cheang MCU, Tutt A, Hall JA, Kos Z, Salgado R, Kok M, Horlings HM; International Immuno-Oncology Biomarker Working Group. Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. *NPJ Breast Cancer*. 2020 May 12;6:15. doi: 10.1038/s41523-020-0155-1. PMID: 32436923; PMCID: PMC7217941.
- 367) de Azambuja E, Trapani D, Loibl S, Delaloge S, Senkus E, Criscitiello C, Poortman P, Gnant M, Di Cosimo S, Cortes J, Cardoso F, Paluch-Shimon S, Curigliano G. ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer. *ESMO Open*. 2020 May;5(Suppl 3):e000793. doi: 10.1136/esmoopen-2020-000793. PMID: 32439716; PMCID: PMC7295852.

- 368) Lin NU, Borges V, Anders C, Murthy RK, Paplomata E, Hamilton E, Hurvitz S, Loi S, Okines A, Abramson V, Bedard PL, Oliveira M, Mueller V, Zelnak A, DiGiovanna MP, Bachelot T, Chien AJ, O'Regan R, Wardley A, Conlin A, Cameron D, Carey L, **Curigliano G**, Gelmon K, Loibl S, Mayor J, McGoldrick S, An X, Winer EP. Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. *J Clin Oncol*. 2020 Aug 10;38(23):2610-2619. doi: 10.1200/JCO.20.00775. Epub 2020 May 29. PMID: 32468955; PMCID: PMC7403000.
- 369) Duso BA, Trapani D, Marra A, D'Amico P, Guerini Rocco E, Fusco N, Mazzearella L, Criscitiello C, Esposito A, **Curigliano G**. Pharmacological management of male breast cancer. *Expert Opin Pharmacother*. 2020 Aug;21(12):1493-1504. doi: 10.1080/14656566.2020.1763305. Epub 2020 Jun 4. PMID: 32496137.
- 370) Coomes EA, Al-Shamsi HO, Meyers BM, Alhazzani W, Alhurairi A, Chemaly RF, Almuhan M, Wolff RA, Ibrahim NK, Chua MLK, Hotte SJ, Elfiki T, **Curigliano G**, Eng C, Grothey A, Xie C. Evolution of Cancer Care in Response to the COVID-19 Pandemic. *Oncologist*. 2020 Sep;25(9):e1426-e1427. doi: 10.1634/theoncologist.2020-0451. Epub 2020 Jul 7. PMID: 32536024; PMCID: PMC7323244.
- 371) Di Cosimo S, Malfettone A, Pérez-García JM, Llombart-Cussac A, Miceli R, **Curigliano G**, Cortés J. Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019. *Eur J Cancer*. 2020 Aug;135:62-65. doi: 10.1016/j.ejca.2020.05.026. Epub 2020 Jun 4. PMID: 32544799; PMCID: PMC7269953.
- 372) Saini KS, Lanza C, Romano M, de Azambuja E, Cortes J, de Las Heras B, de Castro J, Lamba Saini M, Loibl S, **Curigliano G**, Twelves C, Leone M, Patnaik MM. Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy. *Br J Cancer*. 2020 Sep;123(5):694-697. doi: 10.1038/s41416-020-0948-x. Epub 2020 Jun 22. PMID: 32572174; PMCID: PMC7307309.
- 373) Criscitiello C, Vingiani A, Maisonneuve P, Viale G, Viale G, **Curigliano G**. Tumor-infiltrating lymphocytes (TILs) in ER+/HER2-breast cancer. *Breast Cancer Res Treat*. 2020 Sep;183(2):347-354. doi: 10.1007/s10549-020-05771-7. Epub 2020 Jul 3. PMID: 32621251.
- 374) Nicolò E, Zagami P, **Curigliano G**. Antibody-drug conjugates in breast cancer: the chemotherapy of the future? *Curr Opin Oncol*. 2020 Sep;32(5):494-502. doi: 10.1097/CCO.0000000000000656. PMID: 32657795.
- 375) Belli C, Anand S, Gainor JF, Penault-Llorca F, Subbiah V, Drilon A, André F, **Curigliano G**. Progresses Toward Precision Medicine in RET-altered Solid Tumors. *Clin Cancer Res*. 2020 Dec 1;26(23):6102-6111. doi: 10.1158/1078-0432.CCR-20-1587. Epub 2020 Jul 14. PMID: 32665298.
- 376) **Curigliano G**. Cancer Patients and Risk of Mortality for COVID-19. *Cancer Cell*. 2020 Aug 10;38(2):161-163. doi: 10.1016/j.ccell.2020.07.006. Epub 2020 Jul 25. PMID: 32710820; PMCID: PMC7381394.
- 377) Trapani D, **Curigliano G**, Alexandru E, Sternberg CN. The global landscape of drug development for kidney cancer. *Cancer Treat Rev*. 2020 Sep;89:102061. doi: 10.1016/j.ctrv.2020.102061. Epub 2020 Jun 23. PMID: 32738737.
- 378) **Curigliano G**, Banerjee S, Cervantes A, Garassino MC, Garrido P, Girard N, Haanen J, Jordan K, Lordick F, Machiels JP, Michielin O, Peters S, Tabernero J, Douillard JY, Pentheroudakis G; Panel members. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. *Ann Oncol*. 2020 Oct;31(10):1320-1335. doi: 10.1016/j.annonc.2020.07.010. Epub 2020 Jul 31. PMID: 32745693; PMCID: PMC7836806.
- 379) Passaro A, Attili I, Morganti S, Del Signore E, Gianoncelli L, Spitaleri G, Stati V, Catania C, **Curigliano G**, de Marinis F. Clinical features affecting survival in metastatic NSCLC treated with immunotherapy: A critical review of published data. *Cancer Treat Rev*. 2020 Sep;89:102085. doi: 10.1016/j.ctrv.2020.102085. Epub 2020 Jul 22. PMID: 32771858.
- 380) Criscitiello C, Marra A, Morganti S, Zagami P, Viale G, Esposito A, **Curigliano G**. Pretreatment Blood Parameters Predict Efficacy from Immunotherapy Agents in Early Phase Clinical Trials. *Oncologist*. 2020 Nov;25(11):e1732-e1742. doi: 10.1634/theoncologist.2020-0518. Epub 2020 Sep 18. PMID: 32785940; PMCID: PMC7648370.
- 381) Tarantino P, **Curigliano G**. Atezolizumab and Bevacizumab in Hepatocellular Carcinoma. *N Engl J Med*. 2020 Aug 13;383(7):694-695. doi: 10.1056/NEJMc2021840. PMID: 32786200.
- 382) Subbiah V, Lassen U, Élez E, Italiano A, **Curigliano G**, Javle M, de Braud F, Prager GW, Greil R, Stein A, Fasolo A, Schellens JHM, Wen PY, Viele K, Boran AD, Gasal E, Burgess P, Ilankumaran P, Wainberg ZA. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. *Lancet Oncol*. 2020 Sep;21(9):1234-1243. doi: 10.1016/S1470-2045(20)30321-1. Epub 2020 Aug 17. PMID: 32818466.
- 383) Trapani D, **Curigliano G**. How to treat lobular cancer in the adjuvant setting? *Curr Opin Oncol*. 2020 Nov;32(6):561-567. doi: 10.1097/CCO.0000000000000674. PMID: 32826487.
- 384) Corti C, Crimini E, Criscitiello C, Trapani D, **Curigliano G**. Adjuvant treatment of early male breast cancer. *Curr Opin Oncol*. 2020 Nov;32(6):594-602. doi: 10.1097/CCO.0000000000000678. PMID: 32852309.
- 385) Venetis K, Ivernizzi M, Sajjadi E, **Curigliano G**, Fusco N. Cellular immunotherapy in breast cancer: The quest for consistent biomarkers. *Cancer Treat Rev*. 2020 Nov;90:102089. doi: 10.1016/j.ctrv.2020.102089. Epub 2020 Aug 14. PMID: 32889360.
- 386) Saini KS, de Las Heras B, Plummer R, Moreno V, Romano M, de Castro J, Aftimos P, Fredriksson J, Bhattacharyya GS, Olivo MS, Schiavon G, Punie K, Garcia-Foncillas J, Rogata E, Pfeiffer R, Orbegoso C, Morrison K, **Curigliano G**, Chin L, Saini ML, Rekdal Ø, Anderson S, Cortes J, Leone M, Dancy J, Twelves C, Awada A. Reimagining Global Oncology Clinical Trials for the Postpandemic Era: A Call to Arms. *JCO Glob Oncol*. 2020 Sep;6:1357-1362. doi: 10.1200/GO.20.00346. PMID: 32897732; PMCID: PMC7529519.
- 387) Trapani D, Zagami P, Nicolò E, Pravettoni G, **Curigliano G**. Management of Cardiac Toxicity Induced by Chemotherapy. *J Clin Med*. 2020 Sep 7;9(9):2885. doi: 10.3390/jcm9092885. PMID: 32906611; PMCID: PMC7565686.
- 388) Lenihan D, Carver J, Porter C, Liu JE, Dent S, Thavendiranathan P, Mitchell JD, Nohria A, Fradley MG, Pusic I, Stockertl-Goldstein K, Blaes A, Lyon AR, Ganatra S, López-Fernández T, O'Quinn R, Minotti G, Szmit S, Cardinale D, Alvarez-Cardona J, **Curigliano G**, Neilan TG, Herrmann J. Cardio-oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement. *CA Cancer J Clin*. 2020 Nov;70(6):480-504. doi: 10.3322/caac.21635. Epub 2020 Sep 10. PMID: 32910493; PMCID: PMC7934086.
- 389) Saini KS, Tagliamento M, Lambertini M, McNally R, Romano M, Leone M, **Curigliano G**, de Azambuja E. Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies. *Eur J Cancer*. 2020 Nov;139:43-50. doi: 10.1016/j.ejca.2020.08.011. Epub 2020 Sep 2. PMID: 32971510; PMCID: PMC7467090.
- 390) Cardoso F, Paluch-Shimon S, Senkus E, **Curigliano G**, Aapro MS, André F, Barrios CH, Bergh J, Bhattacharyya GS, Biganzoli L, Boyle F, Cardoso MJ, Carey LA, Cortés J, El Saghir NS, Elzayab M, Eniu A, Fallowfield L, Francis PA, Gelmon K, Gligorov J, Haidinger R, Harbeck N, Hu X, Kaufman B, Kaur R, Kiely BE, Kim SB, Lin NU, Mertz SA, Neciosup S, Offersen BV, Ohno S, Pagani O, Prat A, Penault-Llorca F, Rugo HS, Sledge GW, Thomssen C, Vorobiof DA, Wiseman T, Xu B, Norton L, Costa A, Winer EP. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). *Ann Oncol*. 2020 Dec;31(12):1623-1649. doi: 10.1016/j.annonc.2020.09.010. Epub 2020 Sep 23. PMID: 32979513; PMCID: PMC7510449.
- 391) Tarantino P, Marra A, Gandini S, Minotti M, Pricolo P, Signorelli G, Criscitiello C, Locatelli M, Belli C, Bellomi M, **Curigliano G**. Association between baseline tumour burden and outcome in patients with cancer treated with

next-generation immunoncology agents. *Eur J Cancer*. 2020 Nov;139:92-98. doi: 10.1016/j.ejca.2020.08.026. Epub 2020 Sep 24. PMID: 32979647.

392) Jazieh AR, Akbulut H, **Curigliano G**, Rogado A, Alsharm AA, Razis ED, Mula- Hussain L, Errihani H, Khattak A, De Guzman RB, Mathias C, Alkaiyat MOF, Jradi H, Rolfo C; International Research Network on COVID-19 Impact on Cancer Care. Impact of the COVID-19 Pandemic on Cancer Care: A Global Collaborative Study. *JCO Glob Oncol*. 2020 Sep;6:1428-1438. doi: 10.1200/GO.20.00351. PMID: 32986516; PMCID: PMC7529504.

393) Jazieh AR, Chan SL, **Curigliano G**, Dickson N, Eaton V, Garcia-Foncillas J, Gilmore T, Horn L, Kerr DJ, Lee J, Mathias C, Nogueira-Rodrigues A, Pierce L, Rogado A, Schilsky RL, Soria JC, Warner JL, Yoshida K. Delivering Cancer Care During the COVID-19 Pandemic: Recommendations and Lessons Learned From ASCO Global Webinars. *JCO Glob Oncol*. 2020 Sep;6:1461-1471. doi: 10.1200/GO.20.00423. PMID: 32997537; PMCID: PMC7529523.

394) Hollebecque A, Salvagni S, Plummer R, Isambert N, Niccoli P, Capdevila J, **Curigliano G**, Moreno V, Martin-Romano P, Baudin E, Arias M, Mora S, de Alvaro J, Di Martino J, Parra-Palau JL, Sánchez-Pérez T, Aronchik I, Filvaroff EH, Lamba M, Nikolova Z, de Bono JS. Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma. *Clin Cancer Res*. 2021 Jan 15;27(2):438-446. doi: 10.1158/1078-0432.CCR-20-2380. Epub 2020 Oct 12. PMID: 33046517.

395) Marra A, Trapani D, Viale G, Criscitiello C, **Curigliano G**. Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. *NPJ Breast Cancer*. 2020 Oct 16;6:54. doi: 10.1038/s41523-020-00197-2. PMID: 33088912; PMCID: PMC7568552.

396) Tagliabue M, Maffini F, Fumagalli C, Gandini S, Lepanto D, Corso F, Cacciola S, Ranghiero A, Rappa A, Vacirca D, Cossu Rocca M, Alterio D, Guerini Rocco E, Cattaneo A, Chu F, Zorzi S, **Curigliano G**, Chiocca S, Barberis M, Viale G, Ansarin M. A role for the immune system in advanced laryngeal cancer. *Sci Rep*. 2020 Oct 27;10(1):18327. doi: 10.1038/s41598-020-73747-0. Erratum in: *Sci Rep*. 2021 May 3;11(1):9760. PMID: 33110100; PMCID: PMC7591515.

397) El Bairi K, Trapani D, Petrillo A, Le Page C, Zbakh H, Daniele B, Belbaraka R, **Curigliano G**, Afqir S. Repurposing anticancer drugs for the management of COVID-19. *Eur J Cancer*. 2020 Dec;141:40-61. doi: 10.1016/j.ejca.2020.09.014. Epub 2020 Sep 22. PMID: 33125946; PMCID: PMC7508523.

398) Marchetti P, Botticelli A, Ascierto AP, **Curigliano G**, Giannarelli D. Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis. *J Transl Med*. 2020 Nov 25;18(1):446. doi: 10.1186/s12967-020-02588-2. PMID: 33239030; PMCID: PMC7688006.

399) Sessa C, Colombo N, Creutzberg CL, Concin N, Wimberger P, **Curigliano G**, Marinoni K, Douillard JY, Pentheroudakis G, Torri V, Rauh S. Implementing clinical practice guidelines: time to assess it. *ESMO Open*. 2020 Nov;5(6):e001130. doi: 10.1136/esmoopen-2020-001130. PMID: 33239316; PMCID: PMC7689583.

400) Bono P, Massard C, Peltola KJ, Azaro A, Italiano A, Kristeleit RS, **Curigliano G**, Lassen U, Arkenau HT, Hakulinen P, Garratt C, Ikonen T, Mustonen MVJ, Rodon JA. Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours. *ESMO Open*. 2020 Dec;5(6):e001081. doi: 10.1136/esmoopen-2020-001081. PMID: 33262202; PMCID: PMC7709506.

401) **Curigliano G**, Pravettoni G. Use of chemotherapy in elderly patients with early-stage triple-negative breast cancer. *Lancet Oncol*. 2020 Dec;21(12):1543-1545. doi: 10.1016/S1470-2045(20)30694-X. PMID: 33271084.

402) Grande E, Giovannini M, Marriere E, Pultar P, Quinlan M, Chen X, Rahmanzadeh G, **Curigliano G**, Cui X. Effect of capmatinib on the pharmacokinetics of digoxin and rosuvastatin administered as a 2-drug cocktail in patients with MET-dysregulated advanced solid tumours: A phase I, multicentre, open-label, single-sequence drug-drug interaction study. *Br J Clin Pharmacol*. 2020 Dec 9. doi: 10.1111/bcp.14697. Epub ahead of print. PMID: 33300203.

Anno 2021

403) Marra A, Generali D, Zagami P, Cervoni V, Gandini S, Venturini S, Morganti S, Passerini R, Orecchia R, **Curigliano G**. Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2. *Ann Oncol*. 2021 Jan;32(1):113-119. doi: 10.1016/j.annonc.2020.10.473. Epub 2020 Oct 21. PMID: 33098994; PMCID: PMC7577226.

404) Tarantino P, Prat A, **Curigliano G**. New anti-HER2 agents for brain metastasis: histology-agnostic weapons? *Breast Cancer Res Treat*. 2021 Feb;185(3):879-881. doi: 10.1007/s10549-020-05982-y. Epub 2020 Oct 30. PMID: 33128191.

405) Mazzarella L, Giugliano S, D'Amico P, Belli C, Duso BA, Rescigno M, **Curigliano G**. Evidence for interleukin 17 involvement in severe immune-related neuroendocrine toxicity. *Eur J Cancer*. 2020 Dec;141:218-224. doi: 10.1016/j.ejca.2020.10.006. Epub 2020 Nov 10. PMID: 33186857.

406) **Curigliano G**. CDK4/6 inhibitors for HR+/HER2- early stage breast cancer - when to escalate treatment? *Nat Rev Clin Oncol*. 2021 Feb;18(2):67-68. doi: 10.1038/s41571-020-00453-1. PMID: 33235325.

407) Tarantino P, Morganti S, Uliano J, Giugliano F, Crimini E, **Curigliano G**. Margetuximab for the treatment of HER2-positive metastatic breast cancer. *Expert Opin Biol Ther*. 2021 Feb;21(2):127-133. doi: 10.1080/14712598.2021.1856812. Epub 2020 Dec 14. PMID: 33238772.

408) Tarantino P, Prat A, Cortes J, Cardoso F, **Curigliano G**. Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box. *Biochim Biophys Acta Rev Cancer*. 2021 Jan;1875(1):188487. doi: 10.1016/j.bbcan.2020.188487. Epub 2020 Nov 28. PMID: 33259892.

409) Conforti F, Tarantino P, Trillo P, Pala L, Zagami P, Pirola S, Di Venosa B, Catania C, Queirolo P, Pennacchioli E, Della Vigna P, **Curigliano G**, De Pas TM. Pathological and clinical features of enteric adenocarcinoma of the thymus. A pooled analysis of cases from a reference center and systematic review of the literature. *Cancer Treat Rev*. 2021 Jan;92:102133. doi: 10.1016/j.ctrv.2020.102133. Epub 2020 Dec 3. PMID: 33296826.

410) Dubsky P, Pinker K, Cardoso F, Montagna G, Ritter M, Denkert C, Rubio IT, de Azambuja E, **Curigliano G**, Gentilini O, Gnani M, Günther A, Hauser N, Heil J, Knauer M, Knotek-Roggenbauer C, Knox S, Kovacs T, Kuerer HM, Loibl S, Mannhart M, Meattini I, Penault-Llorca F, Radošević-Robin N, Sager P, Španić T, Steyerova P, Tausch C, Peeters MTFDV, Weber WP, Cardoso MJ, Poortmans P. Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox. *Lancet Oncol*. 2021 Jan;22(1):e18-e28. doi: 10.1016/S1470-2045(20)30580-5. PMID: 33387500.

411) Corti C, **Curigliano G**. Commentary: SARS-CoV-2 vaccines and cancer patients. *Ann Oncol*. 2021 Apr;32(4):569-571. doi: 10.1016/j.annonc.2020.12.019. Epub 2021 Jan 12. PMID: 33450404; PMCID: PMC7831848.

412) Belli C, Penault-Llorca F, Ladanyi M, Normanno N, Scazecz JY, Lacroix L, Reis-Filho JS, Subbiah V, Gainor JF, Endris V, Repetto M, Drilon A, Scarpa A, André F, Douillard JY, **Curigliano G**. ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research. *Ann Oncol*. 2021 Mar;32(3):337-350. doi: 10.1016/j.annonc.2020.11.021. Epub 2021 Jan 14. PMID: 33455880.

413) Marra A, **Curigliano G**. Adjuvant and Neoadjuvant Treatment of Triple- Negative Breast Cancer With Chemotherapy. *Cancer J*. 2021 Jan-Feb 01;27(1):41-49. doi: 10.1097/PPO.0000000000000498. PMID: 33475292.

- 414) Rugo HS, Im SA, Cardoso F, Cortés J, **Curigliano G**, Musolino A, Pegram MD, Wright GS, Saura C, Escrivá-de-Romaní S, De Laurentiis M, Levy C, Brown-Glaberman U, Ferrero JM, de Boer M, Kim SB, Petraková K, Yardley DA, Freedman O, Jakobsen EH, Kaufman B, Yerushalmi R, Fasching PA, Nordstrom JL, Bonvini E, Koenig S, Edlich S, Hong S, Rock EP, Gradishar WJ; SOPHIA Study Group. Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial. *JAMA Oncol.* 2021 Apr 1;7(4):573-584. doi: 10.1001/jamaoncol.2020.7932. PMID: 33480963; PMCID: PMC7823434.
- 415) Tarantino P, Gandini S, Trapani D, Criscitiello C, **Curigliano G**. Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: A systematic review and meta-analysis of randomized clinical trials. *Crit Rev Oncol Hematol.* 2021 Mar;159:103223. doi: 10.1016/j.critrevonc.2021.103223. Epub 2021 Jan 19. PMID: 33482345.
- 416) Esposito A, Marra A, Bagnardi V, Frasson S, Morganti S, Viale G, Zagami P, Varano GM, Buccimazza G, Orsi F, Venetis K, Mazzarella L, Viale G, Fusco N, Criscitiello C, **Curigliano G**. Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis. *Eur J Cancer.* 2021 Mar;145:197-209. doi: 10.1016/j.ejca.2020.12.028. Epub 2021 Jan 22. PMID: 33493979.
- 417) Trapani D, Yves Douillard J, Winer EP, Burstein H, Anne Carey L, Cortes J, Lopes G, Gralow JR, Gradishar WJ, Magrini N, **Curigliano G**, Ilbawi AM. The global landscape of treatment standards for breast cancer. *J Natl Cancer Inst.* 2021 Jan 27:djab011. doi: 10.1093/jnci/djab011. Epub ahead of print. PMID: 33502535.
- 418) Criscitiello C, Morganti S, **Curigliano G**. Antibody-drug conjugates in solid tumors: a look into novel targets. *J Hematol Oncol.* 2021 Jan 28;14(1):20. doi: 10.1186/s13045-021-01035-z. PMID: 33509252; PMCID: PMC7844898.
- 419) Onesti CE, Tagliamento M, **Curigliano G**, Harbeck N, Bartsch R, Wildiers H, Tjan-Heijnen V, Martin M, Rottey S, Generali D, Campone M, Cristofanilli M, Pusztai L, Peeters M, Berchem G, Cortes J, Ruhstaller T, Ciruelos E, Rugo HS, Jerusalem G. Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology. *JCO Glob Oncol.* 2021 Feb;7:162-172. doi: 10.1200/GO.20.00589. PMID: 33529077; PMCID: PMC8081548.
- 420) Horgan D, Ciliberto G, Conte P, **Curigliano G**, Seijo L, Montuenga LM, Garassino M, Penault-Llorca F, Galli F, Ray-Coquard I, Querleu D, Riegman P, Kerr K, Van Poppel H, Bjartell A, Codacci-Pisanelli G, Koeva-Balabanova J, Paradiso A, Maravic Z, Fotaki V, Malats N, Bernini C, Buglione S, Kent A, Munzone E, Belina I, Van Meerbeeck J, Duffy M, Jagielska B, Capoluongo E. Bringing Onco-Innovation to Europe's Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised Medicine. *Cancers (Basel).* 2021 Feb 2;13(3):583. doi: 10.3390/cancers13030583. PMID: 33540773; PMCID: PMC7867284.
- 421) Horgan D, Ciliberto G, Conte P, Baldwin D, Seijo L, Montuenga LM, Paz-Ares L, Garassino M, Penault-Llorca F, Galli F, Ray-Coquard I, Querleu D, Capoluongo E, Banerjee S, Riegman P, Kerr K, Horbach B, Büttner R, Van Poppel H, Bjartell A, Codacci-Pisanelli G, Westphalen B, Calvo F, Koeva-Balabanova J, Hall S, Paradiso A, Kalra D, Cobbaert C, Varea Menendez R, Maravic Z, Fotaki V, Bennouna J, Cauchin E, Malats N, Gutiérrez-Ibarluzea I, Gannon B, Mastrois K, Bernini C, Gallagher W, Buglioni S, Kent A, Munzone E, Belina I, Van Meerbeeck J, Duffy M, Sarnowska E, Jagielska B, Mee S, **Curigliano G**. Bringing Greater Accuracy to Europe's Healthcare Systems: The Unexploited Potential of Biomarker Testing in Oncology. *Biomed Hub.* 2020 Sep 14;5(3):182-223. doi: 10.1159/000511209. PMID: 33564664; PMCID: PMC7841733.
- 422) Morganti S, **Curigliano G**. Combinations using checkpoint blockade to overcome resistance. *Ecancermedicalscience.* 2020 Dec 3;14:1148. doi: 10.3332/ecancer.2020.1148. PMID: 33574893; PMCID: PMC7864692.
- 423) Tarantino P, **Curigliano G**. Activity of novel anti-HER2 agents for breast cancer based on hormone receptors expression. *Breast Cancer Res Treat.* 2021 Apr;186(3):885-886. doi: 10.1007/s10549-021-06150-6. Epub 2021 Feb 25. PMID: 33634418.
- 424) Malhotra J, Nikolinakos P, Leal T, Lehman J, Morgensztern D, Patel JD, Wrangle JM, **Curigliano G**, Greillier L, Johnson ML, Ready N, Robinet G, Lally S, Maag D, Valenzuela R, Blot V, Besse B. A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC. *J Thorac Oncol.* 2021 Feb 27:S1556-0864(21)01745-7. doi: 10.1016/j.jtho.2021.02.022. Epub ahead of print. PMID: 33652156.
- 425) Tarantino P, Mazzarella L, Marra A, Trapani D, **Curigliano G**. The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality. *Cancer Treat Rev.* 2021 Mar;94:102169. doi: 10.1016/j.ctrv.2021.102169. Epub 2021 Feb 20. PMID: 33652262.
- 426) Meattini I, Poortmans PM, Aznar MC, Becherini C, Bonzano E, Cardinale D, Lenihan DJ, Marrazzo L, **Curigliano G**, Livi L. Association of Breast Cancer Irradiation With Cardiac Toxic Effects: A Narrative Review. *JAMA Oncol.* 2021 Jun 1;7(6):924-932. doi: 10.1001/jamaoncol.2020.7468. PMID: 33662107.
- 427) Attili I, Tarantino P, Passaro A, Stati V, **Curigliano G**, de Marinis F. Strategies to overcome resistance to immune checkpoint blockade in lung cancer. *Lung Cancer.* 2021 Apr;154:151-160. doi: 10.1016/j.lungcan.2021.02.035. Epub 2021 Mar 3. PMID: 33684660.
- 428) Desai A, Gainor JF, Hegde A, Schram AM, **Curigliano G**, Pal S, Liu SV, Halmos B, Groisberg R, Grande E, Dragovich T, Matrana M, Agarwal N, Chawla S, Kato S, Morgan G, Kasi PM, Solomon B, Loong HH, Park H, Choueiri TK, Subbiah IM, Pemmaraju N, Subbiah V; COVID19 and Cancer Clinical Trials Working Group. COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. *Nat Rev Clin Oncol.* 2021 May;18(5):313-319. doi: 10.1038/s41571-021-00487-z. Epub 2021 Mar 15. Erratum in: *Nat Rev Clin Oncol.* 2021 Mar 23;: PMID: 33723371; PMCID: PMC7957448.
- 429) Quintana Á, Peg V, Prat A, Moliné T, Villacampa G, Paré L, Galván P, Dientsmann R, Schmid P, **Curigliano G**, Muñoz-Couselo E, Perez-García J, Martí M, Blanco-Heredia J, Anjos CD, Vazquez M, De Mattos-Arruda L, Cortés J. Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer. *Eur J Cancer.* 2021 May;148:134-145. doi: 10.1016/j.ejca.2021.01.037. Epub 2021 Mar 17. PMID: 33743482.
- 430) Desai A, Gainor JF, Hegde A, Schram AM, **Curigliano G**, Pal S, Liu SV, Halmos B, Groisberg R, Grande E, Dragovich T, Matrana M, Agarwal N, Chawla S, Kato S, Morgan G, Kasi PM, Solomon B, Loong HH, Park H, Choueiri TK, Subbiah IM, Pemmaraju N, Subbiah V; COVID19 and Cancer Clinical Trials Working Group. Author Correction: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. *Nat Rev Clin Oncol.* 2021 May;18(5):320. doi: 10.1038/s41571-021-00503-2. Erratum for: *Nat Rev Clin Oncol.* 2021 May;18(5):313-319. PMID: 33758378; PMCID: PMC7985918.
- 431) Galardi F, De Luca F, Biagioni C, Migliaccio I, **Curigliano G**, Minisini AM, Bonechi M, Moretti E, Risi E, McCartney A, Benelli M, Romagnoli D, Cappadona S, Gabellini S, Guarducci C, Conti V, Biganzoli L, Di Leo A, Malorni L. Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TReEnd trial. *Breast Cancer Res.* 2021 Mar 24;23(1):38. doi: 10.1186/s13058-021-01415-w. PMID: 33761970; PMCID: PMC7992319.
- 432) Campanale A, Di Napoli A, Ventimiglia M, Pileri S, Minella D, **Curigliano G**, Martelli M, De Vita R, Di Giulio P, Montorsi M, Veronesi P, Giordano S, Iachino A, Lispi L. Chest wall infiltration is a critical prognostic factor in breast implant-associated anaplastic large-cell lymphoma affected patients. *Eur J Cancer.* 2021 May;148:277-286. doi: 10.1016/j.ejca.2021.01.041. Epub 2021 Mar 23. PMID: 33765512.

- 433) Corti C, Crimini E, Tarantino P, Pravettoni G, Eggermont AMM, Delaloge S, **Curigliano G**. SARS-CoV-2 vaccines for cancer patients: a call to action. *Eur J Cancer*. 2021 May;148:316-327. doi: 10.1016/j.ejca.2021.01.046. Epub 2021 Feb 25. PMID: 33770576; PMCID: PMC7904467.
- 434) Vernieri C, Nichetti F, Lalli L, Moscetti L, Giorgi CA, Griguolo G, Marra A, Randon G, Rea CG, Ligorio F, Scagnoli S, De Angelis C, Molinelli C, Fabbri A, Ferraro E, Trapani D, Milani A, Agostinetto E, Bernocchi O, Catania G, Vantaggiato A, Palleschi M, Moretti A, Basile D, Cinausero M, Ajazi A, Castagnoli L, Lo Vullo S, Gerratana L, Puglisi F, La Verde N, Arpino G, Rocca A, Ciccarese M, Pedersini R, Fabi A, Generali D, Losurdo A, Montemurro F, **Curigliano G**, Del Mastro L, Michelotti A, Cortesi E, Guarneri V, Pruneri G, Mariani L, de Braud F. Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET). *Clin Cancer Res*. 2021 Jun 15;27(12):3443-3455. doi: 10.1158/1078-0432.CCR-20-4928. Epub 2021 Mar 30. PMID: 33785482.
- 435) Pérez-García JM, Llombart-Cussac A, G Cortés M, **Curigliano G**, López-Miranda E, Alonso JL, Bermejo B, Calvo L, Carañana V, de la Cruz Sánchez S, M Vázquez R, Prat A, R Borrego M, Sampayo-Cordero M, Seguí-Palmer MA, Soberino J, Malfettone A, Schmid P, Cortés J. Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase II trial. *Eur J Cancer*. 2021 May;148:382-394. doi: 10.1016/j.ejca.2021.02.028. Epub 2021 Mar 29. PMID: 33794440.
- 436) Park K, Chang GC, **Curigliano G**, Lim WT, Soo RA, Molina-Vila MA, Cattani V, Darville H, Gandossi E, Smutna V, Sudey I, Viteri S. Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation. *Lung Cancer*. 2021 May;155:127-135. doi: 10.1016/j.lungcan.2021.03.012. Epub 2021 Mar 13. PMID: 33798902.
- 437) Loibl S, Poortmans P, Morrow M, Denkert C, **Curigliano G**. Breast cancer. *Lancet*. 2021 May 8;397(10286):1750-1769. doi: 10.1016/S0140-6736(20)32381-3. Epub 2021 Apr 1. Erratum in: *Lancet*. 2021 May 8;397(10286):1710. PMID: 33812473.
- 438) Fucà G, Corti F, Ambrosini M, Intini R, Salati M, Fenocchio E, Manca P, Manai C, Daniel F, Raimondi A, Morano F, Corallo S, Prisciandaro M, Spallanzani A, Quarà V, Belli C, Vaiani M, **Curigliano G**, Cremolini C, De Braud F, Di Bartolomeo M, Zagonel V, Lonardi S, Pietrantonio F. Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. *J Immunother Cancer*. 2021 Apr;9(4):e002501. doi: 10.1136/jitc-2021-002501. PMID: 33849927; PMCID: PMC8051394.
- 439) Schettini F, Giudici F, Bernocchi O, Sirico M, Corona SP, Giuliano M, Locci M, Paris I, Scambia G, De Placido S, Rescigno P, Prat A, **Curigliano G**, Generali D. Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis. *Eur J Cancer*. 2021 May;149:134-152. doi: 10.1016/j.ejca.2021.02.035. Epub 2021 Apr 13. PMID: 33862496.
- 440) de Guillebon E, Jimenez M, Mazzarella L, Betsou F, Stadler P, Peták I, Jeannot E, Chanas L, Servant N, Marret G, Duso BA, Legrand F, Kornerup KN, Bernhart SH, Balogh G, Dóczi R, Filotás P, **Curigliano G**, Bièche I, Guérin J, Dirner A, Neuzillet C, Girard N, Borcoman E, Larbi Chérif L, Tresca P, Roufai DB, Dupain C, Scholl S, André F, Fernandez X, Filleron T, Kamal M, Le Tourneau C. Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trial. *ESMO Open*. 2021 Jun;6(3):100106. doi: 10.1016/j.esmoop.2021.100106. Epub 2021 Apr 14. PMID: 33865192; PMCID: PMC8066350.
- 441) Trapani D, Gandini S, Corti C, Crimini E, Bellerba F, Minchella I, Criscitiello C, Tarantino P, **Curigliano G**. Benefit of adjuvant chemotherapy in patients with lobular breast cancer: A systematic review of the literature and metanalysis. *Cancer Treat Rev*. 2021 Jun;97:102205. doi: 10.1016/j.ctrv.2021.102205. Epub 2021 Apr 9. PMID: 33878560.
- 442) **Curigliano G**, Gelderblom H, Mach N, Doi T, Tai D, Forde PM, Sarantopoulos J, Bedard PL, Lin CC, Hodi FS, Wilgenhof S, Santoro A, Sabatos-Peyton CA, Longmire TA, Xyrafas A, Sun H, Gutzwiller J, Manenti L, Naing A. Phase I/II Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spaltalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors. *Clin Cancer Res*. 2021 Apr 21. doi: 10.1158/1078-0432.CCR-20-4746. Epub ahead of print. PMID: 33883177.
- 443) Gyawali B, de Vries EGE, Dafni U, Amaral T, Barriuso J, Bogaerts J, Calles A, **Curigliano G**, Gomez-Roca C, Kiesewetter B, Oosting S, Passaro A, Pentheroudakis G, Piccart M, Roitberg F, Tabernero J, Tarazona N, Trapani D, Wester R, Zarkavelis G, Zielinski C, Zygoura P, Cherny NI. Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring. *ESMO Open*. 2021 Jun;6(3):100117. doi: 10.1016/j.esmoop.2021.100117. Epub 2021 Apr 20. PMID: 33887690; PMCID: PMC8086024.
- 444) Corti F, Lonardi S, Intini R, Salati M, Fenocchio E, Belli C, Borelli B, Brambilla M, Prete AA, Quarà V, Antista M, Fassan M, Morano F, Spallanzani A, Ambrosini M, **Curigliano G**, de Braud F, Zagonel V, Fucà G, Pietrantonio F. The Pan-Immune-Inflammation Value in microsatellite instability-high metastatic colorectal cancer patients treated with immune checkpoint inhibitors. *Eur J Cancer*. 2021 Jun;150:155-167. doi: 10.1016/j.ejca.2021.03.043. Epub 2021 Apr 24. PMID: 33901794.
- 445) Tagliabue M, Maffini F, Fumagalli C, Gandini S, Lepanto D, Corso F, Cacciola S, Ranghiero A, Rappa A, Vacirca D, Cossu Rocca M, Alterio D, Guerini Rocco E, Cattaneo A, Chu F, Zorzi S, **Curigliano G**, Chiocca S, Barberis M, Viale G, Ansarin M. Author Correction: A role for the immune system in advanced laryngeal cancer. *Sci Rep*. 2021 May 3;11(1):9760. doi: 10.1038/s41598-021-89174-8. Erratum for: *Sci Rep*. 2020 Oct 27;10(1):18327. PMID: 33941821; PMCID: PMC8093299.
- 446) **Curigliano G**, Martin M, Jhaveri K, Beck JT, Tortora G, Fazio N, Maur M, Hubner RA, Lahner H, Donnet V, Ajaja O, Li Z, Blumenstein L, Andre F. Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study. *Eur J Cancer*. 2021 Jul;151:49-62. doi: 10.1016/j.ejca.2021.03.042. Epub 2021 May 5. PMID: 33964572.
- 447) Criscitiello C, Corti C, Pravettoni G, **Curigliano G**. Managing side effects of immune checkpoint inhibitors in breast cancer. *Crit Rev Oncol Hematol*. 2021 Jun;162:103354. doi: 10.1016/j.critrevonc.2021.103354. Epub 2021 May 21. PMID: 34029683.
- 448) Trapani D, Giugliano F, Uliano J, Zia VAA, Marra A, Viale G, Ferraro E, Esposito A, Criscitiello C, D'amico P, **Curigliano G**. Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer: a systematic review. *Breast Cancer Res Treat*. 2021 Jun;187(2):323-337. doi: 10.1007/s10549-021-06259-8. Epub 2021 May 27. PMID: 34043122.
- 449) Crimini E, Repetto M, Aftimos P, Botticelli A, Marchetti P, **Curigliano G**. Precision medicine in breast cancer: From clinical trials to clinical practice. *Cancer Treat Rev*. 2021 Jul;98:102223. doi: 10.1016/j.ctrv.2021.102223. Epub 2021 May 12. PMID: 34049187.
- 450) Tarantino P, Trapani D, **Curigliano G**. Mastering the Use of Novel Anti-HER2 Treatment Options. *JCO Oncol Pract*. 2021 Jun 2;OP2100216. doi: 10.1200/OP.21.00216. Epub ahead of print. PMID: 34077256.
- 451) Trapani D, **Curigliano G**. COVID-19 vaccines in patients with cancer. *Lancet Oncol*. 2021 Jun;22(6):738-739. doi: 10.1016/S1470-2045(21)00250-3. PMID: 34087120; PMCID: PMC8169039.
- 452) Gainor JF, **Curigliano G**, Kim DW, Lee DH, Besse B, Baik CS, Doebele RC, Cassier PA, Lopes G, Tan DSW, Garralda E, Paz-Ares LG, Cho BC, Gadgeel SM, Thomas M, Liu SV, Taylor MH, Mansfield AS, Zhu VW, Clifford C, Zhang H, Palmer M, Green J, Turner CD, Subbiah V. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. *Lancet Oncol*. 2021 Jun 9;S1470-2045(21)00247-3. doi: 10.1016/S1470-2045(21)00247-3. Epub ahead of print. PMID: 34118197.
- 453) Subbiah V, Hu MI, Wirth LJ, Schuler M, Mansfield AS, **Curigliano G**, Brose MS, Zhu VW, Lebourneux S, Bowles DW, Baik CS, Adkins D, Keam B, Matos I, Garralda E, Gainor JF, Lopes G, Lin CC, Godbert Y, Sarker D, Miller SG, Clifford C, Zhang H, Turner CD, Taylor MH. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-

label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol. 2021 Jun 9:S2213-8587(21)00120-0. doi: 10.1016/S2213-8587(21)00120-0. Epub ahead of print. PMID: 34118198.

454) Yekedüz E, Trapani D, Xu W, de Vries EG, Labaki C, Gyawali B, Gulati S, Nabhan C, Utkan G, **Curigliano G**, Choueiri TK, Ürün Y. Assessing Population Diversity in Phase III Trials of Cancer Drugs Supporting FDA Approval in Solid Tumors. Int J Cancer. 2021 Jun 14. doi: 10.1002/ijc.33708. Epub ahead of print. PMID: 34124786.

455) Esposito I, Calabria S, Piccinini C, Addeci A, Dondi L, Ronconi G, Pedrini A, Maggioni AP, **Curigliano G**, Listi A, Righi L, Novello S, Buglioni S, Ciliberto G, Pruneri G, Martini N. L'oncologia mutazionale del carcinoma polmonare: marcatori molecolari, farmaci, condizioni negoziali ed esperienze in centri di riferimento nazionale [Mutational oncology of lung cancer: molecular markers, drugs, negotiation conditions and experiences in national reference centers.]. Recenti Prog Med. 2021 Jun;112(6):419-437. Italian. doi: 10.1701/3620.36025. PMID: 34128934.

456) Saini KS, Martins-Branco D, Tagliamento M, Vidal L, Singh N, Punie K, Saini ML, Chico I, **Curigliano G**, de Azambuja E, Lambertini M. Emerging issues related to COVID-19 vaccination in patients with cancer. Oncol Ther. 2021 Jun 16. doi: 10.1007/s40487-021-00157-1. Epub ahead of print. PMID: 34137014.

457) **Curigliano G**, Eggermont AMM. Adherence to COVID-19 vaccines in cancer patients: promote it and make it happen! Eur J Cancer. 2021 May 24:S0959-8049(21)00311-7. doi: 10.1016/j.ejca.2021.05.007. Epub ahead of print. PMID: 34147290.

458) Saini KS, Martins-Branco D, Tagliamento M, Vidal L, Singh N, Punie K, Saini ML, Chico I, **Curigliano G**, de Azambuja E, Lambertini M. Emerging issues related to COVID-19 vaccination in patients with cancer. Oncol Ther. 2021 Jun 16:1-11. doi: 10.1007/s40487-021-00157-1. Epub ahead of print. PMID: 34155481; PMCID: PMC8208766.

459) Repetto M, Conforti F, Pirola S, Calvello M, Pala L, Bonanni B, Catania C, **Curigliano G**, De Pas T. Thymic carcinoma with Lynch syndrome or microsatellite instability, a rare entity responsive to immunotherapy. Eur J Cancer. 2021 Jun 20;153:162-167. doi: 10.1016/j.ejca.2021.05.029. Epub ahead of print. PMID: 34161910.

460) Giugliano F, Crimini E, Tarantino P, Zagami P, Uliano J, Corti C, Trapani D, **Curigliano G**, Ascierto PA, First line treatment of BRAF mutated advanced melanoma: Does one size fit all?, Cancer Treatment Reviews, Volume 99, 2021, 102253, ISSN 0305-7372, <https://doi.org/10.1016/j.ctrv.2021.102253>.

ORGANIZZAZIONE, DIREZIONE E COORDINAMENTO DI CENTRI O GRUPPI DI RICERCA NAZIONALI E INTERNAZIONALI O PARTECIPAZIONE AGLI STESSI

(per ciascuna voce inserire anno, ruolo, gruppo di ricerca, ecc.)

Direzione e Coordinamento di progetti finanziati su base competitiva

1994-1995	Responsabile del Progetto "DNA adducts in transitional cell carcinoma of the bladder", Istituto Toniolo, Milano. Finanziamento 30.000.000 lire.
1995-1998	Responsabile del progetto triennale "Biology and cancerogenesis of transitional cell of the bladder", Fondazione Italiana per la Ricerca sul Cancro. Finanziamento 150.000.000 Lire.
2001-2003	Coordinatore di WP 3, progetto "Identification of gene signature predictive of response to bevacizumab in triple negative breast cancer". Associazione Italiana per la Ricerca sul Cancro. Finanziamento: 150.000 Euro.
2004-2006	Coordinatore di WP 2, progetto "Identification of Mechanisms of resistance to trastuzumab". Ricerca Finalizzata Ministero della Salute. Finanziamento 210.000 Euro.
2006-2008	Coordinatore di WP 2, progetto "Eps8 gene polymorphism and toxicity from cisplatin". Fondazione Cariplo. Finanziamento 60.000 Euro.
2009-2011	Coordinatore di WP 2, progetto "Role of cancer stem cells in anticancer drug resistance", Fondazione Umberto Veronesi. Finanziamento 120.000 Euro
2011-2012	Responsabile del progetto "Genome Remodeling in Luminal B, HER2 and Ductal Triple Negative Breast Cancer Metastasis and Xenograft: Exome sequencing analysis for identification of driver pathways to overcome resistance". Fondazione Umberto Veronesi. Finanziamento: 200.000 Euro.
2012-2013	Responsabile del progetto "Measuring Estrogen Levels During Letrozole Interruption - The SOLE-EST Substudy". Career Catalyst Research (CCR) Komen Foundation Grant. Finanziamento: 450.000 Dollari.
2013-2015	Coordinatore della Task 5 del progetto "Understanding how cancer stem cells drive breast cancer growth and how to exploit them as its Achilles's heel". Associazione Italiana per la Ricerca sul Cancro. Finanziamento 3.000.000 Euro.
2013-2015	Responsabile Nazionale del progetto ERA-Net on translational cancer research (TRANSCAN) "CD3 and CD20 lymphocytes infiltration to predict chemosensitivity in patients with triple negative breast cancer", UGI1. ERA-NET European Union Grant. Finanziamento: 3.000.000 Euro
2015-2017	Responsabile del progetto "Clinical utility of a next generation sequencing-based "oncochip" for therapeutic decision in metastatic breast cancer". Associazione Italiana per la Ricerca sul Cancro. Finanziamento 230.936 Euro.
2016-2019	Responsabile del Progetto "Master protocol of precision medicine for treatment of metastatic breast cancer". Ricerca Finalizzata Ministero della Salute 230.000 Euro
2016-2019	Coordinatore WP 3 del progetto "Development of effective cancer therapies based on functional proteomics and cancer stem cell targeting". Associazione Italiana per la Ricerca sul Cancro. Finanziamento 230.733 Euro.
2019-2021	Coordinatore WP 1 "An interdisciplinary approach for the management of the elderly multimorbid patients with breast cancer therapy induced cardiac toxicity", consorzio CARDIOCARE, Horizon 2020: Finanziamento 2.500.000 Euro
2021-2026	Coordinatore WP 6 "Optimal treatment for patients with solid tumours in Europe through Artificial intelligence" Consorzio OPTIMA; Horizon 2020, Finanziamento 10.000.000 Euro

Incarichi in Società Scientifiche Internazionali

European Society for Medical Oncology (ESMO)

2006-Oggi	Faculty Committee Member Breast Cancer, European Society for Medical Oncology (ESMO)
2008-2018	Scientific Committee Member, IMPAKT Breast Cancer Conference (fondatori: J Baselga e M Piccart)
2014-2014	Scientific Committee Chair, Metastatic Breast Cancer Track, ESMO
2012-2019	Member of the ESMO Press & Media Affairs Committee
2014-2019	Official Spokesman for Breast Cancer, Press & Media Affairs Committee, ESMO
2019-2021	Chair of the Breast Cancer Faculty
2013-2019	ESMO Women for Oncology Committee
2013-Oggi	Member of the Global Policy Committee

2014-2014	Scientific Committee Chair, IMPAKT meeting, ESMO
2017-Oggi	Member of the Membership Committee
2014-Oggi	Member of the Nomination Committee
2016-2017	Scientific Committee Member, Breast Cancer Track, ESMO Asia Congress, Singapore
2016-2018	Scientific Committee Member, Advanced Breast Cancer Track European Breast Cancer Conference 2018,
2016-2018	Scientific Committee Member, Metastatic Breast cancer Track, ESMO Congress 2018, Munich, Germany
2017-Oggi	Chair della Nomination Committee
2018-Oggi	Member of the Precision Medicine Working Group
2019-Oggi	Chair della Clinical Practice Guidelines Committee
2019-Oggi	Membro dell'ESMO Council
2020-2020	Scientific Co-Chair, Advanced Breast cancer Congress (ABC 5), ESMO
2019-2021	Fondatore e Scientific Chair di ESMO Breast Cancer Congress
<u>International Breast cancer study Group (IBCSG)</u>	
2009-Oggi	Componente dello Scientific Advisory Council, IBCSG
2017-2019	Coordinatore Fondatore del Gruppo PINK (Phase I in Breast Cancer)
<u>Breast International Group (BIG)</u>	
2009-Oggi	Componente dello Scientific Advisory Council
<u>International Cardio-Oncology Society (ICOS)</u>	
2014-Oggi	Presidente della Società, Founding Member
<u>St. Gallen Oncology Conferences</u>	
2009-Oggi	Componente del "St. Gallen Early Breast Cancer Consensus Conference", Scientific Committee Member
2016-2021	Conference Scientific Chair, "St. Gallen Oncology Conference on Treatment of Early Breast Cancer" 2017, 2019, 2021
<u>European School of Oncology (ESO)</u>	
2004-Oggi	Breast Cancer Faculty
<u>European Society of Breast Cancer Specialists (EUSOMA)</u>	
2017-Oggi	Coordinatore del Working Group Quality Indicators, membro Executive Committee
<u>Associazione Italiana di Oncologia Medica (AIOM)</u>	
2014-2017	Componente del Working Group Associazione Italiana di Oncologia Medica "Rapporti con ESMO"
2017-2019	Presidente del Comitato Scientifico AIOM
<u>World Health Organization (WHO)</u>	
2019-2020	Coordinamento del Gruppo di lavoro sulla Cancer Workforce di WHO ed ESMO
<u>Society of Immunotherapy of Cancer (SITC)</u>	
2018-Oggi	Scientific Review Board
<u>Attività di valutazione in procedure di selezione competitive internazionali e Steering Committees</u>	
2010-Oggi	Institut National du Cancer, INCa, Scientific Review Board Committee Member
2011-2012	Scientific Peer Review Committee, Komen Foundation
2014-Oggi	Review Committee Member New Drugs Development and Breast Cancer Projects, Cancer Research UK
2016-Oggi	Review Committee Member New Drugs Development and Breast Cancer Projects. Fondation ARC pour la recherche sur le cancer
2016-Oggi	Review Committee Member New Drugs Development and Breast Cancer Projects, Norwegian Cancer Society
2016-Oggi	Review Committee Member, Komen Foundation
2016-Oggi	Review Committee Member New Drugs Development and Breast Cancer Projects, Breast Cancer Now Foundation
2016-Oggi	Review Committee Member New Drugs Development and Breast Cancer Projects, Belgian Foundation against Cancer
2016-Oggi	Membro del Comitato Scientifico della Fondazione Beretta per la ricerca sul Cancro
2016-2018	Membro del Comitato Scientifico della Fondazione IEO-CCM
2018-2018	Steering Committee Chair Terry Fox Foundation, Toronto, Canada
2018-Oggi	Membro del Consiglio di Amministrazione della Fondazione IEO-CCM
2018-Oggi	Membro del Consiglio di Amministrazione e del Consiglio Direttivo Nazionale della Lega Italiana Lotta ai Tumori
2018-Oggi	Componente del Consiglio Superiore di Sanità, Sezione V, Farmaci e Dispositivi
2019-2020	Presidente del Comitato Scientifico della Lega Italiana Lotta ai Tumori
2020	Coordinamento e Relatore presso il Ministero della Salute del Gruppo di Lavoro sul Conflitto di Interesse nella Sperimentazione clinica
2020	Coordinamento e Relatore presso il Ministero della Salute del Gruppo di Lavoro sul Linfoma Anaplastico a Grandi Cellule Associato a Protesi
2021	Componente del Gruppo di Lavoro Agenzia Nazionale per i Servizi Sanitari Regionali (AGENAS) per la definizione di criteri di accreditamento nazionale dei Molecular Tumor Board
2021-Oggi	Componente del Tavolo della Pianificazione Oncologica Nazionale, Ministero della Salute, referente per Innovazione e Ricerca Traslaazionale
<u>Steering Committee Chair e ruolo di Principal Investigator</u>	
2014-Oggi	Chair della Steering Committee (SC) e di Data Safety Monitoring Committee o componente di SC in studi internazionali globali per lo Sviluppo di Nuovi Farmaci in tumori solidi e tumori mammari. Ha contribuito e sta contribuendo allo Sviluppo di trastuzumab emtansine, tucatinib, pralsetinib, trastuzumab deruxtecan, SERD orali, immune-checkpoint inhibitors di nuova generazione
2013-Oggi	Principal Investigator di almeno 150 sperimentazioni di fase I-II-III presso l'Istituto Europeo di Oncologia (IEO)

ATTIVITÀ QUALI LA DIREZIONE O LA PARTECIPAZIONE A COMITATI EDITORIALI DI RIVISTE SCIENTIFICHE
(per ciascuna voce inserire anno, ruolo, rivista scientifica, ecc.)

2013-Oggi	Editor, Annals of Oncology, Breast Cancer Section
2013-2020	Editor, Journal of Clinical Oncology, Breast Cancer Section
2013-Oggi	Editor in Chief, Cancer Treatment Review (con Andrés Cervantes e Rolf A. Stahel)
2014-2018	Editor in Chief, ESMO Post - Official Journal of the ESMO Congress
2014-2016	Associate Editor, The Breast
2014-Oggi	Associate Editor, OncoReview

2015-Oggi	Associate Editor, Cardio-Oncology
2016-Oggi	Editor in Chief, The Breast (con Fatima Cardoso e Nehmat Houssami)
2016-Oggi	Associate Editor, Section Breast Cancer, European Journal of Cancer
2017-Oggi	Associate Editor, Current Opinion in Oncology
2018-Oggi	Editor, Recenti Progressi in Medicina
2021-Oggi	Associate Editor, Breast Cancer Research and Treatment

TITOLARITÀ DI BREVETTI

(per ciascun brevetto, inserire autori, titolo, tipologia, numero brevetto, ecc.)

"Use of the expression of specific genes for the prognosis of patients with triple negative breast cancer" Brevetto 16305838.
Inventors: S. Michiels, M. A. Bayar, F. André, C. Criscitiello e G. Curigliano.

PREMI E RICONOSCIMENTI NAZIONALI E INTERNAZIONALI PER ATTIVITÀ DI RICERCA

(inserire premio, data, ente organizzatore, ecc.)

Socio dell'Associazione Italiana di Oncologia Medica (AIOM), dal 01-01-1996 a oggi
Active Member of American Society of Clinical Oncology (ASCO), dal 01-07-2000 a oggi
Active Member of the European Society of Medical Oncology (ESMO), dal 01-07-2001 a oggi
Active Member American Association for Cancer Research (AACR), dal 21-08-2013 a oggi
Presidente International CardiOncology Society (ICOS), dal 08-07-2014 a oggi
Member of the Society for Immunotherapy of Cancer, dal 06-06-2015 a oggi
30.05.2016 Cavaliere del Lavoro su Iniziativa del Presidente della Repubblica
15.03.2017 Umberto Veronesi Award, Wien, Austria
15.09.2017 Fellowship of the European Academy of Cancer Sciences, Paris, France

PARTECIPAZIONE IN QUALITÀ DI RELATORE A CONGRESSI E CONVEGNI DI INTERESSE INTERNAZIONALE

(inserire titolo congresso/convegno, data, ecc.)

2003, Chicago, USA,	Invited Speaker ASCO 2003, "Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopausal patients",
2006: Atlanta, USA,	Invited Speaker ASCO 2006, Drug Development Track, "What is the role of QTc prolongation assessment in new drugs development phase I oncology trials?"
2007, St Gallen, CH,	Invited Speaker, Saint Gallen Breast Cancer Conference, Saint Gallen, Switzerland, "Immunity and Breast Cancer, Role of vaccination"
2009, St Gallen, CH,	Invited Speaker, Saint Gallen Breast Cancer Conference, Saint Gallen, Switzerland, "Immunity in breast cancer"
2010, Chicago, US,	Invited Speaker, 2010 Annual Meeting of American Society of Clinical Oncology, Chicago, USA, Breast Cancer Track, "Should liver metastases of breast cancer be biopsied to improve treatment choice?"
2010, Boston, USA,	Invited Speaker, Harvard Summer School, "Breast Cancer: New Horizons and Current Controversies", Dana Farber, Brigham Women Cancer Center, Massachussets General Cancer Center Joint Meeting, "Picking the optimal adjuvant chemotherapy regimen".
2011, Ermatingen, CH,	Invited Speaker, ESO-ESMO Masterclass in Medical Oncology, "(Neo)adjuvant treatment of BC"
2011, St Gallen, CH,	Invited Speaker, Saint Gallen Breast Cancer Conference, Saint Gallen, Switzerland, "Immunity and autoimmunity: revising the concepts of response to breast cancer"
2011, Brussels, BE,	Invited Speaker, IMPAKT Breast Cancer Conference, Brussels, Belgium, "Investigating the potential of an immunotherapy: the design of the ideal clinical trial"
2012, Vienna, AU,	Invited Speaker and Scientific Committee Member, ESMO Annual Meeting, Vienna, Austria, "Targeting the host in triple negative breast cancer"
2012, Ermatingen, CH,	Invited Speaker, Invited Speaker, ESO-ESMO Masterclass, "(Neo)adjuvant treatment of BC"
2013, St Gallen, CH,	Invited Speaker and Panelist, Saint Gallen Breast Cancer Conference, "Developing an effective breast cancer vaccine"
2013, Amsterdam, NE,	Invited Speaker, European Cancer Organization, ECCO Cancer Meeting, Amsterdam, The Netherland, "The immunogeneity of breast cancer revisited"
2013, Moscow, RU,	Invited Speaker, Russian Society of Medical Oncology, ESMO-RUSSCO Symposium, "Conceptual approaches to drug therapy of advanced cancers: Breast Cancer"
2013, Porto, PO	Invited Speaker, European Society for Radiotherapy & Oncology (ESTRO Educational Course, Porto, Portugal, "Treatment options in the next 10 years for breast cancer patients"
2013, Amsterdam, NE,	Invited Speaker, European Society of Surgical Oncology Annual Meeting, "Conventional breast pathology or gene profiles"
2013, Geneve, CH,	Invited Speaker, ESMO Symposium on Immuno-Oncology, Geneve, Switzerland, "Breast Cancer"
2014, Madrid, ES,	Scientific Track Chair and Invited speaker, Metastatic Breast Cancer, ESMO Annual Meeting, Madrid, Spain "Design of the ideal trial with Immuno-therapeutics"
2014, Ermatingen, CH	Invited Speaker, ESO-ESMO Masterclass, "Neoadjuvant and adjuvant treatment of HER2+ and TNBC"
2014, Brussels, BE,	Scientific Chair and invited speaker, IMPAKT Breast Cancer Meeting, Brussels, Belgium
2014, Geneva, CH,	Invited Speaker, ESMO Symposium on Immuno-Oncology, Geneva, Switzerland, "Breast Cancer"
2015, Moscow, RU,	Invited Speaker, Russian Society of Medical Oncology, "Immune-checkpoint inhibitors toxicity"
2015, Vienna, AU,	Invited Speaker, European Society for Radiotherapy & Oncology (ESTRO) Educational Course, Vienna, Austria, "Early Breast Cancer Treatment"
2015, Ermatingen, CH	Invited Speaker, Chair Breast Cancer Track, ESO-ESMO Masterclass in Medical Oncology, Ermatingen, Switzerland, "Neoadjuvant and adjuvant treatment of triple negative and HER2 positive breast cancer"; "Treatment of triple negative and HER2 positive advanced breast cancer".
2015, Vienna, AU,	Invited Speaker, Panelist and Scientific Secretary, Saint Gallen Breast Cancer Conference, Vienna, Austria, "Immune pathways and immunome as a target"

2015, Liverpool, UK,	Invited Speaker, European Society of Surgical Oncology Annual Meeting, Liverpool, United Kingdom, "Neoadjuvant chemotherapy in breast cancer"
2015, Vienna, AU,	Invited Speaker, European Cancer Conference 2015 Meeting, Vienna, Austria, "Triple Negative Breast Cancer: biomarkers and opportunities for individualised therapy"
2015, Xiamen, China,	Invited Speaker, 18th Annual Meeting of Chinese Society of Clinical Oncology (CSCO), Xiamen, China, "Immunotherapy in Breast Cancer"
2015, Doha, QA,	Invited Speaker, Breast Cancer Immunotherapy Symposium, "Breast cancer immunogenomics"
2015, Tel Aviv, IS,	Invited Speaker, Israeli Meeting on Cardioncology, "Cardio-Oncology: a clinical perspective"
2015, Brussels, BE,	Invited Speaker, IMPAKT Breast Cancer Meeting, "Microenvironment and metastatic breast cancer"
2015, Lisboa, PO,	Invited Speaker and Panelist, Advanced Breast Cancer International Consensus Conference, "Triple negative: is hope around the corner? Can immune-based therapies by the key?"
2015, Zurich, CH,	Invited Speaker, ESMO Preceptorship on Immuno-Oncology, Zurich, Switzerland, "Breast Cancer"
2015, Doha, QA,	Invited Speaker, Annual Breast Cancer Conference, "Adjuvant Therapy of Early Breast cancer"
2016, Amsterdam, NE,	Invited Speaker, European Breast Cancer Conference, "Are we personalising or just subtyping EBC?"
2016, Bogotá, CO,	Invited Speaker, ESO-ESMO Latin-American Masterclass in Clinical Oncology, "Triple negative BC"
2016, Ermatingen, CH,	Invited Speaker, Chair Breast Cancer Track, ESO-ESMO Masterclass in Medical Oncology, "Neoadjuvant and adjuvant treatment of TN and HER2 positive breast cancer"
2016, Moscow, RU,	Invited Speaker, Co-Chair Breast cancer track, ESO-ESMO Masterclass in Medical Oncology, "Neoadjuvant/Adjuvant chemotherapy and biological agents in early breast cancer"
2016, Budapest, HU,	Invited Speaker, European Society of Surgical Oncology (ESSO) Advanced Course on Oncoplastic Breast Surgery, Budapest, Hungary, "Personalising neoadjuvant treatment to facilitate breast cancer surgery"
2016, London, UK,	Invited Speaker, UK Breast Cancer Research Symposium, Royal College of Physicians, "Immunotherapy in breast cancer: Hype or hope?"
2016, St Petersburg, RU,	Invited Speaker Forum in Oncology, St Petersburg, Russia, "Immunotherapy of breast cancer"
2016, Dubai, EAU,	Invited Speaker, Workshop in Clinical Oncology, "Role of CDK 4-6 inhibitors in advanced breast cancer".
2016, Oxford, UK,	Invited Speaker, ESMO Academy, Oxford, United Kingdom, "Standard of care and future perspectives in metastatic Breast cancer"
2016, Barcelona, ES,	2nd World Congress on Controversies in Breast Cancer, September 8-11, Barcelona, Spain; "Sequencing of agents in HER2 positive breast cancer"; "Select patients with metastatic breast cancer who can be cured"
2016, Cluj, RU	Invited Speaker, American Society of Clinical Oncology (ASCO) international Clinical Trial Workshop (ICTW), "Clinical Trial Design in the era of personalized medicine"
2016, Abu Dhabi, AE,	Invited Speaker, Genome 2016 Meeting, "Optimizing treatment of hormonal positive Metastatic breast cancer: case based discussion"
2016, Singapore,	Invited Speaker, ESMO ASIA 2016 "The role of mentors and sponsorship in women's careers"
2016, Zurich, CH,	Invited Speaker, "ESMO Preceptorship on Immuno-Oncology", "Breast Cancer"
2016, Lausanne, CH,	Invited Speaker, "ESMO Symposium on Immuno-Oncology", "Immuno-oncology clinical in BC"
2016, Lisboa, PO,	Invited Speaker, "ESMO Preceptorship on Breast Cancer", "(Neo) Adjuvant systemic therapy in TNBC"
2016, Vancouver, CAN	Invited Speaker, Global Cardio- Oncology Summit 2016", "Novel Breast cancer therapy: Should we have any cardiovascular concerns?"
2016, New York, USA	Invited Speaker, PRISM 2016 "Breast Oncology's Second Annual Prism Summit Meeting"
2017, Chicago, USA	Invited Speaker, ASCO 2017 Annual Meeting, "Phase 2 Study of Pembrolizumab Monotherapy for previously treated metastatic triple negative Breast cancer"
2017, Paris, FR	Invited Speaker, 1st Annual Paris Breast Cancer Conference, "Neoadjuvant chemotherapy"
2017, Limassol, CY	Invited Speaker, 6th ESO Masterclass in Clinical Oncology, "Neoadjuvant/adjuvant chemotherapy and biological agents", "Management of HER2+ advanced breast cancer "
2017, Amsterdam, NL	Invited Speaker, The European Cancer Congress - ECCO 2017, "Introduction to Immunotherapy and the Science Behind it (Novice)"
2017, Oxford, UK	Invited Speaker, ESMO Academy 2017, "Standard of care and future perspectives in Breast cancer"
2017, Singapore, SGP	Invited Speaker, ESMO Asia congress, "Breast Cancer"
2017, Geneva, CH	Invited Speaker, ESMO Congress on Immuno-Oncology, "Identification of genetic determinants of breast cancer immunogenicity"
2017, Queretaro, MEX	Invited Speaker, ESMO "35 CONGRESO NACIONAL DE ONCOLOGIA SMEO", "Nuevas opciones de tratamiento en cancer de mama RE+ y HER-2+"
2017, Munich, GER	Invited Speaker, ESMO Annual Meeting, Discussant "Atezolizumab in TNBC"
2017, Krakow, KR	Invited Speaker, ESO Refresher Course on Breast Cancer, Keynote lecture: "New therapeutic approaches for breast cancer: established signaling pathways and immune therapy"
2017, Cambridge, UK	Invited Speaker, ESO Masterclass in Oncology Basics for Beginners, "Principles of systemic therapy"
2017, San Jose, CR	Invited Speaker, 3rd ESO-ESMO Latin American Masterclass in Clinical Oncology, "(Neo)Adjuvant chemotherapy and biological agents"
2017, Frankfurt, GER	Invited Speaker, European Breast Cancer Horizon Board, "Immunotherapeutic compounds in development for breast cancer"
2017, Dubai, AE	Invited Speaker, "Current Treatment Landscape of ER+ HER2- ABC"
2017, Belgium, BE	Invited Speaker, IMPAKT, Breast cancer conference, "Overview of Immunotherapy antibodies in BC"
2017, Mumbai, IND	Invited Speaker, Indian National Society of Medical Oncology, "Overcoming Endocrine Resistance in BC"
2017, Tokyo, JAP	Invited Speaker, Japanese Society of Medical Oncology "Palbociclib in metastatic breast cancer",
2017, Lisbon, PT	Invited Speaker, ESMO Preceptorship on Breast Cancer, "Systemic therapy for TNBC"
2017, Berlin, GER	Invited Speaker, 16th ESO-ESMO Masterclass in Clinical Oncology, "Breast Cancer, treatment of TNBC"
2017, New York, USA	Invited Speaker, "Role of LIV1A in Triple-Negative Breast Cancer", Breast Cancer Oncology Summit
2017, Wien, AT	Invited Speaker, Breast cancer International Symposium, "Treatment of DCIS"
2017, Salzburg, AT	Invited Speaker, Salzburg Breast Cancer Talks, "Combination strategies with checkpoint-inhibitors"
2017, Lucerne, CH	Invited Speaker, SAMO Interdisciplinary Workshop on Prospects in Personalized Medicine
2017, San Antonio, USA	Invited Speaker, San Antonio Breast Cancer Symposium, "The role of CDK 4-6 inhibitors in breast cancer"
2017, Sao Paulo, BR	Invited Speaker, São Paulo Breast Cancer Conference, "Immunotherapy of breast cancer"
2017, Jeddah, UAE	Invited Speaker, South Arabia Breast Oncology, "Should Combine Endocrine Therapy with Targeted agents now be the Standard of Care for ER+ Metastatic Breast Cancer?"

2017, Frankfurt, GER	invited Speaker, "Immunotherapeutic compounds in development for breast cancer"
2017, Shanghai, CHN	invited Speaker, 1st Global conference on integrated traditional Chinese and Western medicine and treatment of Breast disease, "Breast: Medical Oncology View"
2017, Taiwan, TW	Invited Speaker, Taipei International Breast Cancer Symposium, "Oncoimmunology of Breast Cancer"
2017, Halle, GER	Invited Speaker, Tumor immunology meets oncology (TIMO XIII), "Prediction of response to IO"
2017, Wien, AT	Invited Speaker, Symposium in Vienna - NGS and predictive biomarkers, "Clinical Challenges and treatment allocation after molecular tumor profiling"
2017, Zurich, CH	Invited Speaker, Second Zurich Immuno-Oncology Symposium, "Breast tumors"
2018, Amsterdam, NL	Invited Speaker, Translational Breast Cancer Symposium, "Developments of immunotherapy in BC"
2018, Chicago, USA	Invited Speaker, 2018 ASCO Annual meeting, "Early data on antibody drug conjugated anti HER2"
2018, Yerevan, AM	Invited Speaker, ESO-ASCO Masterclass in Armenia, "Breast cancer treatment"
2018, Lugano, CH	Invited Speaker, 4th Breast Cancer in Young Women Conference, "News in adjuvant therapy in TNBC"
2018, Il Cairo, EGY	Invited Speaker, 2nd AfME Breast Cancer Forum, "Approaches to Endocrine Resistant HR+ HER2- MBC"
2018, Limassol, CY	Invited Speaker, 7th ESO Arab and Southern European Countries Masterclass in Clinical Oncology, "Neoadjuvant/adjuvant chemotherapy and biological agents, "Management of HER2+ ABC"
2018, Copenhagen, DK	Invited Speaker, Alfred Benzon symposium, "Targeting breast and ovarian cancer-from"
2018, Cracow, PL	Invited Speaker, Second International Colloquium on Cardio-Oncology, "Mechanisms and clinical course of cardiovascular toxicity of cancer treatment"
2018, Dubai, UAE	Invited Speaker, Molecular Profiling / Foundation Medicine Event, "Evolution of personalized healthcare", "Clinical evidence of profiling", "Breast cancer data and experience"
2018, Dubai, UAE	Invited Speaker, Global Women Oncology Summit, "Treatment of premenopausal women with early stage hormone receptor positive breast cancer"
2018, Barcelona, ES	Invited Speaker, EBCC, The 11th European Breast Cancer Conference, "New agents on the horizon"
2018, Munich, GER	Invited Speaker, ESMO congress, "Immunotherapy in triple negative breast cancer"
2018, Oxford, UK	Invited Speaker, ESMO, Third ESMO Academy, "Standard of care and future perspectives in BC"
2018, Barcelona, ES	Invited Speaker, ESMO Symposium on Signalling Pathways in Cancer, "Are CDK 4-6 inhibitors equal?"
2018, Lugano, CH	Invited Speaker, ESMO Preceptorship on Immuno-Oncology, "Breast cancer"
2018, Ginevra, CH	Invited Speaker, ESMO Immuno-Oncology Congress, "Defining the immunogram of breast cancer: Evidences from clinical trials"
2018, Barcellona, ES	Invited Speaker, ESO Biosimilars, "Biosimilars in Cancer Care: Challenges and opportunities for Health Professionals and Patients"
2018, Mexico, MEX	Invited Speaker, 4th ESO-ESMO Latin American Masterclass in Clinical Oncology, "(Neo)Adjuvant chemotherapy and biological agents"
2018, Parigi, FR	Invited Speaker, ESSO - Advanced Course on Breast Cancer Surger, "Factors influencing response rates", "Systemic therapy and fertility preservation"
2018, Budapest, HU	Invited Speaker, ESSO - The 38th Congress of the European Society of Surgical Oncology, "New strategies for increasing pCR after treatment"
2018, Freiburg, GER	Invited Speaker, Breast Cancer Academy, "Clinical trials: answering the critical questions in BC"
2018, Istanbul, TR	Invited Speaker, Breastanbul, "Hormone receptor positive metastatic breast cancer"
2018, Kyoto, JAP	Invited Speaker, The 26th Annual Meeting of the Japanese Breast Cancer Society & Kyoto Breast, "Endocrine therapy of ER positive metastatic breast cancer"
2018, Songdo, KR	Invited Speaker, Global Breast Cancer Conference, "Strategies for the combination of IO"
2018, Kuwait, KWT	Invited Speaker, Kuwait Advanced BC Symposium, "CDK4/6 inhibitors"
2018, Lisbon, PT	Invited Speaker, ESMO Preceptorship on Breast Cancer, "Systemic therapy in TNBC"
2018, Madrid, ES	Invited Speaker, Breast Cancer Symposium_ 23rd, "Treatment of HR+ EBC"
2018, Manchester, UK	Invited Speaker, 1st UK Interdisciplinary Breast Cancer Symposium, "Triple Negative Breast Cancer"
2018, Berlin, GER	Invited Speaker, 17th ESO-ESMO Masterclass in Clinical Oncology, "Treatment of triple negative"
2018, Munich, GER	Invited Speaker, Monitoring in Patients With Advanced Breast Cancer
2018, Oxford, UK	Invited Speaker, EBCTCG Collaborators' Meeting
2018, Prague, CZ	Invited Speaker, Global Expert Meeting on Comprehensive Genomic Profiling, "Profiling in BC"
2018, New York, USA	Invited Speaker, Breast Oncology Innovation Summit (PRISM), "Role of PARP inhibitors in breast cancer"
2018, Moscow, RUS	Invited Speaker, ESMO-RUSSCO Joint Session at XXII Russian National Cancer Congress, "Breast carcinoma"
2018, Salzburg, AT	Invited Speaker, the Salzburg Breast Cancer Talk 2018: "Mastering translational immuno-oncology"
2018, San Antonio, USA	Invited Speaker, the 2018 San Antonio Breast Cancer Symposium, "Dasatinib in metastatic BC"
2018, Seattle, USA	invited Speaker, BHGI Global Summit: "Integration of Breast Care Strategies into Existing Health Systems"
2018, Taipei, TW	Invited Speaker, Taipei International Breast Cancer Symposium, "How to augment anti-tumor immunity"
2018, Halle, GER	Invited Speaker, Tumor immunology meets oncology (TIMO XIV), "Breast cancer immune-landscape"
2018, Zurich, CH	Invited Speaker, Third Zurich Immuno-Oncology Symposium, "Breast tumours"
2019, Boston, USA	Invited Speaker, AACR-NCI-EORTC Targets meeting Third, "Antibody drug conjugates/biotherapeutics"
2019, Chicago, USA	Invited Speaker, ASCO Annual Meeting, "CDK 4-6 inhibitors: Optimizing care in ER positive breast cancer"
2019, Boston, USA	Invited Speaker, Early Immuno-Oncology (IO) Summit, "TIM3 analysis"
2019, Atlanta, USA	Invited Speaker, AACR annual meeting, Plenary session presentation, "Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spatalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors"
2019, Il Cairo, EG	Invited Speaker, Cairo University Oncology Conference, "Hormonal treatment beyond CDK4/6 inhibitors"
2019, Seoul, KR	Invited Speaker, Korean Society of Medical Oncology, "Emerging HER2-targeted therapies"
2019, Copenhagen, DK	Invited Speaker, Benzon Symposium, "Defining the immunogram of Breast Cancer"
2019, Dubai, UAE	Invited Speaker, Middle East Medical Oncology Society, "Talazoparib in patients with BRCA+ BC"
2019, Barcelona, ES	Invited Speaker, ESMO 2019, "Phase I Study of CC-90011 in Patients With Advanced Solid Tumors"
2019, Oxford, UK	Invited Speaker, ESMO Academy, "breast cancer: metastatic disease"
2019, Singapore, SGP	Invited Speaker, ESMO Asia Congress, "Impact of germline genetics on current care of breast cancer",
2019, Ginevra, CH	Invited Speaker, ESMO Immuno-Oncology Congress, "Immuno landscape in metastatic BC"
2019, Kazan, RUS	Invited Speaker, ESMO Summit Russia, "Current standards and practice changing studies in EBC"
2019, Zurich, CH	Invited Speaker, ESMO Preceptorship on breast cancer, "(Neo-)Adjuvant systemic therapy I TNBC"
2019, Lima, PE	Invited Speaker, 5th ESO-ESMO Latin American Masterclass, "(Neo-)adjuvant chemotherapy in TNBC"

2019, Ioannina, GR	Invited Speaker, 14th Educational Seminar of Molecular Oncology & Targeted Therapy, "All patients with resected luminal-type breast cancer should receive extended duration adjuvant hormonal therapy"
2019, Jeddah, KSA	Invited Speaker, International Breast Cancer Conference, "Clinical application of ASCO CAP Her 2 guidelines"
2019, Songdo, KR	Invited Speaker, Global Breast Cancer Conference, "Breast Cancer Subtypes & Immunotherapy"
2019, Lisbona, PT	Invited Speaker, ESMO Preceptorship on Breast Cancer, "(Neo-)adjuvant systemic therapy in TNBC"
2019, Lucerna, CH	Invited Speaker, Breast Surgery Toolbox Meeting, "Local Therapy in the age of Primary Systemic Therapy"
2019, Lugano, CH	Invited Speaker, ESMO 2020 - 1SSC meeting, "Breast cancer, early stage"
2019, Berlin, GER	Invited Speaker, The 18th ESO-ESMO Masterclass in Clinical Oncology, "Breast Cancer"
2019, Nizza, FR	Invited Speaker, European Congress of Pathology, "Assessing HER2: Expert Insights and Guidance"
2019, Oman, OM	Invited Speaker "CDK4/6 inhibitors: considerations for therapy selection and management"
2019, Rio de Janeiro, BR	Invited Speaker, ESMO Summit Latin America, "Current standards and practice changing studies in ABC"
2019, Riyadh, SA	Invited Speaker, Saudi Arabia Society of Medical Oncology, "Treatment of Premenopausal Women"
2019, Salisburgo, GER	Invited Speaker, Salzburg Breast Cancer Talk, "Immunotherapy strategies beyond PD1/PD-L1 inhibition"
2019, San Antonio, USA	Invited Speaker, San Antonio Breast Cancer Symposium, "Mechanisms of resistance in TNBC"
2019, Amsterdam, NL	Invited Speaker, "Future potential role of tucatinib in HER2+ mBC"
2019, Wien, AT	Invited Speaker, St. Gallen Breast Cancer Conference, "Role of Immunotherapy"
2019, Paris, FR	Invited Speaker, ESMO TAT 2019, "PARP and PD-1/PDL1 inhibition"
2019, Teheran, IR	Invited Speaker, Iranian Society of Medical Oncology, "International Breast Cancer Congress of Iran"
2019, China, CHN	Invited Speaker, SIMOS meeting, "Emerging HER2-targeted therapies: The role of ADCs"
2020, San Diego, USA	Invited Speaker, AACR - American Association Cancer Research, "Pralsetinib in RET positive solid tumors"
2020, Abu Dhabi, EAU	Invited Speaker, 5th MEA Oncology Summit, "Optimizing treatment sequence in ER+ ABC"
2020, Chicago, USA	Invited Speaker, ASCO Global Webinar on COVID19, "Strategies to minimize risk to staff from COVID-19", "Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors"
2020, Chicago, USA	Invited Speaker, the 2020 ASCO Quality Care Symposium, "Quality Care in the Time of COVID"
2020, London, UK	Invited Speaker, UCL breast cancer meeting, "HER2+ Breast Cancer Evolving Treatment Landscape"
2020, Atene, GR	Invited Speaker, 6th Symposium on Cancer Immunology and Immunotherapy, "Genetic determinants of immune response in breast cancer"
2020, Lugano, CH	Invited Speaker, Breast Cancer in Young Women - Fifth ESO-ESMO International Consensus Symposium (BCY5), "Adjuvant chemo- and targeted therapies"
2020, Berna, GER	Invited Speaker, Swiss ECHO event2, "ER+, HER2- advanced breast cancer"
2020, Riyadh, KSA	Invited Speaker, Saudi Arabia Society of Medical Oncology, "Treatment of HER2 positive disease"
2020, Il Cairo, EGY	Invited Speaker, 12th BGIICC, "Hormonal treatment beyond CD4/6 inhibitors in MBC"
2020, CapeTown, SA	Invited Speaker, ESMO South Africa, "The Role of CD 4/6 Inhibitors in the Treatment Landscape of MBC"
2020, China, CHN	Invited Speaker, CSCO-ASCO Joint Session, "ASCO update in TNBC" "Update on HER2+ Breast Cancer"
2020, New York, USA	Invited Speaker, MSKCC Meeting, "Treatment of Breast Cancer Patients during COVID-19"
2020, Dubai, UAE	Invited Speaker, Best of ESMO UAE 2020, "Breast Cancer, Metastatic"
2020, Barcellona, ES	Invited Speaker, EBCC 12, "Should all TN early breast cancer receive platinum salts?"
2020, Madrid, ES	Invited Speaker, ESMO 2020, "Role of Immunotherapy in TNBC"
2020, Dublin, IRL	Invited Speaker, ESMO Academy, "Standard of Care and Future Perspectives in MBC"
2020, Berlin, GER	Invited Speaker, ESMO Breast cancer 2020 congress, "How to predict sensitivity to anti-PD(L)1"
2020, Mexico City, MEX	Invited Speaker, ASCO-ESMO 38 Congreso nacional de Oncologia, "Treatment of breast cancer"
2020, Mexico City, MEX	Invited Speaker, ESMO Summit Latin America, "Practice changing studies in TNBC"
2020, Geneve, CH	Invited Speaker, ESMO VIRTUAL Preceptorship on Breast cancer, "Adjuvant chemotherapy", "ET for advanced breast cancer", "When CT is needed for luminal advanced breast cancer"
2020, Buenos Aires, ARG	Invited Speaker, 6th ESO-ESMO Latin American Masterclass in Clinical Oncology, "(Neo-)Adjuvant chemotherapy and biological agents", "Recommended management for triple-negative ABC"
2020, Barcelona, ES	Invited Speaker, 19th ESO-ESMO Masterclass in Clinical Oncology, "Breast cancer"
2020, Ioannina, GR	Invited Speaker, 14 Educational Seminar of Molecular Oncology & Targeted Therapy, "HER2 blockade in patients with low expression of HER2: What is the evidence?"
2020, Jeddah, SA	Invited Speaker, 12th International Breast Cancer Conference, "Should All Breast Cancer Patients be Offered Germline Genetic Testing?"
2020, Kyoto, JP	Invited Speaker, KBCCC2020, "Positioning of CDK4/6i on ER(+), HER2(-) ABC"
2020, Libano, LB	Invited Speaker, 2020 Middle East Biomarkers Days - Biomarkers in Molecular and Immuno-Oncology
2020, London, UK	Invited Speaker, University of Manchester, "Genomics in breast cancer"
2020, Morocco, MA	Invited Speaker, Moroccan Breast Cancer Event, "Therapeutic Strategies in localised TNBC"
2020, Boston, USA	Invited Speaker, Breast cancer conference, "COVID-19 and cancer: A European and Italian perspective"
2020, Munich, GER	Invited Speaker, Breast cancer meeting, Munich University, "Therapy landscape in HER2+ ABC"
2020, Singapore, SGP	Invited Speaker, Singapore Society of Medical Oncology, "The impact of COVID-19 on BC management"
2020, Lisbona, PT	Invited Speaker, ESMO Preceptorship on Breast Cancer, "(Neo-)Adjuvant Systemic Therapy"
2020, San Antonio, USA	Invited Speaker, San Antonio Breast Cancer Symposium, Discussant poster session on HER2 positive ABC, Lecture on Management of breast cancer during COVID pandemics
2020, Singapore, SGP	Invited Speaker, 9th APBCS 2020, "PIK3CA data and relevant clinical experience"
2020, Taiwan, CHN	Invitation Speaker, TBCS, "Advances in the use of PARP inhibitor therapy for breast cancer"
2020, Paris, FR	Invited Speaker, ESMO TAT 2020, "Antibody-drug conjugate (ADC) technology"
2020, Madrid, ES	Invited Speaker, Virtual Cardio-Oncology Summit, "Year in review: The evolving field of Cardio-Oncology"
2021, Philadelphia, USA	Invited Speaker, AACR Virtual Meeting: Special lecture COVID-19 and Cancer, "Overcoming Resistance in the Tumor Microenvironment: Novel Immunomodulatory Agents"
2021, Ulm, GER	Invited Speaker, AGO 2021, "Early Breast Cancer: prognostic factors and beyond"
2021, Chicago, USA	Invited Speaker, ASCO 2021, "Update of HER2-CLIMB study" Poster discussion
2021, Il Cairo, EGY	Invited Speaker, 13th BGIICC, "Treatment of metastatic triple negative breast cancer"
2021, Barcelona, ES	Invited Speaker, 19th ESO-ESMO Masterclass in Clinical Oncology, "Breast Cancer"
2021, Buenos Aires ARG	Invited Speaker, 6th ESO-ESMO Masterclass in Clinical Oncology in Latin America "Breast Cancer"
2021, Tokyo, JAP	Invited Speaker, Japanese Society of Surgery, "Advances in Breast Cancer"
2021, Kyoto, JAP	Invited Speaker, The Japanese Society of Medical Oncology Annual Meeting (JSMO2021), "Advances in early breast cancer care from the perspective of Escalation and deescalation"

2021, Tokyo, JAP	Invited Speaker, JSMO, "Role of abemaciclib in ER+/HER2 negative metastatic breast cancer" "RET testing"
2021, Miami, USA	Invited Speaker, 38th Annual Miami Breast Cancer Conference, "The role of immunotherapy in EBC"
2021, Mumbai, IN	Invited Speaker, 2nd Conference of Indian Society of Oncology, "Metastatic Breast Cancer Management"
2021, Dubai, UAE	Invited Speaker, Breast Cancer meeting_Gulf, "Optimizing CDK4/6 Inhibitors (AE Management)"
2021, Saint Gallen, CH	Invited Speaker, St. Gallen International Breast Cancer Conference, "Accelerating progress in TNBC"
2021, Seoul, KR	Invited Speaker, 10th Global Breast Cancer Conference (GBCC 10), "Treatment for HR+/HER2- mBC"
2021, Singapore, SGP	Invited Speaker, The 9th Asia-Pacific Breast Cancer Summit, "What's on the horizon for new drug development? (session, Tumor Biology & Assessment)"
2021, Zurich, CH	Invited Speaker, 5th Zurich Immuno-Oncology Symposium, "Breast and Gynecological cancers"
2021, Paris, FR,	Invited Speaker, ESMO TAT, "Antibody-drug conjugate (ADC) technology"
2021, Berlino, GER	ESMO Breast Cancer Conference 2021, "Immunotherapy in treatment of breast cancer"

ATTIVITÀ GESTIONALI, ORGANIZZATIVE E DI SERVIZIO

INCARICHI DI GESTIONE E AD IMPEGNI ASSUNTI IN ORGANI COLLEGIALI E COMMISSIONI, PRESSO RILEVANTI ENTI PUBBLICI E PRIVATI E ORGANIZZAZIONI SCIENTIFICHE E CULTURALI, OVVERO PRESSO L'ATENEO O ALTRI ATENEI

(inserire incarico/impegno, ente, data, ecc.)

2016-Oggi	Membro del Comitato Scientifico della Fondazione Beretta per la ricerca sul Cancro
2016-2018	Membro del Comitato Scientifico della Fondazione IEO-CCM
2017-Oggi	Membro della Executive Committee di European Society of Breast Cancer Specialists (EUSOMA)
2017-2019	Presidente del Comitato Scientifico di AIOM
2018-2021	Nominating Committee Chair, European Society for Medical Oncology (ESMO)
2018-Oggi	Membro del Comitato scientifico dell'Accreditation Council of Oncology in Europe (ACOE)
2018-Oggi	Membro del Consiglio di Amministrazione della Fondazione IEO-CCM
2018-Oggi	Membro del Consiglio Direttivo Nazionale della Lega Italiana Lotta ai Tumori (LILT)
2018-Oggi	Componente della Giunta del Dipartimento di Oncologia ed Emato-Oncologia, Università di Milano
2018-Oggi	Referente per l'Internazionalizzazione, Dipartimento di Oncologia ed Emato-Oncologia, Università di Milano
2018-Oggi	Componente del Consiglio Superiore di Sanità, Sezione V, Farmaci e Dispositivi
2018-Oggi	Componente del Comitato di Direzione, Corso di Laurea in Medicina e Chirurgia, Università di Milano
2019-2020	Presidente del Comitato Scientifico della Lega Italiana Lotta ai Tumori (LILT)
2019-2022	Guidelines Committee Chair della European Society for Medical Oncology (ESMO)
2020	Coordinamento e Relatore presso il Consiglio Superiore di Sanità del Gruppo di Lavoro sul Conflitto di Interesse nella Sperimentazione clinica
2020	Coordinamento e Relatore presso il Consiglio Superiore di Sanità del Gruppo di Lavoro sul Linfoma Anaplastico a Grandi Cellule Associato a Protesi
2021	Componente del Gruppo di Lavoro Agenzia Nazionale per i Servizi Sanitari Regionali (AGENAS) per la definizione di criteri di accreditamento nazionale dei Molecular Tumor Board
2021-Oggi	Componente del Tavolo della Pianificazione Oncologica Nazionale, Referente per Innovazione e Ricerca Traslationale, Ministero della Salute

ATTIVITÀ CLINICO ASSISTENZIALI

(indicare, data, durata, ruolo, ente presso il quale si è prestata attività assistenziale, ecc.)

Dal Gennaio 1993 a Gennaio 1994:	Post-Doctoral Fellowship su Immunologia Clinica presso la Medical University of South Carolina, South Carolina Medical School, Department of Clinical Immunology Charleston, SC, USA.
Dal Gennaio 1994 al Gennaio 1998:	Scuola di Specializzazione in Oncologia Medica presso la Divisione di Oncologia Medica del Policlinico Gemelli, Università Cattolica del Sacro Cuore, Roma.
Dal Gennaio 1995 al Gennaio 1997:	Post-Doctoral Fellowship presso la Columbia University, College of Physician and Surgeons, Columbia Comprehensive Cancer Center, New York, NY, USA.
Dal 01.01.1999 al 01.01.2001:	Titolare di Borsa di Studio su studi clinici di fase I-II presso la Divisione di Oncologia Medica dell'Istituto Europeo di Oncologia.
Dal 01.01.2001 al 01.01.2006:	Assistente a Tempo Indeterminato presso la Divisione di Farmacologia Clinica e Nuovi farmaci, Istituto Europeo di Oncologia.
Dal 01.01.2006 al 01.01.2010:	Vicedirettore con contratto a Tempo Indeterminato presso la Divisione di Oncologia Medica, Istituto Europeo di Oncologia
Dal 01.01.2010 al 30.01.2010:	Visiting Clinical Scientist presso il Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Dal 01-01-2010 al 01-01-2013:	Co-direttore della Divisione di Oncologia Medica, Istituto Europeo di Oncologia (Questo periodo è stato committed sulla gestione di studi accademici e sponsorizzati sul tumore mammario).
Dal 01.01.2013 ad oggi:	Direttore Struttura Complessa Divisione Sviluppo Nuovi Farmaci per Terapie Innovative e Condirettore del Programma di terapie Sperimentali, Istituto Europeo di Oncologia.
Dal Gennaio 2019:	Fondatore e coordinatore del Molecular Tumor Board di IEO

Data

29.06.2021

Luogo

Milano